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ABSTRACT OF THE DISSERTATION 
Ketone Body Metabolism Preserves Hepatic Function during Adaptation to Birth and in Overnutrition 
by 
David Graham Cotter 
Doctor of Philosophy in Biology & Biomedical Sciences 
Molecular Cell Biology 
Washington University in St. Louis, 2015 
Professor Peter Crawford, Chair 
Mammalian ketone body metabolism partially oxidizes hepatic acyl-chains to ketone body intermediates, 
which can serve as alternative fuels in extrahapetic tissues during carbohydrate restricted states. Ketone 
body production (ketogenesis) occurs primarily in liver, due to hepatocyte-specific expression of the fate 
committing ketogenic enzyme, mitochondrial 3-hydroxymethylglutaryl-CoA synthase (HMGCS2). In 
contrast, the fate committing enzyme of ketone body oxidation, mitochondrial Succinyl-CoA:3-oxoacid 
CoA Transferase (SCOT), is expressed ubiquitously, except in liver. Here I demonstrate novel roles for 
ketone body metabolism during a classically ketogenic period, the transition to birth, and in a classically 
‘non-ketogenic’ state, overnutrition, using novel genetic mouse models, high-resolution measures of 
dynamic metabolism using 13C-labeled substrates, and systems physiology approaches. I show that 
germline SCOT-knockout (KO) mice cannot oxidize ketone bodies in any tissue. These mice developed 
lethal hyperketonemia and hypoglycemia within the first 48 hr of life and died in a manner that 
phenocopied human sudden infant death syndrome. Nonetheless, my studies of tissue-specific SCOT-KO 
mice revealed that ketone body oxidation is dispensable during the transition to birth and during 
starvation in the adult when individually eliminated in neurons, cardiomyocytes, or skeletal myocytes, 
which comprise the three largest consumers of ketone bodies. Surprisingly, the inability to dispose of 
ketone bodies in germline SCOT-KO mice drove derangements of carbohydrate and fatty acid 
metabolism, oxidized redox potential, and inhibited ketogenesis in liver. Moreover, I show that adult-
onset loss of HMGCS2 ablated the liver’s capacity to effectively convert fat into ketone bodies, and thus 
x 
induced ketogenesis insufficiency. Ketogenesis insufficient mice exhibited increased hepatic 
gluconeogenesis from pyruvate and mild hyperglycemia in the fed state. High-fat diet feeding of 
ketogenesis insufficient mice caused extensive hepatocyte injury and inflammation that was associated 
with decreased glycemia due to fatty acid-induced sequestration of free coenzyme A that caused 
secondary derangements of hepatic tricarboxylic acid (TCA) cycle intermediate concentrations and 
impaired gluconeogenesis. Together, my studies have revealed a critical and novel role for ketone body 
metabolism in preservation of the dynamic intermediary metabolic network in liver during the adaptation 




"Though it be in deep sadness and pain,  
in cold or heat...  
gasping after breath... I will go on!  
Now! Open the Gate!" 
… Along the Road of the Sun L he journeyed— 
one league he traveled...,  
dense was the darkness, light there was none, 
neither what lies ahead nor behind does it allow him to see.  
Two leagues he traveled...,  
dense was the darkness, light there was none, 
neither what lies ahead nor behind does it allow him to see.  
[22 lines are missing here.] 
Four leagues he traveled..., 
dense was the darkness, light there was none, 
neither what lies ahead nor behind does it allow him to see.  
Five leagues he traveled...,  
dense was the darkness, light there was none, 
neither what lies ahead nor behind does it allow him to see.  
Six leagues he traveled..., 
dense was the darkness, light there was none, 
neither what lies ahead nor behind does it allow him to see.  
Seven leagues he traveled... 
dense was the darkness, light there was none, 
neither what lies ahead nor behind does it allow him to see.  
Eight leagues he traveled and cried out! 
dense was the darkness, light there was none, 
neither what lies ahead nor behind does it allow him to see.  
Nine leagues he traveled... the North Wind.  
It licked at his face,  
dense was the darkness, light there was none,  
neither what lies ahead nor behind does it allow him to see. 
Ten leagues he traveled... 
… is near, 
… four leagues 
…Eleven leagues he traveled and came out before the sun(rise). 
Twelve leagues he traveled and it grew brilliant. 
...it bears lapis lazuli as foliage,  
bearing fruit, a delight to look. 
From The Epic of Gilgamesh 
Translated by Maureen Gallery Kovacs 
Electronic Edition by Wolf Carnahan, 1998  
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Chapter 1: Introduction 
Ketone Body Metabolism and Cardiovascular Disease 
The work presented in this chapter has been adapted from: 
Cotter, D. G., Schugar, R. C., and Crawford, P. A. (2013). Am J Physiol Heart Circ Physiol 304(8), 
H1060-1076 
Abstract 
Ketone bodies are metabolized through evolutionarily conserved pathways that support bioenergetic 
homeostasis, particularly in brain, heart, and skeletal muscle when carbohydrates are in short supply. The 
metabolism of ketone bodies interfaces with the tricarboxylic acid cycle, β-oxidation of fatty acids, de 
novo lipogenesis, sterol biosynthesis, glucose metabolism, the mitochondrial electron transport chain, 
hormonal signaling, intracellular signal transduction pathways, and the microbiome. Here we review the 
mechanisms through which ketone bodies are metabolized, and how their signals are transmitted. We 
focus on the roles this metabolic pathway may play in cardiovascular disease states, the bioenergetic 
benefits of myocardial ketone body oxidation, and prospective interactions among ketone body 
metabolism, obesity, metabolic syndrome, and atherosclerosis. Ketone body metabolism is non-invasively 
quantifiable in humans and is responsive to nutritional interventions. Therefore, further investigation of 
this pathway in disease models and in humans may ultimately yield tailored diagnostic strategies and 
therapies for specific pathological states.  
 
I. Introduction 
Metabolism of ketone bodies is conserved among Eukarya, Bacteria, and Archaea (1-3). Ketone bodies 
are synthesized in liver from acetyl-CoA derived primarily from fatty acid oxidation and are transported 
to extrahepatic tissues for terminal oxidation during physiological states characterized by limited 
carbohydrate and surplus fatty acid availability [reviewed in (4,5); (Figs. 1.1A-B)]. Ketone body 
oxidation becomes a significant contributor to overall energy metabolism within extrahepatic tissues in 
numerous physiological states, including the neonatal period, starvation, post-exercise, and adherence to 
low carbohydrate diets, when circulating ketone body concentrations increase from ~ 50 µM in the 
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normal fed state to up to 7 mM. Circulating ketone body concentrations rise to ~1 mM after 16-20h of 
fasting in healthy adult humans, but can accumulate to as high as 20 mM in pathological states like 
diabetic ketoacidosis (2,4,6). Ketone body metabolism is not solely rooted in energy metabolism, as 
ketone bodies also serve as lipogenic and sterol biosynthetic substrates in many tissues, including the 
developing brain, lactating mammary gland, and liver (7-10) (Fig. 1.1C). Furthermore, hepatic 
ketogenesis interfaces with fatty acid β-oxidation, the tricarboxylic acid (TCA) cycle, and 
gluconeogenesis (Fig. 1.2). Derangements of ketone body metabolism occur in numerous disease states, 
including types 1 and 2 diabetes and heart failure, and ketone body metabolism changes over the course 
of normal aging (11-19). In this review we examine (i) the biochemistry of ketone body metabolism and 
its regulation (Section II), (ii) the roles of ketone body metabolism in normal and pathological states of 
the myocardium (Sections III-IV), (iii) the concept, and prospective cardiovascular disease relevance of 
extrahepatic ketone body production, which may channel ketone bodies into lipogenesis (Section 1.V; 
Fig. 1.3), and (iv) intersections among ketone body metabolism, cellular signaling pathways, and the gut 
microbiota (Sections VI-VII). Analysis of the known and prospective cardiovascular disease targets of 
ketone body metabolism is also provided (Section VIII). The effects of ketone body metabolism are 
summarized in Table 1.1. 
 
II. Ketone body metabolism 
The fundamental biochemical and physiological roles of ketone body metabolism have been extensively 
studied and reviewed (4,5,20). In this Section, we provide a brief overview of ketone body metabolism, 
and then focus on recent studies revealing novel aspects of the pathway’s regulatory mechanisms. 
A. Hepatic ketogenesis. In liver, 3-hydroxymethylglutaryl-CoA synthase 2 (encoded by the nuclear gene 
Hmgcs2) catalyzes a fate committing ketogenic reaction: condensation of β-oxidation-derived 
acetoacetyl-CoA (AcAc-CoA) and acetyl-CoA to generate HMG-CoA, which is cleaved by HMG-CoA 
lyase (HMGCL) to generate acetoacetate (AcAc). AcAc is reduced to D-β-hydroxybutyrate (D-βOHB), in 
an NAD+/NADH-coupled near equilibrium reaction catalyzed by phosphatidylcholine-dependent 
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mitochondrial D-βOHB dehydrogenase (BDH1), in which the Keq favors D-βOHB formation (21,22) 
(Fig. 1.1A). Because the BDH1 catalyzed reduction/oxidation of AcAc and D-βOHB is common to the 
final reaction of ketogenesis and the first reaction of ketone body oxidation (Figs. 1.1A-B) (22,23), BDH1 
modulates mitochondrial redox potential in liver and extrahepatic tissues, wherein the AcAc/βOHB ratio 
is directly proportional to the mitochondrial NAD+/NADH ratio (24). A cytoplasmic D-βOHB-
dehydrogenase (BDH2) with only 20% sequence identity to BDH1 has been identified (25). More work is 
needed to elucidate the mechanisms by which the BDH enzymes are regulated and function in vivo. AcAc 
is also non-enzymatically decarboxylated to acetone. Ketone bodies are released by the liver via solute 
carrier 16A (SLC16A) family members 1, 6, and 7 and circulate to extrahepatic tissues where they 
primarily undergo terminal oxidation (26,27). 
A.1. Ketogenic substrates. Ketogenesis occurs predominantly in liver mitochondria at rates proportional 
to β-oxidation when dietary carbohydrates are limiting, and is highly integrated with the TCA cycle and 
gluconeogenesis (Fig. 1.2). Biochemical studies by pioneering investigators including Krebs, McGarry, 
and Foster demonstrated that hepatic metabolic fluxes of acetyl-CoA govern rates of ketogenesis 
[reviewed in (5,20)]. Fatty acid β-oxidation-derived AcAc-CoA and acetyl-CoA are the primary 
ketogenic substrates. Glucose metabolism accounts for less than 1% of circulating ketone bodies in states 
of low carbohydrate intake because pyruvate enters the hepatic TCA cycle predominantly via 
carboxylation to oxaloacetate or malate, rather than decarboxylation (to acetyl-CoA) (28-30). In addition, 
amino acid catabolism accounts for a small percentage of circulating ketone bodies, with leucine 
catabolism generating up to 4% of circulating ketone bodies in the post-absorptive state (31).  
A.2. Regulation of ketogenic mediators. Key regulatory steps in ketogenesis include lipolysis of fatty 
acids from triacylglycerols, transport to and across the hepatocyte plasma membrane, transport into 
mitochondria via allosterically-regulated carnitine palmitoyltransferase 1 (CPT1), the β-oxidation spiral, 
and the hormonal regulators of these processes, predominantly glucagon and insulin. These classical 
mechanisms have been reviewed (5,32-34). Hepatic ketogenesis is a spillover pathway for β-oxidation-
derived acetyl-CoA generated in excess of the liver’s energetic needs (Fig. 1.2). Acetyl-CoA subsumes 
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several roles integral to hepatic intermediary metabolism beyond ATP generation via terminal oxidation. 
Acetyl-CoA allosterically activates (i) pyruvate carboxylase, thereby activating a metabolic control 
mechanism that augments anaplerotic entry of metabolites into the TCA cycle (35,36) and (ii) pyruvate 
dehydrogenase kinase, which phosphorylates and inhibits pyruvate dehydrogenase (37), thereby further 
enhancing flow of pyruvate into the TCA cycle via anaplerosis. Furthermore, cytoplasmic acetyl-CoA, 
whose pool is augmented by transport mechanisms that convert mitochondrial acetyl-CoA to 
transportable metabolites (see Section V.B.), inhibits fatty acid oxidation: acetyl-CoA carboxylase 
catalyzes the conversion of acetyl-CoA to malonyl-CoA, the lipogenic substrate and an allosteric inhibitor 
of mitochondrial CPT1, decreasing delivery of acyl chains to the mitochondrial matrix for terminal 
oxidation [reviewed in (5,38)]. Thus, the mitochondrial acetyl-CoA pool regulates and is regulated by the 
spillover pathway of ketogenesis, which orchestrates key aspects of hepatic intermediary metabolism. The 
studies described below focus on recently discovered mechanisms of ketogenic regulation.  
Following procession through β-oxidation, ketogenic fate is determined by HMGCS2, whose 
regulatory mechanisms are schematized in Fig. 1.4A. Because of its ability to support high rates of 
hepatic ketogenesis, divergence of this mitochondrial HMGCS ~500 Mya from the gene encoding 
cytoplasmic HMGCS1 may have supported the emergence of increasing brain-weight/body-weight ratios 
during vertebrate evolution (39-41). The Hmgcs2 gene and encoded protein are regulatory targets during 
the transition to extrauterine life, starvation, diabetes, during adherence to low carbohydrate/high fat 
(ketogenic) diets, and in aging (2,11,20,42-44). The Hmgcs2 gene is dynamically regulated at the 
transcriptional level. Methylation of 5’ regulatory sequences within the Hmgcs2 gene silences its 
transcription in fetal liver, and in non-ketogenic adult tissues (45). At birth, hepatic Hmgcs2 becomes 
hypomethylated and thereby becomes responsive to circulating hormones (34,46). Insulin suppresses 
Hmgcs2 transcription, prospectively via phosphorylation-induced sequestration of FOXA2 from the 
nucleus, while glucagon induces it via activation of the cAMP regulatory element binding protein (44-49). 
In addition, free fatty acids induce Hmgcs2 in a peroxisome proliferator activated receptor (PPAR)-α 
dependent manner (50,51). In fact, Hmgcs2 is induced in vivo in the post-absorptive state and by 
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adherence to ketogenic diet through the activities of the fibroblast growth factor (FGF)-21/PPARα axis 
(50,52,53). HMGCS2 may also reciprocally induce Fgf21 gene expression (54). In addition, following 
cysteine palmitoylation, HMGCS2 translocates to the nucleus, physically interacts with PPARα, and 
potentiates its own gene transcription (55,56). Inhibition of mTORC1 signaling has been identified as a 
primary mechanism responsible for de-repression of PPARα-mediated transcriptional changes responsible 
for the induction of ketogenesis in the post-absorptive state (11,57). Hepatic Bdh1 also exhibits a 
developmental expression pattern, increasing in brain and liver from birth to weaning, and is also induced 
by ketogenic diet in an FGF21 dependent-manner (53,58). 
 In addition to cysteine palmitoylation, HMGCS2 enzymatic activity is responsive to forms of 
post-translational modification. Mitochondrial activity of HMGCS2 is inhibited through allosteric 
regulation by succinyl-CoA (44,59,60) and through succinylation of lysine residues (44,46,47,61). While 
the regulatory mechanisms remain to be determined, desuccinylation is stimulated by glucagon (47), and 
recent discoveries that identify sirtuin (silent mating type information regulation 2 homolog) 5 (SIRT5) as 
a mitochondrial NAD+ dependent lysine desuccinylase prompt the hypothesis that SIRT5 function 
dynamically regulates mitochondrial HMGCS2 activity (62,63). HMGCS2 activity is also induced in the 
post-absorptive state by SIRT3, a mitochondrial NAD+ dependent deacetylase (64). Because SIRT3 
regulates multiple enzymatic mediators of β-oxidation, sirtuins may be multi-tiered regulators of 
ketogenesis. Genetically obese mice were recently shown to exhibit increased hepatic HMGCS2 serine 
phosphorylation, a post-translational modification that enhances HMGCS2 activity in vitro and was 
correlated with elevated serum D-βOHB levels in vivo (65). 
Despite all of the described transcriptional and post-translational mechanisms that regulate 
HMGCS2, it is unknown if regulation of Hmgcs2 gene expression correlates with changes in protein 
abundance, and if these changes in gene expression directly regulate ketogenesis. Importantly, it remains 
undetermined if HMGCS2 post-translational modification itself is a primary determinant of ketogenic 
flux. Nonetheless, HMGCS2 activity is required for the normal ketogenic response to states of diminished 
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carbohydrate intake, as its absence in humans yields hypoketotic hypoglycemia and fatty liver in states of 
diminished carbohydrate intake (66-68).  
B. Ketone body utilization. Ketone body catabolism generates acetyl-CoA that can be terminally 
oxidized within the TCA cycle or utilized for sterol biosynthesis and de novo lipogenesis (DNL). Ketone 
bodies are an alternative and glucose-sparing fuel source, avidly oxidized in heart and muscle. Moreover, 
neurons do not effectively generate high-energy phosphates from fatty acids, and consequently oxidize 
ketone bodies during starvation and in the neonatal period [presented and reviewed in (2,4,69-71)]. Below 
we review the biochemical activities of the enzymes of ketone body utilization, focusing on recent studies 
that reveal the precise physiological roles of ketone body utilization in vivo. 
B.1. Ketone body oxidation. Ketone bodies are extracted from the circulation by peripheral tissues via 
SLC16A1 and -7 (26). Within mitochondria of peripheral organs, BDH1 catalyzes the oxidation of D-
βOHB to AcAc. AcAc is activated to AcAc-CoA by succinyl-CoA:3-oxoacid-CoA transferase (SCOT, 
CoA transferase), the only mammalian CoA transferase, which catalyzes a near equilibrium reaction that 
exchanges coenzyme A between succinate and AcAc (Fig. 1.1B).  The free energy released by hydrolysis 
of AcAc-CoA is greater than that of succinyl-CoA (72,73). Therefore, the equilibrium of this reaction 
thermodynamically favors the formation of AcAc, [(74), also see Section V]. Thus, ketone body 
oxidative flux occurs by mass action: an abundant supply of AcAc and rapid utilization of acetyl-CoA 
through citrate synthase favors AcAc-CoA formation and contribution of ketone bodies to the TCA cycle. 
A reversible AcAc-CoA thiolase reaction yields two molecules of acetyl-CoA, which enter the TCA cycle 
(Fig. 1.1B) (4,74-76). CoA transferase is necessary, but not sufficient, for ketone body oxidation in mice 
and humans [see below and (77-81)].  
Ketone body oxidation becomes a primary contributor to bioenergetic homeostasis during ketotic 
states, during which ketone bodies are oxidized in proportion to their delivery in heart, brain, and muscle 
until saturation of either uptake or oxidation occurs (2,43,71,82-84). Relative to ketogenesis, little is 
known about the regulation of mediators of ketone body oxidation. Perhaps paradoxically, expression of 
the gene encoding CoA transferase (Oxct1), CoA transferase protein abundance, and CoA transferase 
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enzymatic activity are all diminished in rodent heart and muscle during states of sustained ketosis (51,85-
89). In pathological contexts such as diabetic ketoacidosis, diminution of CoA transferase abundance and 
activity limit ketone body disposal, while insulin deficiency (or severe impairment of its signaling) 
stimulates peripheral fatty acid mobilization and unabated hepatic ketogenesis. This mismatch of 
ketogenesis and peripheral disposal predisposes to the extreme hyperketonemia that can emerge in 
diabetic ketoacidosis.  
In ketotic states, expression of Oxct1 may be negatively regulated through mechanisms involving 
PPARs that are abrogated by insulin [(51); Fig. 1.4B]. Myocardial Oxct1 expression may also be down-
regulated under select non-ketotic metabolic states, as transgenic mice overexpressing the non-insulin-
dependent glucose transporter (GLUT1/SLC2A1) in cardiomyocytes exhibit decreased Oxct1 expression 
and diminished ketone body oxidation (90). Future experiments are needed to determine whether 
regulation of Oxct1 expression occurs through transcriptional or post-transcriptional mechanisms (or 
both), which may help support insight into whether these events are adaptive or maladaptive. Post-
translational modification of CoA transferase occurs through non-enzymatic tyrosine nitration, which has 
been observed in hearts of endotoxin-treated rats, hearts of streptozotocin-treated rats, and hearts of db/db 
mice (86,91,92). Tyrosine nitration correlates with impairments of enzymatic activity (Fig. 1.4B). 
Conversely, nitration of CoA transferase on tryptophan residues in aged rat hearts and kidneys appears to 
augment enzymatic activity (93,94). Molecular mechanisms of residue-specific nitration or de-nitration 
designed to modulate CoA transferase activity may exist and require elucidation, as do additional 
prospective post-translational modifications of CoA transferase.  
Although touted as energy efficient substrates (95,96), an energetic requirement for ketone body 
oxidation at the cellular level has never been demonstrated, even in states of diminished carbohydrate 
supply. Nonetheless, human inborn errors of ketone body oxidation do result in clinically significant 
disease, as approximately 30 CoA transferase-deficient patients have been identified. These patients 
present early in life with severe ketoacidosis that results in lethargy, vomiting, and coma, requiring 
aggressive intravenous hydration, bicarbonate, and glucose and insulin therapy (79-81,97-101). Some 
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CoA transferase deficient patients also present with hypoglycemia, and CoA transferase deficiency may 
contribute to a subset of idiopathic ketotic hypoglycemia cases (79,102-106). If maintained on 
carbohydrate-rich diets that are mildly reduced in protein content, CoA transferase-deficient patients seem 
to thrive, albeit with persistent hyperketonemia. To mechanistically dissect the homeostatic roles of 
ketolysis, germline CoA transferase-knockout (SCOT-KO) mice were developed (78). These mice cannot 
oxidize ketone bodies, and invariably die within 48h of extrauterine life due to hyperketonemic 
hypoglycemia that is marked by hypolactatemia and an increase in the serum AcAc/D-βOHB ratio. The 
mechanisms and consequences of this unusually high ratio remain to be determined. Despite the critical 
nature of CoA transferase and ketone body disposal at an organismal level, recently published studies 
demonstrated that mice with selective loss of CoA transferase in either cardiomyocytes, neurons, or 
skeletal myocytes – the three greatest consumers of ketone bodies (4,107) – survive the neonatal period 
and starvation as adults, with only subtle metabolic abnormalities in these two states (108). Future studies 
using these and related models will be important to determine the metabolic and bioenergetic adaptations 
to CoA transferase deficiency and the inability to derive energy from ketone bodies.   
B.2. Non-oxidative metabolism of ketone bodies. Ketone bodies also contribute to lipogenesis and 
sterol biosynthesis in developing brain, lactating mammary gland, and liver following enzymatic and 
endergonic activation of AcAc to AcAc-CoA by cytoplasmic acetoacetyl-CoA synthetase (AACS) [(7-10) 
and Fig. 1.1C]. While AcAc-CoA serves as a direct substrate for cytoplasmic HMGCS1, which catalyzes 
the fate-committing step of sterol biosynthesis, channeling of AcAc-CoA into DNL requires a thiolytic 
cleavage reaction (i.e., cytoplasmic ketolysis) to yield acetyl-CoA, which becomes the lipogenic substrate 
malonyl-CoA upon carboxylation (8,109-112). Recent studies support the physiological importance of 
ketone bodies as anabolic substrates. Genetic knockdown of AACS in mouse liver lowered total blood 
cholesterol in vivo, and in vitro AACS knockdown impaired differentiation of primary mouse embryonic 
neurons, and inhibited adipocyte differentiation of 3T3-L1 cells [(113-115), also see Section V]. While 
lipogenic fates of ketone bodies may support essential biological functions, these pathways do not serve 
as a primary pathway for disposal of ketone bodies when hepatic ketogenesis is stimulated, because CoA 
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transferase deficiency in mice and humans, which abrogates terminal ketone body oxidation, causes 
severe hyperketonemia (77-81). Nonetheless, future studies in models of AACS disruption are merited to 
firmly establish the physiological roles for non-oxidative fates of ketone bodies. 
 
III. Bioenergetics of Myocardial Ketone Body Oxidation 
In the normal adult heart, mitochondrial oxidative phosphorylation provides more than 95% of the ATP 
generated for its mechanical, electrical, and homeostatic activities. Fatty acid oxidation provides up to 
70% of the ATP produced by the heart, with metabolism of glucose, lactate, amino acids, and ketone 
bodies supplying the balance [reviewed in (116)]. Cardiomyocytes demonstrate considerable metabolic 
flexibility during dynamic alterations of nutrient state and hemodynamic stress – conferring an important 
adaptive property to the myocardium (117-120). Myocardium is the highest ketone body consumer per 
unit mass (2,43,76). Cardiomyocytes oxidize ketone bodies in proportion to their delivery, at the expense 
of terminal fatty acid oxidation and glucose oxidation (90,117,121-126). Competition between oxidation 
of ketone bodies and fatty acids is independent of changes in myocardial malonyl-CoA concentrations 
(127).  
Ketone body oxidation is more energetically efficient than terminal fatty acid oxidation. While 
terminal fatty acid oxidation yields the highest theoretical payoff of ATP per C2 unit of all the myocardial 
substrates, the initial ATP investment required to activate long chain fatty acids for oxidation (i.e. to 
generate a fatty acyl-CoA thioester) and fatty acid-induced expression of uncoupling proteins may 
actually confer greater energetic density to ketone bodies (96). Furthermore, unlike terminal fatty acid 
oxidation all of the reducing equivalents generated by ketone body oxidation are delivered via NADH to 
complex I within the electron transport chain. Oxidation of βOHB also increases the redox span between 
complexes I and III, by keeping mitochondrial ubiquinone oxidized. This may increase the potential 
energy harvested from oxidation of ketone bodies (relative to fatty acids), thereby yielding more energy 
available for ATP synthesis per molecule of oxygen invested (P/O ratio), improving the energetic 
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efficiency of oxidizing ketone bodies over fatty acids (95,96,128). Because unrestrained mitochondrial 
fatty acid oxidation may augment the generation of reactive oxygen species (ROS) to levels that exceed 
scavenging mechanisms, competitive contribution of ketone bodies to the TCA cycle in cardiomyocytes 
may be adaptive under conditions in which the ability to switch between fatty acids and glucose becomes 
impaired (95,96,128). Moreover, ketone bodies diminish oxidative stress by scavenging free radicals and 
by maintaining ubiquinone in the oxidized state (Fig. 1.5) (96,129,130).  
CoA transferase dependent activation of AcAc to AcAc-CoA sequesters free CoA-SH (131,132). 
Rodent hearts perfused ex vivo with AcAc alone exhibit depleted free CoA-SH pools and require addition 
of either CoA precursors or anaplerotic substrates to maintain anaplerotic and TCA cycle flux, and to 
prevent functional decline in cardiac performance (132-134). Although ketone bodies do not serve as the 
sole myocardial fuel under any in vivo circumstance, these studies underscore the important role of 
cardiac anaplerosis in maintaining myocardial bioenergetic homeostasis and cardiac function, a topic that 
was recently reviewed by Des Rosiers and colleagues (135). 
Until recently, it was not known how the myocardium adapts to chronic ketosis – an important 
question relevant to the role that ketone body metabolism may serve in myopathic hearts. Mouse models 
of physiologic ketotic nutritional states (24h of fasting or four weeks of a ketogenic diet) demonstrate that 
the myocardium engages a transcriptional program including, as described above, transcriptional 
suppression of Oxct1 and diminution of CoA transferase protein (51). Consistent with diminution of CoA 
transferase, nuclear magnetic resonance (NMR) profiling demonstrated that maintenance on a ketogenic 
diet decreased myocardial 13C-enrichment of glutamate from 13C-labeled ketone bodies that were 
delivered in vivo or ex vivo by 25%, indicating diminished terminal oxidation of ketone bodies in the TCA 
cycle (51,136). Furthermore, attenuation of ketone body oxidation correlated with failure of ketone bodies 
to inhibit contribution of fatty acids to the TCA cycle. Together, these results indicate that ketotic nutrient 
environments induce mechanisms that modulate myocardial utilization of ketone bodies. Because 
hemodynamic parameters were preserved in hearts of mice fed a ketogenic diet, these results suggest that 
modulation of ketone body metabolism may be adaptive in the setting of sustained ketosis. 
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IV. Ketone Bodies and Myocardial Disease 
Numerous experimental approaches have established that cardiomyopathy is associated with changes in 
cardiac substrate and energy metabolism, and that altered energy metabolism can cause cardiomyopathy 
[reviewed in (116,135,137-144)]. Both metabolic and bioenergetic lines of evidence indicate that ketone 
body metabolism could play a significant role in the myopathic heart. Hepatic ketogenesis is stimulated 
and ketone bodies circulate at increased concentrations in the setting of heart failure – in a relationship 
directly proportional to filling pressure (13-17). As previously noted, the myocardium oxidizes ketone 
bodies at the expense of fatty acid oxidation (117,124,127,145), and thus reductions of myocardial fatty 
acid oxidation that occur during the development of advanced cardiomyopathy may not be coupled to 
reductions of ketone body oxidation (116,141,144). A study in humans with advanced heart failure 
indicated that myocardial extraction of delivered ketone bodies is maintained in the failing heart, but not 
skeletal muscle (146). Similarly, the contribution of ketone bodies to cardiac energy metabolism may be 
elevated in patients with dilated and hypertrophic cardiomyopathies (147). Therefore, while the data on 
ketone body metabolism in heart failure are currently very limited, diminished myocardial ketone body 
oxidation could promote pathological outcomes. Of the identified CoA transferase-deficient patients, two 
were reported to present with dilated cardiomyopathy (98,148,149). Future studies in humans that 
specifically measure CoA transferase function and ketone body oxidation in cardiomyopathic states, 
complemented by mechanistic studies using tissue-selective genetic rodent models, will be required to 
definitively determine how myocardial ketone body metabolism changes in pathophysiological states, and 
the contexts in which myocardial ketone body utilization may be adaptive or maladaptive. 
Studies in rodents demonstrate a possible role for ketone body metabolism in myocardial 
adaptation to ischemia/reperfusion injury. In two studies using ex vivo perfusion approaches in rat hearts, 
maintenance on low carbohydrate diets prior to ischemia/reperfusion protocols gave conflicting results 
with regard to infarct size and hemodynamic performance (150,151). Prospective cardioprotective effects 
of a low carbohydrate diet may be attributable to an increase in the number of myocardial mitochondria or 
transcriptional upregulation of key mediators of oxidative phosphorylation (150,152). Cardioprotective 
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effects have been observed using in vivo ischemia/reperfusion approaches in rats subjected to starvation-
induced ketosis, initiated through prolonged fasting, and also via intravenous injection of DL-βOHB 
immediately prior to ischemic injury, which conferred a significant decrease in both infarct size and 
myocardial cell death (153,154). These studies should stimulate further investigation using genetic and 
pharmacological approaches to determine the validity and mechanisms of these preliminary studies, and 
whether the observations actually relate to myocardial metabolism of ketone bodies. 
Relationships among ketone body metabolism, membrane excitability, and arrhythmogenesis 
have also been reported. Metabolomic and proteomic analysis of atrial tissue harvested during cardiac 
surgeries demonstrated an increase in both myocardial βOHB content and CoA transferase abundance in 
patients with atrial fibrillation, compared to control patients (155). Although myocardial ketone body 
utilization in the setting of atrial fibrillation has not been investigated, mechanisms that directly link 
ketone bodies to membrane excitability and arrhythmogenesis have been preliminarily assessed. βOHB 
blocks the transient outward K+ current (Ito) in murine ventricular myocytes, causing action potential 
prolongation (156). However, only L-βOHB inhibits the Ito current. L-βOHB is measurable in myocardial 
extracts, but does not circulate and likely results from hydrolysis of the β-oxidation intermediate L-
βOHB-CoA (157-160). Hepatic ketogenesis only produces D-βOHB, which is the only form that is a 
BDH substrate, and thus, a substrate for oxidation. SLC16A transporters in rat myocytes demonstrate no 
stereoselectivity for βOHB (161). Prospective pathophysiological significance of the L-βOHB 
stereoisomer requires investigation. 
 
V. Reversibility of the CoA Transferase Reaction Extends Cardiovascular Disease Targets of 
Ketone Body Metabolism  
Each enzyme involved in ketone body oxidation catalyzes a reversible reaction. Thus, each tissue that 
oxidizes ketone bodies has the enzymatic potential to synthesize them.  
A. Pseudoketogenesis. Brunengraber and colleagues quantified exchange between isotopically labeled 
fatty acids and unlabeled ketone bodies in rat hearts perfused ex vivo (162). Des Rosiers et al. 
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subsequently quantified dilution of labeled ketone bodies in hepatectomized dogs in vivo (163). This 
isotopic dilution by extrahepatic tissues was termed pseudoketogenesis, which occurs because CoA 
transferase and AcAc-CoA thiolase catalyze reversible reactions. While a physiological role for 
pseudoketogenesis has yet to be established, the process leads to overestimation of ketone body turnover 
in whole-body tracer dilution studies, because its rate is up to one-third of the rate of ketone body uptake 
(162).  
B. CoA transferase-dependent ketogenesis in extrahepatic tissues. CoA transferase is expressed in all 
mammalian cells that harbor mitochondria, except hepatocytes, but not all cell types oxidize ketone 
bodies, suggesting that CoA transferase may mediate non-oxidative metabolic functions in certain tissues 
or physiological states (74,107,164,165). Because AcAc exits mitochondria via monocarboxylate 
transporters, ketogenic flux through thiolase and CoA transferase may permit carbon efflux from 
mitochondria independent of citrate synthase, thus generating a monocarboxylate transport system that 
complements both citrate-dependent tricarboxylate transport (Fig. 1.3) and acetylcarnitine transport (166). 
Such a role for CoA transferase reflects its dual evolutionary history as an enzyme of ketone body 
production and utilization (167,168). Ketogenic flux through mitochondrial thiolase and CoA transferase 
may be poised to regulate discrete cellular functions directly relevant to metabolic syndrome, diabetes, 
and atherosclerosis, because ketone bodies are substrates for cytoplasmic DNL and sterol biosynthesis 
[Fig. 1.3 and (8,109-111)]. A series of studies have implicated ketogenic flux through CoA transferase as 
a putative mechanism through which ketone bodies act as insulin secretagogues in pancreatic β cells (169-
172). The authors of these reports demonstrated that ketone bodies and ketone body precursors potentiate 
insulin release, possibly by contributing to formation of cytoplasmic short-chain acyl-CoAs 
(169,171,172), and that diminished CoA transferase expression correlated with impaired glucose 
stimulated insulin secretion in a rat insulinoma cell line (170). Future experiments will be required to 
determine the biological roles of ketogenic flux in cell types not classically associated with lipogenesis, 
including β cells of the pancreas and cardiomyocytes.  
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An additional non-oxidative role for CoA transferase may emerge in macrophages, which exhibit 
robust CoA transferase enzymatic activity, but do not terminally oxidize ketone bodies (173,174). Recent 
discoveries have highlighted the importance of macrophage metabolism in cardiovascular disease 
[reviewed in (175)]. As macrophage-specific deficiency of the enzyme required for DNL, fatty acid 
synthase (FAS), ameliorates diet-induced atherosclerosis in mice (176), it is intriguing to consider that 
anabolic procession of metabolites through mitochondrial thiolase and CoA transferase acts upstream of 
FAS to contribute to macrophage DNL flux. CoA transferase is also abundantly expressed in adipose 
tissue, in which the enzyme that catalyzes the reaction downstream from CoA transferase, AACS (Fig. 
1.3), is dynamically regulated by PPARγ, a key mediator of adipogenesis and adipocyte function 
(113,177,178). Adipocyte-specific FAS deficiency increases baseline energy expenditure and improves 
diet-induced obesity in mice (179). Because ketone bodies have been proposed as quantitatively 
significant DNL substrates in multiple cell types (8,180), these recent findings suggest that use of genetic 
models is warranted to draw mechanistic and cardiovascular disease-relevant links among CoA 
transferase, lipogenesis from ketone bodies, and metabolic and vascular diseases. 
 
VI. Signaling Roles for Ketone Bodies  
Because serum ketone body concentrations vary over a large dynamic range, they may act as 
physiologically relevant signals for cell-surface and intracellular receptors. In fact, D-βOHB is an 
endogenous ligand for a niacin receptor, G protein-coupled receptor 109A (GPR109A), with an EC50 of 
770 mM (181). Like niacin, D-βOHB can inhibit adipose tissue lipolysis, which has been proposed to 
create a negative feedback loop in which ketosis curtails ketogenesis by limiting delivery of non-esterified 
fatty acids to the liver (182,183). GPR109A signaling also promotes reverse cholesterol transport in 
macrophages (184). It is unknown if D-βOHB plays a role in this cascade.  
βOHB signaling may also influence cardiovascular biology through additional G protein-Coupled 
Receptors (GPCRs). A recent study in mice revealed that βOHB decreases sympathetic outflow and 
reduces heart rate and total energy expenditure by antagonizing (through an unknown mechanism) 
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GPR41, a Gi/o-coupled receptor for short chain fatty acids (SCFAs, e.g., acetate, propionate, and butyrate) 
that is abundantly expressed in sympathetic ganglia (185). Thus, evidence implicating ketone bodies as 
signaling molecules further supports roles for ketone bodies that transcend energy metabolism, indicating 
that additional experimentation is required to elucidate the receptors and mechanisms through which 
ketone bodies serve as extracellular signals.  
 Recently published findings also demonstrated that D-βOHB inhibits Class I histone deacetylases 
(HDACs), resulting in increased histone acetylation, and thus, increased expression of genes encoding 
mediators of resistance to oxidative stress (186). The molecular effects of D-βOHB were observed at high 
IC50 concentrations (2.4 – 5.3 mM, depending on the HDAC isoform), and were recapitulated by caloric 
restriction, fasting, or AcAc. To determine if these effects were dependent on D-βOHB metabolism, small 
interfering RNAs (siRNAs) against BDH1/2 were transfected into cells, which were then treated with D-
βOHB. The authors observed that, up to 3 mM D-βOHB, the effects on histone acetylation were 
preserved, leading to the conclusion that most of the influence of D-βOHB on HDAC function was 
independent of D-βOHB metabolism. However, residual BDH persisted in the siRNA-transfected cells, 
and the control experiment confirming diminished D-βOHB oxidation in BDH ‘knockdown’ cells was not 
performed. Thus, it remains plausible that oxidation of D-βOHB to AcAc by BDH1 could alter 
mitochondrial redox potential, and that CoA transferase-dependent contribution of AcAc to the TCA 
cycle for terminal oxidation could alter cellular energy metabolism (see Section II.B.1 and Fig. 1.5), each 
of which may contribute to the observed effects on histone acetylation. Nonetheless, these observations 
reveal exciting roles for ketone body metabolism in a multitude of disease states, which will benefit from 
the development and application of both pharmacological and genetic tools.  
  
VII. Ketone Body Metabolism, the Microbiota, and Cardiovascular Biology and Disease 
A therapeutically tractable interface between ketone body metabolism and cardiovascular disease is 
offered through the dynamic community of microorganisms living on our cutaneous and mucosal surfaces 
– the microbiota. This ecosystem of ~100 trillion cells – 10 times the total number of our own cells – 
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comprises a ~1 kg ‘organ’ that harbors a massive aggregate of genomes (the microbiome) encoding 
millions of genes – 100 times that of the human genome – that influence the human metabolome and 
coordinate immune function [recently reviewed in (187-195)]. The data supporting causal links between 
the microbiota and host cardiovascular disease, in both rodent models and humans, are compelling. Gut 
microbial ecology undergoes marked transformation in obese and type 2 diabetic humans and rodents, 
and the dynamic energy-harvesting capacity of the gut microbial community plays a significant 
contributing role to energy homeostasis in the host (196-209). Acting in synergy, the host’s genome and 
microbiome coordinate ‘supraorganismal’ metabolic processes, creating a suite of co-metabolites that 
influence a panoply of pathophysiological processes including nonalcoholic fatty liver disease (NAFLD), 
hypertension, insulin resistance, and atherosclerosis (210-213). Furthermore, the ability of indigenous 
microbial communities to coordinate the functions of the host’s immune system is likely a key influence 
over the development of cardiovascular disease [reviewed in (189)], including the development of type 1 
diabetes (214). Together, comparative genomics, metabolomics, and gnotobiotic studies (Greek roots: 
gnosis, knowledge; bios, life; a technology that allows cultivation of experimental animal models in the 
presence of defined microbial communities) may usher an era that ultimately allows caregivers to 
administer individualized forms of therapy that configure the microbiota using probiotics and prebiotics 
to ameliorate cardiovascular disease. 
 Studies of gnotobiotic animals have revealed intriguing relationships among the microbiota, 
ketone bodies, and cardiovascular biology. Normalized to tibial length or body weight, hearts of germ free 
mice, which are born and raised in sterile gnotobiotic isolators, are ~15% smaller than those of normally-
colonized mice, but myocardial mass increases within two weeks of microbial colonization (126). In vivo 
and ex vivo functional parameters of hearts of germ free mice are normal, but myocardial glucose 
oxidation rates are higher. A systematic assessment of substrate delivery and metabolism in germ free 
mice revealed that while circulating ketone body concentrations were not significantly different under fed 
conditions, ketosis was blunted during nutrient deprivation in germ free mice, due to diminished hepatic 
ketogenesis (126). While reduced adiposity of germ free mice (205) is a likely contributor to blunted 
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ketogenesis during fasting, hepatic ketogenic machinery, including expression of Hmgcs2, was curtailed 
in fasting germ free mice. The reduction in cardiac size and alterations of systemic and myocardial 
metabolism were abrogated when germ free mice were maintained on a ketogenic diet (126). It is also 
intriguing to consider the aforementioned cross-talk between SCFAs and ketone bodies [(185); see 
Section VI]. SCFAs are produced through the fermentative actions of glycan-digesting enzymes 
uniquely-encoded by the microbiome, contributing to the host’s energy harvest and to signaling through 
GPR41 (185,215). Thus, the microbiome may supervise an expansive and integrated network in which 
ketone bodies influence cardiac metabolism, size, and physiology. Future studies using genetically-
modified gnotobiotic animals will permit further construction of the relationship between ketone 
metabolism and the microbiome in diseases of the heart and vasculature. 
 
VIII. Diagnostic and Therapeutic Targets of Ketone Body Metabolism 
The diversity of metabolic and signaling processes in which ketone body metabolism participates 
provides a range of diagnostic and therapeutic applications, only a subset of which is under active 
investigation.  
A. Abnormalities of Ketone Body Oxidation. CoA transferase deficient humans typically present early in 
life with severe ketoacidosis that can result in vomiting, coma, and death if intravenous glucose and 
insulin therapy is not rapidly instituted (79,97,98). Neonatal mice with complete loss of terminal ketone 
body oxidation (SCOT-KO mice) invariably die within the first 48 hr of life in a manner that mimics 
human sudden infant death syndrome (SIDS) (78). Furthermore, a recent observational study that 
performed metabolic autopsies on 255 SIDS patients found that three exhibited underlying disorders of 
ketone body metabolism (216). Therefore, a small subset of cases that ultimately receive a diagnosis of 
SIDS may actually be attributable to latent abnormalities of CoA transferase function. However, 
statewide neonatal screening protocols in the United States do not currently detect newborns with isolated 
disorders of ketone body oxidation, who exhibit hyperketonemia, but generally normal organic acid and 
acylcarnitine profiles (99). Improved screening methods, measuring both AcAc and D-βOHB, may detect 
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patients with latent deficiency of ketone body oxidation, further reduce SIDS incidence, and predict 
metabolic complications which may manifest later in life.  
B. Dietary Therapies: Ketogenic Diets, Ketone Esters, and Odd-Chain Fatty Acids. Ketogenic diets are 
actively used for weight loss and anticonvulsant therapy, and are intensively studied as potential 
adjunctive therapy for brain cancers and neurodegenerative diseases including Parkinson’s and 
Alzheimer’s diseases (217-221). Additionally, limited studies raise the possibility that humans with 
NAFLD could benefit from low carbohydrate diet therapy (222,223). An experimental ketogenic diet has 
been used to mitigate a mitochondrial cardiomyopathy in mice (152). The full scope of cardiovascular 
diseases responsive to nutritional and/or pharmacological manipulation of ketone body metabolism, and 
the associated metabolic mechanisms remain underexplored. 
 Ketogenic diets are often unpalatable, which leads to poor patient compliance. Additionally, such 
diets raise blood cholesterol and free fatty acids, and increase the risk of nephrolithiasis and cause 
constipation (224-226). Therefore, Veech and Clarke developed and tested ingestible ketone ester 
compounds, which can rapidly generate ketoses exceeding 5 mM in rats and humans (227-229), while 
sparing the adverse consequences of high fat diets. A small preliminary study indicates that oral ketone 
esters are safe in humans (227). Rodents fed these compounds acutely decrease food intake. Although 
these animals do not exhibit changes in body weight over an extended time period, they do become more 
insulin sensitive, possibly due to increased expression of uncoupling proteins in brain and brown adipose 
tissue (228,229). Further studies will evaluate the efficacy of these compounds in the mitigation and 
prevention of metabolic, myocardial, and neurological diseases in rodent and human subjects. 
 In the last decade, studies analyzing the beneficial roles of the anaplerotic five-carbon (C5)-
ketone bodies and their precursor odd-chain fatty acids for the treatment of long chain fatty acid oxidation 
(LCFAO) disorders have emerged (230,231). Conventional management of LCFAO disorders consists of 
dietary therapy with the medium-chain fatty acid octanoate. Substitution of octanoate for the odd-chain 
fatty acid heptanoate (given as the triglyceride triheptanoin) further improves clinical outcomes, 
specifically by reducing the incidence of rhabdomyolysis and cardiomyopathy (230,231). While only 
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trace levels of C5 ketone bodies are normally found in human body fluids (232,233), ingestion of odd 
chain fatty acids promotes hepatic C5-ketogenesis: β-oxidation of odd chain fatty acids yields propionyl-
CoA, an anaplerotic substrate, which, in the liver, can also be packaged into C5 ketone bodies (234). 
Oxidation of C5-ketone bodies in peripheral tissues occurs through CoA transferase (235), regenerating 
propionyl-CoA. However, as oxidation of heptanoate within myocytes locally generates anaplerotic 
propionyl-CoA, direct evidence linking C5-ketone body metabolism to improved clinical outcome in 
LCFAO disorders currently remains lacking. Thus, it may be useful to cross experimental models of 
tissue-specific CoA transferase deficiency to existing models of LCFAO defects (108,236) to establish 
the metabolic roles of C5-ketone body metabolism in myocyte oxidation. Future studies of the role of 
these three approaches: low carbohydrate ketogenic diets, ketone ester-containing diets, or anaplerotic 
odd-chain fatty acid-containing diets in cardiomyopathy remain to be systematically performed, but are 
warranted (135,237). 
C. Modifying Ketone Body Enzymatic Pathways: Targeting HMGCS2 and CoA transferase. As both 
nutrients and hormonal factors affect ketogenic regulation, it is not surprising that ketone body 
metabolism is dynamically regulated in mouse models of diet-induced obesity and in humans with 
metabolic syndrome. Hepatic ketogenesis becomes suppressed at later stages of the evolution of 
hyperinsulinemic obesity (12,42,238-240). Because transgene mediated Hmgcs2 overexpression within 
hepatocytes enhances ketogenesis and simultaneously diminishes circulating free fatty acid concentrations 
in vivo (241), regulation of HMGCS2 activity (Section II.A.2) becomes a prospective therapeutic target. 
Diversion of hepatic fatty acyl chains into ketone bodies could diminish carbon that would otherwise 
require terminal oxidation, storage, or packaging into lipoproteins for secretion, prospectively mitigating 
hepatic steatosis and insulin resistance. 
Whole-body ketone body turnover is non-invasively quantifiable in humans, as is tissue-level 
oxidative flux of ketone bodies via positron emission tomography using 11C-labeled ketone body tracers, 
which have been used for studies in brain, but not yet in other organs (242,243). Additionally, ketone 
body metabolism and the mitochondrial enzyme CoA transferase are amenable to a number of nutritional, 
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and perhaps ultimately, pharmacological therapies. Importantly, as described above, myocardial CoA 
transferase activity plays an important role in the regulation of substrate selection, mitochondrial ROS 
generation, and cardiac work and bioenergetic efficiency (Fig. 1.5). Therefore, analysis of animal models 
with sophisticated genetic manipulations of ketone body metabolism, coupled with pharmacological 
targeting strategies may provide rationale for a suite of translational and clinical studies that validate 
ketone body metabolism as a myocardial therapeutic target. Additionally, CoA transferase and AACS 
activities may ultimately serve as therapeutic targets in contexts in which the ketone body-lipogenic 
pathways play significant roles, particularly within adipocytes, hepatocytes, and macrophages. 
 
IX. Conclusions  
Ketone body metabolism maintains bioenergetic homeostasis when dietary carbohydrates are limiting. 
Defects in either the synthetic or oxidative arms of ketone body metabolism result in disease pathogenesis 
in humans, and ketone body oxidation is required for maintenance of glycemia and survival in neonatal 
mice. Ketone bodies regulate mitochondrial metabolism, energetics, and ROS production via their 
oxidation, and may therefore have significant signaling roles within cardiomyocytes. Ketogenic flux 
through CoA transferase channels ketone bodies to lipogenesis, which could regulate signaling processes 
in many cell types, including macrophages, adipocytes and pancreatic β cells, which express CoA 
transferase abundantly, but may have relatively diminished need to harvest energy from ketone bodies. 
Therefore, the metabolism of ketone bodies may influence numerous human disease states relevant to 
cardiovascular disease, including obesity, diabetes, atherosclerosis, and heart failure. Because both CoA 
transferase and HMGCS2 experience multi-tiered regulation, these enzymes may be tractable to 
pharmacological manipulation. Before these ends are achieved, the scope of viable therapeutic targets of 
ketone body metabolism must first be developed. Integrative experiments in both animal models and 
humans that exploit the convergence of sophisticated genetic approaches, quantitative substrate fate-
mapping (‘fluxomics’), metabolomic profiling, physiological studies, and quantification of mitochondrial 
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function are needed to elucidate the mechanisms through which ketone body metabolism influences 




Fig. 1.1. Ketone body metabolism pathways. (A) Ketogenesis within hepatic mitochondria is the 
primary source of circulating ketone bodies. (B) The primary metabolic fate of ketone bodies is terminal 
oxidation within mitochondria of extrahepatic tissues via CoA transferase (SCOT). Substrate competition 
with pyruvate-derived and fatty acyl-CoA-derived (the corkscrew arrows represent the activities of the β-
oxidation spiral) acetyl-CoA are shown.  (C) Cytoplasmic DNL and cholesterol synthesis are non-
oxidative metabolic fates of ketone bodies. For simplicity of panel C, only acetoacetate (AcAc) is 
depicted, although β-hydroxybutyrate (βOHB) is also a substrate for lipogenesis after it has been oxidized 
to AcAc via mitochondrial βOHB dehydrogenase (BDH1). Additional abbreviations: AACS, acetoacetyl-
CoA synthetase; ACC, acetyl-CoA carboxylase; AcAc-CoA, acetoacetyl-CoA; ATP, adenosine 
triphosphate; CoA-SH, free coenzyme A; FAS, fatty acid synthase; HMG-CoA, 3-
hydroxymethylglutaryl-CoA; HMGCL, HMG-CoA lyase; HMGCS1, cytoplasmic HMG-CoA synthase; 
HMGCS2, mitochondrial HMG-CoA synthase; HMGCR, HMG-CoA reductase; NAD+(H), nicotinamide 
adenine dinucleotide oxidized (reduced); PDH, pyruvate dehydrogenase; SCOT, succinyl-CoA:3-
oxoacid-CoA transferase; TCA, tricarboxylic acid; mThiolase, mitochondrial thiolase; cThiolase, 
cytoplasmic thiolase. Thiolase activity is encoded by at least six genes: ACAA1, ACAA2 (encoding an 
enzyme known as T1 or CT), ACAT1 (encoding T2), ACAT2, HADHA, and HADHB. 
 
Fig. 1.2. Hepatic integration of ketogenesis. Integration of hepatic ketogenesis with hepatic TCA cycle, 
DNL, and pyruvate cycling/glucose metabolism. FAO, β-oxidation of fatty acids; GDH, glutamate 
dehydrogenase; OAA, oxaloacetate; ME, malic enzyme; PEPCK, phosphenolpyruvate carboxykinase; 
PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; PK, pyruvate kinase; PEP, phosphenol 
pyruvate; CS, citrate synthase; DNL, de novo lipogenesis. 
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Fig. 1.3. Ketogenic flux through CoA transferase. Because CoA transferase catalyzes an equilibrium 
reaction, select spatiotemporal metabolic conditions may favor channeling of mitochondrial acetyl-CoA 
to AcAc, generating a monocarboxylate shuttle that complements the citrate-dependent tricarboxylate 
shuttle and permits mitochondrial efflux of β-oxidation-derived acetyl-CoA independent of the TCA 
cycle. ACLY, ATP-citrate lyase. 
 
Fig. 1.4. Regulatory mechanisms for HMGCS2 and CoA transferase (SCOT). (A) HMGCS2 and (B) 
SCOT both undergo transcriptional (red) and post-translational modes of regulation (blue). Some 
regulatory factors exhibit both classes of effects (violet). mTORC1, mammalian target of rapamycin 
complex 1; PPARα, peroxisome proliferator activated receptor-α; PTM; post-translational modification; 
SIRT3, sirtuin (silent mating type information regulation 2 homolog) 3. 
 
Fig. 1.5. Diverse roles of CoA transferase in mitochondrial function. βOHB and AcAc cross the 
plasma membrane via SLC16A family members, and may employ these or other transporters to enter the 
mitochondrial matrix. Within the mitochondria, D-βOHB is oxidized to AcAc by the inner-membrane 
bound and phosphatidylcholine-dependent BDH1. CoA transferase (SCOT) catalyzes a near equilibrium 
reaction through which coenzyme A is exchanged between succinate and AcAc. Oxidation of ketone 
bodies occurs by mass action, and may diminish reactive oxygen species (ROS) formation, compared to 
oxidation of fatty acids. See text for details. ADP, adenosine diphosphate; ANT, adenine nucleotide 
transporter; CPT, carnitine palmitoyltransferase; Cyt C, cytochrome C; e-, electron; H+, hydrogen ion; I, 
II, II, IV, complexes I-IV of the electron transport chain; IMM, inner mitochondrial membrane; OMM, 
outer mitochondrial membrane; Q, ubiquinone; ψm, electrochemical potential across the inner 



















Obligate role for ketone body oxidation in neonatal metabolic homeostasis 
The work presented in this chapter has been adapted from: 
Cotter, D. G., d'Avignon, D. A., Wentz, A. E., Weber, M. L., and Crawford, P. A. (2011) J Biol Chem 
286(9), 6902-6910 
Abstract 
To compensate for the energetic deficit elicited by reduced carbohydrate intake, mammals convert energy 
stored in ketone bodies to high-energy phosphates. Ketone bodies provide fuel particularly to brain, heart, 
and skeletal muscle in states that include starvation, adherence to low carbohydrate diets, and the neonatal 
period. Here, we use novel Oxct1-/- mice, which lack the ketolytic enzyme succinyl-CoA:3-oxo-acid CoA-
transferase (SCOT), to demonstrate that ketone body oxidation is required for postnatal survival in mice. 
Although Oxct1-/- mice exhibit normal prenatal development, all develop ketoacidosis, hypoglycemia, and 
reduced plasma lactate concentrations within the first 48 h of birth. In vivo oxidation of 13C-labeled β-
hydroxybutyrate in neonatal Oxct1-/- mice, measured using NMR, reveals intact oxidation to acetoacetate 
but no contribution of ketone bodies to the tricarboxylic acid cycle. Accumulation of acetoacetate yields a 
markedly reduced β-hydroxybutyrate:acetoacetate ratio of 1:3, compared with 3:1 in Oxct1+  littermates. 
Frequent exogenous glucose administration to actively suckling Oxct1-/- mice delayed, but could not 
prevent, lethality. Brains of newborn SCOT-deficient mice demonstrate evidence of adaptive energy 
acquisition, with increased phosphorylation of AMP-activated protein kinase α, increased autophagy, and 
2.4- fold increased in vivo oxidative metabolism of [13C]glucose. Furthermore, [13C]lactate oxidation is 
increased 1.7-fold in skeletal muscle of Oxct1-/- mice but not in brain. These results indicate the critical 
metabolic roles of ketone bodies in neonatal metabolism and suggest that distinct tissues exhibit specific 






Transition from the intrauterine to the extrauterine environment incurs a marked shift in nutrient delivery 
and energy metabolism. A continuous pipeline replete with glucose and lactate, but calorically reduced in 
lipid, is replaced by a reduced carbohydrate, high fat milk diet that is cyclically interrupted by periods of 
nutrient deprivation (20,71,244). High energy-requiring organs like heart and skeletal muscle are poised 
to meet the energetic demands of this new nutrient environment because they are endowed with 
enzymatic machinery that avidly generates high energy phosphates from oxidative metabolism of fatty 
acids and lactate (245). Unlike cardiomyocytes and skeletal myocytes, most neurons oxidize fatty acids 
poorly and therefore remain dependent on hepatic gluconeogenesis to support energetic needs 
(69,70,246,247). However, because newborn brain comprises 10% of body weight and requires up to 60% 
of total body energy expenditure, maintenance of energetic homeostasis in the nervous system requires 
allocation of multiple fuels for metabolic homeostasis in the neonatal period. The rate of ketone body 
extraction by human neonatal brain is up to 40-fold higher than adult brain. Furthermore, ketones 
contribute uniquely to maturation within the nervous system (2,4,9,20,71,76,82,244,248-250).  
Most ketogenesis occurs in the liver and is driven primarily by rates of fatty acid oxidation. 
Mitochondrial fatty acid oxidation-derived acetoacetyl-CoA (AcAc-CoA) and acetyl-CoA together serve 
as the primary ketogenic substrates. Ketogenic reactions are sequentially catalyzed by HMG-CoA 
synthase 2 and HMG-CoA lyase, generating acetoacetate (AcAc), which is converted to D-β-
hydroxybutyrate (βOHB) in an NAD+/NADH-coupled redox reaction catalyzed by βOHB dehydrogenase. 
AcAc and βOHB diffuse into the bloodstream and are delivered to ketolytic organs, in which they are 
exceptionally energy-efficient substrates (5,39,76,95,96,251,252). Within mitochondria of ketolytic 
organs, βOHB is oxidized back to AcAc in a reaction catalyzed by βOHB dehydrogenase. AcAc receives 
a CoA moiety from succinyl-CoA, generating AcAc-CoA in a reaction catalyzed by succinyl-CoA:3-oxo-
acid CoA-transferase (SCOT, EC 2.8.3.5), encoded by nuclear Oxct1. This enzyme is not expressed in 
liver (76,164). Mitochondrial AcAc-CoA thiolase catalyzes conversion of AcAc-CoA to acetyl-CoA, 
which is terminally oxidized within the tricarboxylic acid cycle. 
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Reports of ~20 individuals who harbor homozygous or compoundheterozygous OXCT1 loss-of-
function mutations (Online Mendelian Inheritance in Man 245050) indicate that afunctional allele is 
required for ketone body oxidation, and as such patients typically present in infancy with spontaneous 
ketoacidosis (79-81,98,100,148,149,253). Numerous single-nucleotide polymorphisms have been 
identified within the human OXCT1 locus, but functional significance has been ascribed to relatively few 
of them.  
Adverse consequences of ketoacidosis are well appreciated, and physiological states that increase 
ketone body turnover have been extensively analyzed. Nonetheless, experimental models to date have not 
definitively revealed whether loss of ketone oxidation can be energetically tolerated, particularly at the 
tissue level, and the metabolic adaptations to ketolytic insufficiency are unknown. In this study, we use 
novel Oxct1-/- mice to examine the metabolic roles of ketone body oxidation in the neonatal period and the 
adaptations to its absence. 
 
Experimental Procedures 
Animals— Oxct1-/- C57BL/6 mouse embryonic stem (ES) cells (clone EPD0082-1-CO2) were acquired 
through the National Institutes of Health knock-out mouse project (KOMP) consortium. The targeting 
sequence inserts two transcriptional terminators (pA) within intron 5 of the Oxct1 locus, which is 
upstream from sequence that encodes critical catalytic SCOT residues (Fig. 2.1A) (254,255). Genotyping 
was performed using primer sets schematized in Fig. 1A and listed in supplemental Table S2.1. ES cells 
were microinjected into embryonic day 3.5 (E3.5) C57BL/6 blastocysts, and four chimeric mice 
(determined by tail biopsy PCR) were obtained. Transmission of the targeted allele was achieved by 
breeding chimeric males to C57BL/6 wild-type females. Heterozygote (Oxct1+/-) progeny were then 
crossed to generate Oxct1-/- mice. All mice were maintained on standard polysaccharide-rich chow diet 
(Lab Diet 5053) and autoclaved water ad libitum. Lights were off between 1800 and 0600. All P0 litters 
were obtained at 0900, and tissues/blood were harvested mid-morning. All experiments were performed 
using protocols approved by the Animal Studies Committee at Washington University. 
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Plasma Metabolite and Insulin Measurement— Measurements of plasma glucose, AcAc, βOHB, free 
fatty acids, and triglycerides were performed using biochemical assays coupled to colorimetric substrates 
(Wako), as described previously (51). Plasma lactate was measured using a colorimetric assay 
(BioVision). Blood glucose was measured in duplicate using a glucometer (Aviva). Measurement of 
plasma insulin was performed by ELISA (Millipore) as described previously (51). 
Gene Expression Analysis— Quantification of gene expression was performed using real-time RT-
quantitative PCR using the ΔΔCt approach as described, normalizing to Rpl32, using primer sequences 
listed within supplemental Table S2.1 (51).  
Immunoblotting— Immunoblots, using protein lysates from neonatal brain, heart, and 
quadriceps/hamstring muscles to detect Oxct1/SCOT (rabbit anti-SCOT; Proteintech Group) were 
performed as described (51). Detection of phospho-AMPKα (p-AMPKα Thr-172) and total AMPKα was 
performed as described previously (126). Microtubule-associated protein 1 light chain 3 (LC3) was 
detected using rabbit polyclonal anti-LC3 (NB100-2220; Novus Biologicals) and donkey anti-rabbit IgG 
conjugated to horseradish peroxidase (NA9340; GE Healthcare). Band intensities were quantified 
densitometrically using QuantityOne software (Bio-Rad).  
Measurement of in Vivo Substrate Utilization— P0 mice were injected intraperitoneally with 10 µmol of 
sodium [2,4- 13C2]βOHB, [1-13C]glucose, or sodium [3-13C]lactate (Cambridge Isotope Laboratories) per 
g of body weight. Because P1 Oxct1-/- mice are hypoglycemic and hypolactatemic, 13C-isotope injections 
were supplemented in these animals with either 20µmol/g naturally occurring glucose, for [1-13C]glucose 
studies, or 10 µmol/g naturally occurring lactate, for [3-13C]lactate studies, to ensure tissue delivery of 
total and 13C-labeled substrate would remain equal among genotypes. After the indicated incubation 
durations in minutes, neonatal mice were killed by decapitation, and tissues were rapidly freeze-clamped 
in liquid N2. Neutralized perchloric acid extracts were profiled using gradient heteronuclear single-
quantum correlation 13Cedited proton NMR measured at 11.75 T. Quantification of integrals of carbon 2 
of [13C]taurine (a normalizing metabolite whose tissue concentrations were constant across conditions and 
which is not enriched by administration of these substrates) and [13C]glutamate (carbon 4) was performed 
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as described previously (51). Signals were collected from extracts dissolved in 300 µl of D2O + 1 mM 
trimethylsilyl propionate, loaded into high precision, thin walled 5-mm tubes (Shigemi). 




Ketolytic Deficiency in Oxct1-/- Mice—To determine the energetic role of ketone bodies in the neonatal 
period, Oxct1-/- mice were generated on the C57BL/6 genetic background (Fig. 2.1, A and B). 
Genotyping analysis of Oxct+/- X Oxct1+/- live progeny from 12 litters examined on postnatal days 0–1 
(P0–P1) indicated that progeny are born in a Mendelian ratio: 19 +/+, 40 +/-, and 25 -/- mice (χ2 = 0.5, p 
= 0.78). Body weights among +/+, +/-, and -/- mice did not vary on P0 or P1; gastric milk spots were 
observed with equal frequency within each genotype; and no gross anatomic or behavioral abnormalities 
were observed in P0–P1 Oxct1-/- mice (Table 1). As expected, Oxct1 mRNA and SCOT protein were 
reduced ~50% in P0 Oxct1+/- mice and were absent in Oxct1-/- mice (Fig. 2.1, C and D). Independent 
measurements of plasma biochemical metabolites on P0 and P1 revealed marked and progressive 
hyperketonemia in Oxct1-/- mice, with total ketone body concentrations increasing to ~16mM in Oxct1-/- 
mice on P1, consistent with accumulation of unmetabolized substrate (Table 2.1). An abnormally 
increased ratio of AcAc to βOHB is also consistent with a ketolytic lesion at the reaction catalyzed by 
SCOT: ligation of a CoA moiety to AcAc. Measurement of in vivo metabolism of [13C]βOHB in skeletal 
muscle of P0 Oxct1-/- mice, using 13C-edited proton NMR of extracts acquired 30 min after labeled 
substrate administration, confirmed the absence of 13C-enriched glutamate, a quantitative surrogate for 
procession of carbon through the tricarboxylic acid cycle, and accumulation of [13C]acetone and 
[13C]AcAc, products of [13C]βOHB that remain unmetabolized due to the absence of SCOT (Fig. 2.1E) 
(51,136). These findings were corroborated in P1 skeletal muscle and in P0 and P1 brain (supplemental 
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Fig. S2.1). Taken together, these results indicate that (i) Oxct1-/- mice are ketolysis-deficient and (ii) 
ketone body oxidation in mice does not notably proceed through SCOT-independent pathways.  
Ketoacidosis, Hypoglycemia, and Neonatal Lethality of Oxct1-/-Mice— Unlike P0–P1 progeny of Oxct+/- 
X Oxct1+/- pairings, genotyping analysis of live progeny from 14 litters between P2 and P10 yielded 34 
+/+, 50 +/-, and zero -/-mice (χ2 = 24.7, p = 0.0001). No lethality phenotype was evident in heterozygotes 
(χ2 = 0.92, p = 0.34). In addition to hyperketonemia, hypoglycemia and reduced plasma lactate 
concentrations were also observed in P1, but not P0 Oxct1-/- animals. Significant differences in plasma 
insulin, free fatty acid, and triglyceride concentrations were not observed (Table 2.1). In particular, the 
rise in plasma free fatty acid concentrations that occurs after birth in association with suckling of high fat 
milk was preserved in P1 Oxct1-/- mice(256,257).  
Although P1 Oxct1-/- mice exhibit marked hyperketonemia, relatively reduced plasma glucose and 
plasma lactate concentrations indicate that ketolytic insufficiency also results in diminution of other 
circulating metabolic fuels. To determine whether suckling Oxct1-/- mice could be rescued from these  
Metabolic abnormalities and prospective energetic deficiency, we performed metabolic resuscitation 
experiments using newborn progeny of Oxct+/- X Oxct1+/- mice. Serial subcutaneous injections of 155 mM 
NaHCO3 ± 10% glucose were delivered to suckling neonates (50 µl every 3–6 h; seven injections were 
administered/24 hr period). Although NaHCO3 partially buffers the acidifying effects of ketone bodies, 
glucose provides an additional energetic substrate that stimulates insulin release, thereby inhibiting 
ketogenesis and prospectively curtailing ketoacidosis in suckling Oxct1-/- mice (12,258). As expected, 
survival analysis revealed that control suckling Oxct1-/- mice injected with 155mM NaHCO3 alone 
exhibited similar survival and weight course as uninjected suckling Oxct1-/- animals, indicating that partial 
buffering of the acidifying effects of ketone bodies had no impact on survival (Fig. 2.2, n = 20 
pups/group). On the other hand, serial administration of NaHCO3 + glucose markedly improved the 
survival and weight trajectory of suckling Oxct1-/- mice in the first 48 h of life. However, by P3, Oxct1-/- 
animals maintained on the NaHCO3 + glucose regimen had fallen off a normal growth curve, and all 
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gradually died over an additional 2–3 days. No significant effects of the NaHCO3 + glucose, or NaHCO3 
alone regimens were observed in Oxct1+/+ or Oxct1+/- animals.  
To determine whether the failure-to-thrive phenotype observed within NaHCO3 + glucose-
resuscitated Oxct1-/- animals was attributable to an insufficiency of glucose uptake, plasma glucose 
concentrations were measured in resuscitated animals 30 and 180 min after NaHCO3 + glucose 
administrations in P2 Oxct1+/+, Oxct1+/-, and Oxct1-/- mice. In addition, because SCOT-dependent ketone 
body metabolism within pancreatic β cells may influence glucose-stimulated insulin secretion, we also 
measured plasma insulin 30 min after NaHCO3 + glucose administration in these mice (169,170). Our 
results indicate that postinjection glucose disposal and plasma insulin concentrations were not reduced in 
Oxct1-/- mice (Fig. 2.3, A and B). However, despite treatment with the resuscitation regimen, suckling 
Oxct1-/- mice still developed marked hyperketonemia (Fig. 2.3C). These results indicate that although 
systemic glucose uptake is intact in Oxct1-/- mice, the lethal metabolic consequences of ketolytic 
insufficiency in suckling mice are refractory to frequent glucose administration.  
Metabolic Adaptations of Oxct1-/- Mice— To determine whether the development of hypoglycemia and 
reduced plasma lactate concentrations result from metabolic adaptations to the loss of ketolytic capacity, 
we performed a series of experiments in neonatal Oxct1-/- mice and their littermates. First, we measured 
the abundance of the phosphorylated (active) form of the energy sensor/effector AMPKα in skeletal 
muscle, heart, and brain of untreated P0 Oxct1-/- mice and their P0 Oxct1+/+ littermates. To ensure that 
measured responses of Oxct1-/- mice were not downstream consequences of ketoacidosis and 
hypoglycemia, P0 mice were harvested within 3 h of birth. Protein lysates from skeletal muscle and heart 
of Oxct1-/- mice did not reveal evidence of AMPKα activation, but the phosphorylated form of AMPKα 
was augmented 6.9  ± 1.4-fold in brain of Oxct1-/- mice, suggesting tissue-specific adaptation to the 
absence of ketolysis (n = 7/group, p = 0.01; Fig. 2.4).  
Second, we determined whether autophagy was altered in Oxct1-/- mice. Autophagy is an AMPK-
activated self-degradative intracellular process in which organelles are recycled, prospectively in part for 
the purpose of energy conservation during periods of nutrient deprivation (259-261). Adaptation to 
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extrauterine life requires normal autophagic progression (262). To determine whether ketolytic deficiency 
in brain of P0 Oxct1-/- mice is accompanied by induction of autophagy, we measured a key biomarker of 
autophagic progression, the differential processing/migration of protein LC3 on SDS-PAGE (263). The 
relative abundance of the faster migrating form of LC3 (LC3-II:LC3-I ratio) was increased 2.0 ± 0.2-fold 
(n = 7/group, p = 0.001) in brain lysates of Oxct1-/- mice (Fig. 2.5). This result, which was not observed in 
skeletal muscle (data not shown), is consistent with a proautophagic response to energy deficiency in 
brain of Oxct1-/- mice.  
Third, to determine whether ketolytic insufficiency and the associated ultimate development of 
reduced plasma glucose and lactate concentrations were linked to increases in glucose and lactate 
utilization by tissues that normally oxidize ketones in Oxct1-/- mice, we used NMR to measure in vivo 
oxidative metabolism of independently administered [13C]glucose or [13C]lactate in brains and skeletal 
muscle of P0 and P1 Oxct1-/- mice and their littermates. Brain extracts obtained from P0 neonates 30 min 
after intraperitoneal administration of 10 µmol/g body weight [13C]glucose revealed 2.4  ± 0.2-fold 
increased accumulation of 13C-enriched glutamate in brains of Oxct1-/- mice compared with Oxct1+ mice 
(from 3.6 ± 0.8% to 8.5   ± 1.7%; n = 7/group, p = 0.002; Fig. 2.6A; no differences were observed 
between Oxct1+/+ and Oxct1+/- mice, which are combined and represented as Oxct1+). As expected, at the 
time of tissue harvest, tissue 13C enrichment of glucose (35.3% and 41.3% in Oxct1+and Oxct1-/- mice, 
respectively, p = 0.51) and total blood glucose concentrations were also equivalent between groups that 
received [13C]glucose, indicating that increased 13C-enrichment of glutamate could not be explained by 
increased delivery of 13C-substrate. These findings were corroborated in brain extracts of P0 animals 
collected 45 min after substrate injection: 13C-enrichment of glutamate was increased 2.8 ± 0.3-fold in 
brains of Oxct1-/- mice (n = 5/group, p = 0.02). Evidence for increased glucose utilization persisted in 
brains of Oxct1-/- mice on P1, which exhibited 1.8 ± 0.2-fold greater 13C-enrichment of glutamate in 
Oxct1-/- brains than by brains of Oxct1+ littermates 30 min after substrate administration (n = 7/group, p = 
0.02; Fig. 2.6A). Because P1 Oxct1-/- mice are hypoglycemic, this experiment was performed by 
administering a mixture of 13C-labeled and naturally occurring glucose (see “Experimental Procedures”), 
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which prevented disproportionately high delivery of labeled glucose to brains of Oxct1-/- mice. Taken 
together, these results are consistent with a higher rate of glucose oxidation in brains of Oxct1-/- mice on 
both P0 and P1, which possibly contributes to the ultimate development of hypoglycemia.  
Unlike brain of Oxct1-/- mice, evidence for increased glucose oxidation was not observed in 
skeletal muscle, which, after 30 min of [13C]glucose administration, revealed only scant 13C-enrichment of 
glutamate in Oxct1+ (1.4 ± 0.2%) or Oxct1-/- mice (1.9 ± 0.3%). After 45 min, 13C-enrichment of 
glutamate increased equally to ~3% in Oxct1+ and Oxct1-/- mice. Similar results were observed in muscle 
of P1 mice.  
To obtain surrogates of in vivo lactate oxidation in neonatal mice, we measured [13C]glutamate in 
brains and skeletal muscles of P0 animals 30 min after administration of 10 µmol/g [13C]lactate. In Oxct1+ 
and Oxct1-/- mice, 13C labeling of glutamate in brain was greater through [13C]lactate than that delivered 
through [13C]glucose. Nonetheless, there was no difference between brains of Oxct1+ and Oxct1-/- mice 
(11.1 ± 3.0% and 12.0 ± 3.7%, respectively, n = 5/group, p – 0.84). Conversely, 13C enrichment of 
glutamate from lactate was enhanced in skeletal muscle of P0 Oxct1-/- mice by 1.7 ± 0.2-fold compared 
with skeletal muscle of Oxct1-/- mice (7.9 ± 0.8% and 4.5 ± 0.7%, respectively, n = 5/group, p = 0.02; Fig. 
2.6B). As expected, 13C enrichment of substrate was not greater in skeletal muscle of P0 Oxct1-/- mice. 
Increased lactate oxidation rates did not persist to P1 in skeletal muscle, which were 5.5 ± 0.4% and 5.0 ± 
0.8% in P1 Oxct1+ and Oxct1-/- mice, respectively (n = 5/group, p = 0.6; Fig. 2.6B). Taken together, these 
results indicate (i) increased oxidation of lactate in skeletal muscle of P0 but not P1 and Oxct1-/- mice and 
(ii) adaptation of both neonatal brain and skeletal muscle to ketolytic insufficiency. 
 
Discussion 
Introduction to the extrauterine environment creates new metabolic and energetic demands. Studies of 
metabolic flux and ketone turnover have indicated that ketone bodies serve an important role in neonatal 
rodents and humans (20,71,244,248,256,257). This is the first study to use a genetic model to demonstrate 
that oxidation of ketones is required for postnatal survival in mice. Oxct1-/- mice exhibit no evidence of 
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terminal ketone body oxidation and develop ketoacidosis, indicating that the SCOT pathway is required 
for ketolysis in mice. Furthermore, plasma glucose and lactate levels become depleted in Oxct1-/- mice 
after the first 24 h of extrauterine life. Increased oxidation of glucose and lactate is observed, starting 
prior to the depletion of these metabolites in plasma, suggesting that increased consumption, at least in 
part, contributes to their depletion.  
Although reduced nutrient ingestion could also contribute to ketoacidosis, hypoglycemia, and 
hypolactatemia, our results, together with those of prior investigators, strongly suggest that these 
abnormalities occur in actively suckling neonatal Oxct1-/- mice. First, because mice and rats (unlike 
humans) possess very little white adipose stores at birth, neonatal ketogenesis, robust in Oxct1-/- mice, is 
dependent on suckling (256,257,264). Second, plasma free fatty acid concentration, a reporter of milk 
intake and a key determinant of ketogenesis, exhibited increases in P1 versus P0 Oxct1-/- mice, 
comparable with the increase observed in Oxct1+ littermates. Plasma triglyceride concentrations were also 
not reduced in Oxct1-/- mice. Although ingested milk volumes were not formally quantified, Oxct1-/- mice 
exhibited gastric milk spots with equal frequency to their littermates on P0 and P1. Thus, these studies 
indicate that loss of ketone oxidation in postnatal mice provokes a metabolic state that ultimately proves 
lethal, despite access to metabolic fuels through milk.  
Reduced plasma glucose and lactate concentrations in P1 Oxct1-/- mice are prospectively 
explained by increased oxidation of glucose and lactate, but hypoglycemia and hypolactatemia also may 
occur due to insufficient biosynthesis. During the rodent suckling period, biosynthesis of glucose and 
lactate are driven by hepatic gluconeogenesis and extrahepatic glycolysis, respectively (20). Altered 
mitochondrial redox potential of Oxct1-/- mice could contribute to prospective synthetic deficiencies. In 
neonatal Oxct1+ mice, plasma βOHB:AcAc ratio is 3:1, consistent with reported ratios in ketotic states 
(2,258). In hyperketonemic Oxct1-/- mice, this ratio is markedly reduced to 1:2 on P0, due to oxidation of 
βOHB to, and no further than, AcAc, which significantly alters mitochondrial [NAD+]:[NADH] ratio, 
particularly in extrahepatic tissues. Altered mitochondrial redox potential could in turn impair flux 
through the malate-aspartate shuttle, whose function is important for glycolysis, the source of lactate. In 
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turn, curtailed lactate production deprives the liver of a key gluconeogenic substrate, via the Cori cycle. 
Furthermore, in P1 Oxct1-/- mice, plasma concentrations of βOHB and AcAc accumulate to very high 
concentrations, while remaining in a ratio of 1:3, which may evoke extrahepatic and hepatic impairments 
of the tricarboxylic acid cycle and fatty acid oxidation. Oxidative impairment within liver disrupts 
gluconeogenesis (20,265-267). Emergence of attenuated extrahepatic oxidative capacity was evident in  
Oxct1-/- mice on P1, when glucose oxidation in brain and lactate oxidation in skeletal muscle were both 
reduced in Oxct1-/- mice, relative to P0 Oxct1-/- mice.  
An additional abnormality of ketone metabolism may also occur in Oxct1-/- mice. In humans, up 
to 37% of AcAc is spontaneously decarboxylated to acetone (268). Therefore, with accumulation of high 
concentrations of AcAc, it is likely that acetone also accumulates in normally ketolytic tissues of Oxct1-/- 
mice, a notion supported by our NMR findings. Acetone is disposed through breath and urine, but a 
significant proportion of acetone can also be used as a substrate for anabolic and catabolic processes 
through SCOT-independent pathways (268). High circulating concentrations of acetone may also cause 
central nervous system depression.  
It is important to note that the precise roles of neonatal ketone metabolism differ between mice 
and humans. Humans are born at a more mature point in development, and as indicated above, at the time 
of birth, body fat percentage is higher in humans than in rats and mice (256,264,269-271). In these 
neonatal rodents, ketogenesis is driven by suckling, rather than fasting (256,257). Moreover, due to 
increased fat/carbohydrate ratio, rodent milk is more ketogenic than most human milk and infant formulas 
(9,20). It is likely for these reasons that two features of Oxct1-/- mice are distinct from those of SCOT 
deficient humans: (i) autosomal recessive OXCT1 mutations in humans are compatible with life (albeit 
with aggressive nutritional support), whereas analysis of ~100 litters of Oxct1+/- X Oxct1+/- pairings has 
yet to reveal any male or female Oxct1-/- neonate that spontaneously survives past 48 h of extrauterine life; 
and (ii) Oxct1-/- mice develop hypoglycemia, unlike most SCOT-deficient humans. Despite these 
differences, deficiencies of ketone metabolism in neonatal mice bear significant relevance to human 
infant metabolism. First, physiological ketosis (1-2mM) occurs in the early neonatal period in both 
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humans and mice (2,71,244,272,273). Second, human infants are particularly prone to develop 
hyperketonemia and thus, increased energetic utilization of ketones, in response to relatively short periods 
of nutrient deprivation, due to adipose lipolysis (2,4,20,248,274). Consequences of common viral 
illnesses can rapidly trigger ketosis. Third, human milk exhibits significant variations of macronutrient 
content distribution, even within the same mother over different collections (275,276).  Therefore, it is 
plausible that energetic crisis and/or ketoacidosis could emerge in infants with unsuspected ketolytic 
insufficiency. Current newborn screening regimens do not detect individuals with isolated ketolytic 
disorders, who exhibit ketosis but normal acylcarnitine and organic acid profiles (99). Therefore, a small 
subset of cases which ultimately receive a diagnosis of sudden infant death syndrome (SIDS) may 
actually be attributable to SCOT deficiency.  
Although our studies did not directly measure prospective changes in glycolytic flux or metabolic 
shifts within myocardium (the particularly low mass of neonatal mouse heart, ~10 mg, prevented tractable 
NMR approaches), these results indicate both toxic effects of and metabolic adaptation to ketolytic 
insufficiency in the neonatal period. Future experiments will determine definitively the relative 
contributions of ketoacidosis, hypoglycemia, and energy deficiency to lethality of Oxct1-/- mice. Further 
measurement of the energetic roles of ketone bodies in mouse models will be best supported through 
studies in which (i) a lower fat nonketogenic nutrient formula replaces mother’s milk in the neonatal 
period and/or (ii) additional genetic approaches selectively induce a ketolytic defect within individual 
tissues. Such studies will ultimately permit determination of energetic and disease-modifying roles of 
ketolysis in neonates and adults in conditions that include nutrient deprivation, maintenance on low 
carbohydrate diets, and diabetes. Finally, with increasing utilization of low and very low carbohydrate 
diets in clinical trials for conditions including adult obesity, pediatric and adult epilepsy, and 
malignancies of the central nervous system, it is important to consider the metabolic and clinical 
consequences of latent ketolytic defects that are revealed later in life, possibly caused by single nucleotide 
polymorphisms within the OXCT1 locus; case reports describe marked variations of tolerance to 
ketogenic milieus (277-279). These studies indicate the critical metabolic role that ketone body oxidation 
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Figure 2.1. Ketolysis-deficient Oxct1-/- mice. A, targeting strategy for the Oxct1 locus in ES cells. WT, 
wild-type locus; Null, loss-of-function allele. Arrows indicate locations of genotyping PCR primers. See 
supplemental Table S1 for a list of primer sequences. B, PCR genotyping of Oxct1-/- P0 mice. NTC, no 
template control. C, expression of Oxct1 mRNA in heart of P0 Oxct1+/+, Oxct1+/-, and Oxct1-/- mice, 
determined by RT-quantitative PCR; n = 5/group. D, immunoblot of SCOT and actin using protein 
lysates from brain, heart, and quadriceps/hamstrings skeletal muscle of P0 Oxct1+/+, Oxct1+/- , and Oxct1-/- 
mice. E, 13C-edited proton NMR spectrum (2.1–2.5 ppm, relative to chemical shift of trimethylsilyl 
propionate internal standard) from quadriceps/hamstrings of P0 Oxct1+/+ and Oxct1-/- mice that had been 
injected with [2,4-13C2]βOHB 30 min prior to collection of tissues and generation of extracts. 
[13C]Glutamate is a reporter of tricarboxylic acid flux of a 13C-labeled substrate that is selectively absent 
in extracts from Oxct1-/- mice. C2 and C4 correspond to carbon position. 
 
Figure 2.2. Metabolic resuscitation of Oxct1-/- mice. A, Kaplan-Meier curves for neonatal mice in the 
untreated, treated with 155 mM NaHCO3 alone, or treated with 155 mM NaHCO3 + 10% glucose (glc) 
states. Subcutaneous injections were performed every 3–6 h, starting within 3h of birth, with seven 
injections over a 24-h period. Oxct1+/+ and Oxct1+/- mice showed no differences and were pooled (noted as 
Oxct1+). Within the first 90 h of life, no statistically significant differences were observed among treated 
Oxct1+ mice, untreated Oxct1+ mice, and Oxct1-/- mice treated with NaHCO3 + glucose. Likewise, no 
statistically significant difference was observed between Oxct1-/- mice treated with NaHCO3 alone and 
untreated Oxct1-/- mice. However, addition of glucose to the NaHCO3 regimen significantly improved 
survival of Oxct1-/- mice in the first 90 h of life (p < 0.001 by log-rank test, n = 20/group). B, relative 
weights of animals within the genotype and treatment groups described in A. ***, p < 0.001 by two-way 
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ANOVA with post hoc Bonferroni testing, independently compared with each of the other treatment 
groups. 
 
Figure 2.3. Normal glucose disposal but refractory hyperketonemia in glucose-resuscitated suckling 
Oxct1-/- mice. A, blood glucose concentrations measured on P2 within neonatal mice treated with the 
NaHCO3 + glucose resuscitation regimen every 3–6 h. Measurements were taken independently 30 and 
180 min after administration of NaHCO3 + glucose. B, plasma insulin concentrations within resuscitated 
mice, 30 min after NaHCO3 + glucose administration. NS, not significant. C, total plasma ketone 
concentration ( βOHB + AcAc) within resuscitated mice, 30 min after NaHCO3 + glucose administration. 
For all comparisons, Oxct1+/+ and Oxct1-/- mice showed no differences and were pooled (noted as Oxct1+). 
n = 7/group; ***, p < 0.001 by Student’s t test. 
 
Figure 2.4. Increased phosphorylation of AMPKα  within brain of Oxct1-/- mice. A–C, immunoblots 
of lysates from untreated animals: skeletal muscle (A), heart (B), and brain (C) protein lysates from P0 
Oxct1+/+ and Oxct1-/- mice for phospho-AMPKα (p-AMPKα), total AMPKα, SCOT, and actin. D, 
densitometric quantification of p-AMPKα:AMPKα ratio in brain lysates. **, p < 0.01 by Student’s t test. 
 
Figure 2.5. Enhanced autophagy in brain of Oxct1-/- mice. A, immunoblots of P0 brain protein lysates 
for LC3 and actin. B, densitometric quantification of LC3-II:LC3-I ratios in brain lysates. ***, p < 0.001 
by Student’s t test. 
 
Figure 2.6. Tissue-specific adaptations to ketolytic insufficiency. A, accumulation of [13C]glutamate 
carbon 4 (C4) in brains of P0 (left) and P1 (right) mice injected with [1-13C]glucose, measured by 13C-
edited proton NMR. n = 7/group. B, accumulation of [13C]glutamate in skeletal muscle of P0 (left) and P1 
(right) mice injected with [3-13C]lactate, measured by 13C-edited proton NMR. n = 5/group; **, p < 0.01 
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by Student’s t test. 
 
Figure S2.1. Absence of terminal ketone body oxidation in muscle and brain of Oxct1-/-  mice. 13C-
edited proton NMR spectra (2.1-2.5 ppm, relative to chemical shift of TSP internal standard) from 
extracts derived from muscle (A) and brain (B) of P0 (left panels) or P1 (right panels) Oxct1+/+ and Oxct1-
/-
  mice. Animals were injected with 10 µmol/g body weight [2,4-13C2]βOHB 30 min prior to collection of 
tissues and generation of extracts. 13C-glutamate (glu; resonances of protons on carbon #4 are shown) is a 
reporter of tricarboxylic acid flux of a 13C-labeled substrate that is selectively absent, above naturally-











































Successful adaptation to ketosis by mice with tissue-specific deficiency of ketone body oxidation   
The work presented in this chapter has been adapted from: 
Cotter, D. G., Schugar, R. C., Wentz, A. E., d'Avignon, D. A., and Crawford, P. A. (2013) Am J Physiol 
Endocrinol Metab 304(4), E363-374 
Abstract 
During states of low carbohydrate intake, mammalian ketone body metabolism transfers energy substrates 
originally derived from fatty acyl chains within the liver to extrahepatic organs. We previously 
demonstrated that the mitochondrial enzyme CoA transferase (succinyl-CoA:3-oxoacid CoA transferase, 
SCOT, encoded by nuclear Oxct1) is required for oxidation of ketone bodies, and that germline SCOT-
knockout (KO) mice die within 48h of birth due to hyperketonemic hypoglycemia. Here, we use novel 
transgenic and tissue-specific SCOT-KO mice to demonstrate that ketone bodies do not serve an obligate 
energetic role within highly ketolytic tissues during the ketogenic neonatal period or during starvation in 
the adult. While transgene-mediated restoration of myocardial CoA transferase in germline SCOT-KO 
mice is insufficient to prevent lethal hyperketonemic hypoglycemia in the neonatal period, mice lacking 
CoA transferase selectively within neurons, cardiomyocytes, or skeletal myocytes, are all viable as 
neonates. Like germline SCOT-KO neonatal mice, neonatal mice with neuronal CoA transferase 
deficiency exhibit increased cerebral glycolysis and glucose oxidation, and while these neonatal mice 
exhibit modest hyperketonemia, they do not develop hypoglycemia. As adults, tissue-specific SCOT-KO 
mice tolerate starvation, exhibiting only modestly increased hyperketonemia. Finally, metabolic analysis 
of adult germline Oxct1+/- mice demonstrates that global diminution of ketone body oxidation yields 
hyperketonemia, but hypoglycemia emerges only during a protracted state of low carbohydrate intake. 
Together, these data suggest that, at the tissue level, ketone bodies are not a required energy substrate in 
the newborn period or during starvation, but rather that integrated ketone body metabolism mediates 




Adaptation to limited carbohydrate availability and increased fatty acid supply, as encountered during the 
initial transition to extrauterine life, starvation, and adherence to low-carbohydrate diets, requires shifts in 
metabolic substrate utilization (2,4,5,20). While many organs are poised to meet the bioenergetic 
demands imposed by fat-dominated energy economies, neurons do not effectively derive high-energy 
phosphates from fatty acids (69,70). Thus, provision of alternate fuel sources may be required to preserve 
bioenergetic homeostasis within some tissues when carbohydrates are limiting. Ketone body metabolism 
supports this function by oxidizing hepatic fatty acyl-coenzyme A species (acyl-CoAs) to water-soluble 
four carbon ketone body intermediates (via ketogenesis) that are shared with extrahepatic tissues for 
terminal oxidation. Most ketogenesis occurs within hepatic mitochondria, at rates proportional to β-
oxidation of fatty acids (5). Sequential ketogenic reactions catalyzed by mitochondrial thiolase, 
hydroxymethylglutaryl-CoA synthase (HMGCS2) and hydroxymethylglutaryl-CoA lyase convert acetyl-
CoA to the ketone body acetoacetate (AcAc), which is reduced by mitochondrial D-β-hydroxybutyrate 
(βOHB)-dehydrogenase (BDH1) to D-βOHB in an NAD+/NADH-coupled redox reaction (44). D-βOHB 
and AcAc are secreted from the liver via monocarboxylate SLC16A transporters, transported into 
extrahepatic cells via SLC16A transporters, and oxidized in the mitochondrial matrix (4,26,27). 
Mitochondrial BDH1 re-oxidizes D-βOHB to AcAc, and covalent activation of AcAc by CoA is 
catalyzed by the mitochondrial matrix enzyme succinyl-CoA:3-oxoacid CoA transferase [SCOT (encoded 
by the nuclear gene Oxct1), the only mammalian CoA transferase] to generate AcAc-CoA, which upon 
thiolytic cleavage, liberates acetyl-CoA that enters the tricarboxylic acid (TCA) cycle for terminal 
oxidation (74). CoA transferase catalyzes a near equilibrium reaction in which CoA is exchanged between 
succinate and AcAc (72,280). As such, unlike glucose and fatty acids, ketone bodies do not directly 
require commitment of ATP for activation of the substrate prior to oxidation. 
Ketone bodies are efficient energetic substrates that are oxidized in proportion to their delivery 
(4,20). The neonatal brain extracts ketones at rates up to 40 times those of the adult brain, and ketone 
body oxidation can support as much as 25% of the neonate’s basal energy requirements (71,248). 
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Neurons oxidize fatty acids poorly, and glucose utilization accounts for only 70% of the postnatal brain’s 
energetic needs (69,71). Thus, ketogenesis, which converts up to two-thirds of hepatic β-oxidation-
derived acetyl-CoA into ketones (281), has been proposed as a facilitator of evolution of the vertebrate 
brain and of human brain size (40,41). Nonetheless, an energetic requirement for ketone body oxidation 
has never been demonstrated, even though it is thought to become a primary contributor to bioenergetic 
homeostasis (2,84). Ketogenesis is also required for normal fitness in humans, as loss-of-function 
mutations in the gene encoding the fate-committing hepatic ketogenic enzyme HMGCS2 result in 
pediatric hypoketonemic hypoglycemia (66,68), and CoA transferase deficiency in humans manifests as 
spontaneous pediatric ketoacidosis (80,81,98), which is associated with hypoglycemia in severe cases, 
and may account for a subset of cases of idiopathic ketotic hypoglycemia (79,102). Germline SCOT-KO 
mice, which cannot terminally oxidize ketone bodies in any tissue, universally die within 48 hr of birth 
due to hyperketonemic hypoglycemia (78). Here we use novel genetic mouse models of gain- and loss-of-
CoA transferase function to determine whether ketone body oxidation is required within specific cell 
types for metabolic adaptation and survival during the neonatal period and in adult starvation. 
 
Materials and Methods 
Animals. Oxct1-/- (germline SCOT-KO) mice were previously generated by using targeted C57BL/6 
mouse embryonic stem cells obtained from the NIH-Knockout Mouse Project (clone EPD0082-1-CO2), 
which were obtained and injected into C57BL/6 blastocysts in house (78). Transgenic mice that 
overexpress CoA transferase in cardiomyocytes (SCOT-Heart-OVEX mice) were generated on the 
C57BL/6 background. Murine Oxct1 cDNA was sub-cloned downstream of the α-MHC (myosin heavy 
chain, Myh6) promoter (282), and after liberation of vector sequences, the expression cassette (Fig. 3.1A) 
was purified and injected into the male pronucleus of fertilized oocytes prior to implantation. One founder 
strain expressing the transgene was obtained, and these SCOT-Heart-OVEX mice are viable, fertile, and 
indistinguishable from wild-type littermates. SCOT-Heart-OVEX mice were successively crossed to 
Oxct1+/- mice to generate α-MHC-Oxct1;Oxct1-/- mice (SCOT-Heart-OVEX; SCOT-KO mice). 
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The targeting construct for the gene that encodes CoA transferase, Oxct1, permitted a ‘germline 
knockout first’ (283) approach that allows subsequent generation of a conditional ‘floxed’ allele. To 
generate tissue-specific SCOT-KO mice, Oxct1+/- mice were first crossed to C57BL/6 mice that 
ubiquitously express Flp recombinase (β-actin-Flp, Jackson Laboratory) to generate Oxct1+/flox mice, 
through germline recombination. An additional round of breeding yielded Oxct1flox/flox mice (Fig. 3.1B). 
Oxct1 exon 6 contains 107 nucleotides, which in the Oxct1flox allele (which encodes functional CoA 
transferase) is flanked by loxP recognition sequences for Cre recombinase. Therefore, when excised by 
cell type-specific Cre recombinase, the recombination event results in a nonsense coding mutation. See 
Table 3.1 for a list of primers used for genotyping. 
Cardiomyocyte-, skeletal muscle-, or neuron-specific SCOT-KO mice were generated by 
successive rounds of breeding of Oxct1flox/flox mice independently to three strains expressing Cre 
recombinase, each on the C57BL/6 background: α-MHC-Cre, HSA-Cre (human skeletal muscle actin 
promoter), or Synapsin I-Cre, respectively (284-286). Each of these strains effects cell type-specific 
recombination through loxP recognition sites by embryonic day (E)12.5 (284-287). In addition, Synapsin 
I-Cre mediates recombination of floxed alleles in the male germline (288). This facilitated generation of 
SCOT-Neuron-KO mouse lines with either one (flox/rec) or two (flox/flox) functional Oxct1 alleles in the 
germline (Fig. 3.1B). Mice with the germline flox/rec genotype are functionally whole-body 
heterozygotes, and germline flox/flox mice are functionally wild-type mice. 
Unless otherwise noted, all mice were maintained on standard polysaccharide-rich chow diet (Lab 
Diet 5053) and autoclaved water ad libitum. For the ketogenic diet studies, mice were maintained for two 
weeks on a low protein, very low carbohydrate, and high fat ketogenic diet (Bio-Serv F3666) in which 
94.1% of calories are from fat, 4.6% from protein, and 1.3% from carbohydrates. Lights were off between 
1800 and 0600. All postnatal day (P)0 (i.e., the first day of extrauterine life) litters were obtained at 0900 
and tissues and blood were harvested mid-morning. Mice were housed in groups of 3-5 for fasting 
experiments on sawdust bedding. Fasting and ketogenic diet were initiated in six week-old male mice. All 
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experiments were conducted using protocols approved by the Animal Studies Committee at Washington 
University. 
CoA transferase activity assay. CoA transferase enzymatic activity was measured in neonatal tissue 
lysates using an adapted protocol (92). Neonatal tissues were collected and snap frozen in liquid nitrogen 
and stored at -80º C until processing. Tissues were homogenized in phosphate-buffered saline (PBS, pH 
7.2) with protease inhibitors (complete mini EDTA-free protease inhibitor cocktail, Roche) in a glass 
dounce homogenizer on ice. Lysates were centrifuged at 20,000 x g at 4º C for 20 min and supernatants 
were used as a source of CoA transferase. Assays contained 100 µg protein (determined by Micro BCA 
Protein Assay Kit, Thermo Scientific) in a final volume of 100 µL, consisting of 50 mM Tris-HCl pH 8.5, 
10 mM MgCl2, and 4 mM iodoacetamide. Absorbance at 313 nm, at which AcAc-CoA absorbs 
maximally, was followed in unstimulated and stimulated (1 mM succinyl-CoA + 10 mM AcAc) replicates 
for 2 min and normalized to an AcAc-CoA standard curve to determine rates of AcAc-CoA production. 
Base hydrolysis of ethyl-AcAc (Sigma W241512) was performed by addition of 50% NaOH to pH 12 and 
incubation at 60º C for 30 min. Base hydrolyzed AcAc was adjusted to pH 8.5, and [AcAc] was 
confirmed using standard biochemical assays coupled to colorimetric substrates (Wako), as described 
previously (51).   
Serum metabolite measurements. Measurements of serum AcAc, D-βOHB, free fatty acids, and glucose 
were performed using standard biochemical assays coupled to colorimetric substrates (Wako), as 
described previously (51). AcAc concentrations were determined by measuring total ketone body (TKB) 
concentrations and subtracting the corresponding measured D-βOHB concentration. Neonatal blood 
glucose was measured in duplicate using glucometers (Aviva).  
Gene expression analysis. Quantification of gene expression was performed using real-time RT-
quantitative PCR using the ΔΔCt approach as described, normalizing to Rpl32, using primer sequences 
listed within Table 3.2 (51). 
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Immunoblotting. Lysates from neonatal brain, heart, and quadriceps/hamstring muscles were generated in 
a protein lysis buffer: 20 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% phosphatase 
inhibitor cocktail (Sigma), and protease inhibitor cocktail (complete mini EDTA-free, Roche), pH 7.5. 
Immunoblots to detect CoA transferase (rabbit anti-SCOT, Proteintech Group) and actin (rabbit anti-actin, 
Sigma) were performed as described (78). Band intensities were quantified densitometrically using 
QuantityOne software (Bio-Rad). For hippocampal immunoblots, brains were rapidly isolated and 
hippocampal dissections were performed in PBS on ice using a dissecting microscope. 
In vivo substrate utilization. Neonatal mice were injected intraperitoneally with 10 µmol [1-13C]glucose 
(Cambridge Isotope Laboratories) per g of body weight. After 30 min incubation durations, neonatal mice 
were killed by decapitation, and tissues were rapidly freeze-clamped in liquid N2. Neutralized and 
lyophilized perchloric acid extracts were profiled using gradient heteronuclear single-quantum correlation 
[13C]edited proton nuclear magnetic resonance (NMR) measured at 11.75 T. Signals were collected from 
extracts dissolved in 275 µL D2O + 1 mM trimethylsilyl propionate, loaded into high precision, thin 
walled 5-mm tubes (Shigemi). Quantification of integrals of carbon 2 of [13C]taurine (a normalizing 
metabolite whose tissue concentrations were constant across conditions and which is not enriched by 
administration of these substrates),  [13C]lactate (carbon 2), and [13C]glutamate (carbon 4) was performed 
as described previously (78).  
Measurements of body composition. Percent body fat and lean body mass were determined in awake adult 
animals using an EchoMRI instrument (Echo Medical Systems, Houston, TX). 
 
Results  
Restoration of myocardial ketone body oxidation in germline SCOT-KO mice does not prevent lethal 
hyperketonemic hypoglycemia. Tissues that lack CoA transferase protein and activity cannot terminally 
oxidize ketone bodies, and germline SCOT-KO mice invariably die within 48 hr of birth due to lethal 
hyperketonemic hypoglycemia (78). Myocardium is the highest ketone body consumer per unit mass 
(2,43,76). To determine if selective restoration of myocardial CoA transferase activity was sufficient to 
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prevent lethal hyperketonemic hypoglycemia in SCOT-KO mice, transgenic mice harboring Oxct1 cDNA 
under control of the α-MHC promoter (α-MHC-Oxct1) were successively bred to Oxct1+/- heterozygous 
mice to ultimately yield SCOT-Heart-OVEX; SCOT-KO mice (Fig. 3.1). Selective restoration of CoA 
transferase expression and activity on the first postnatal day, P0, was confirmed by immunoblot (Fig. 
3.2A) and CoA transferase enzyme activity assays (Fig. 3.2B) using neonatal tissue extracts. Despite 
restoration of myocardial CoA transferase activity to a magnitude that modestly exceeded wild type 
levels, SCOT-Heart-OVEX; SCOT-KO mice still develop hyperketonemic hypoglycemia with 
abnormally elevated AcAc/D-βOHB serum ratios (Fig. 3.2C-D). Genotypic analysis of > 25 litters 
derived from α-MHC-Oxct1; Oxct1+/- crosses did not yield any SCOT-Heart-OVEX; SCOT-KO mice 
after P1 (data not shown), indicating that neonatal lethality ensues despite restoration of myocardial 
ketolysis in germline SCOT-KO mice. 
Tissue-specific CoA transferase knockout mice are viable. To mechanistically dissect the energetic roles 
of ketone body oxidation in individual tissues, we individually eliminated CoA transferase from the three 
cell types most adapted to ketone body oxidation (2,76) – cardiomyocytes, skeletal myocytes, and 
neurons – to generate SCOT-Heart-KO, SCOT-Muscle-KO, and SCOT-Neuron-KO mice, respectively 
(see Fig. 3.1B). Tissue-specific loss of CoA transferase protein was confirmed in each tissue-specific 
mouse strain on P0 by immunoblot and CoA transferase activity assay (Fig. 3.3A-C). CoA transferase is 
present and active in astrocytes (70,289), and likely explains residual enzymatic activity in brains of 
SCOT-Neuron-KO neonates (Fig. 3.3C). Absence of CoA transferase in neurons of SCOT-Neuron-KO 
mice was further confirmed by immunoblot of protein lysates derived from adult hippocampi 
(hippocampus exhibits an increase in neuronal density relative to other brain regions) (Fig. 3.3D). Each 
tissue-specific SCOT-KO mouse strain is viable, exhibits normal body size (see below), and is fertile. 
Unlike germline SCOT-KO mice, which develop neonatal hyperketonemic hypoglycemia with 
abnormally elevated plasma AcAc/βOHB ratios by the second postnatal day (P1) [Fig. 3.2C and ref (78)], 
tissue-specific SCOT-KO neonatal mice do not exhibit hypoglycemia, marked hyperketonemia, or 
abnormal ratios of serum AcAc/βOHB (Fig. 3.4A-B). The Synapsin-1-Cre transgene, used to generate 
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SCOT-Neuron-KO mice, also mediates recombination of floxed alleles within the male germline, 
resulting in a null (rec) allele (Fig. 3.1B), which is transmitted to most progeny (288). This enabled 
generation of SCOT-Neuron-KO and control mice with either one (flox/rec) or two (flox/flox) functional 
Oxct1 alleles in the germline. Hypoglycemia and hyperketonemia do not develop in neonatal flox/rec 
mice (Fig. 3.4), consistent with previous observations of neonatal Oxct1+/- mice (78). Of the three tissue-
specific models of CoA transferase deficiency, only SCOT-Neuron-KO mice develop mild 
hyperketonemia on P1 (mean serum total ketone body concentrations 0.85 ± 0.05 mM vs. 1.60 ± 0.25 
mM, in flox/flox control and SCOT-Neuron-KO mice on the flox/flox germline background, respectively, 
n = 5-8 per group, p  < 0.001) (Fig. 3.4B). On P1, ketonemia did not differ between SCOT-Neuron-KO 
mice on the flox/flox and flox/rec germline backgrounds (Fig. 3.4B). Furthermore, unlike the large 
increase in AcAc/βOHB ratios of germline SCOT-KO mice compared to littermate controls (Fig. 3.2C), 
these ratios did not significantly differ in any of the tissue-specific models (Fig. 3.4B). 
Neuronal CoA transferase deficiency results in increased glucose utilization in the neonatal brain. 
Because brains of neonatal germline SCOT-KO mice exhibit increased glucose oxidation (78), we 
quantified the fates of [13C]glucose in brains of P2 SCOT-Neuron-KO mice (flox/rec background) and 
genotype control mice, and observed increased glycolytic and oxidative metabolism of glucose in brains 
SCOT-Neuron-KO mice: [13C]lactate abundance, a reporter of glycolytic metabolism, was 2.31 ± 0.45 
fold greater (p < 0.05, n = 4/group Fig. 3.5A), and [13C]glutamate abundance, which quantitatively reports 
the rate of entry of [13C]acetyl-CoA into the TCA cycle for terminal oxidation (136), was 2.11 ± 0.29 fold 
greater in SCOT-Neuron-KO mice, compared to flox/rec control neonatal mice (p < 0.05, n = 4/group; 
Fig. 3.5B). Nevertheless, SCOT-Neuron-KO mice remain euglycemic (Fig. 3.4A) and do not exhibit 
molecular signatures of enhanced hepatic gluconeogenesis [expression of the mRNA encoding 
phosphoenolpyruvate carboxykinase (Pck1) is normal in livers of SCOT-Neuron-KO mice], or altered 
ketogenesis (hepatic Hmgcs2 and Bdh1 expression were also normal, Fig. 3.5C).  
Oxidation of ketone bodies within neurons, cardiomyocytes, and skeletal myocytes is dispensable during 
moderate starvation in the adult. Ketone body metabolism supports bioenergetic homeostasis when 
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carbohydrate supply is limited, such as in starvation, by providing an alternative fuel source to energy 
sensitive tissues (2,4). To directly test the hypothesis that individual tissues require ketone bodies for 
energy transfer to support survival and glycemia in the post-absorptive state, SCOT-Neuron-KO (on the 
flox/flox and flox/rec germline backgrounds), SCOT-Heart-KO, and SCOT-Muscle-KO mice were fasted 
for 48h. Surprisingly, none of these tissue-specific SCOT-KO mouse strains exhibited fasting-induced 
hypoglycemia, compared to fasted genotype- and age-matched control mice (Fig. 3.6A). While SCOT-
Muscle-KO and SCOT-Neuron-KO mice exhibit hyperketonemia compared to SCOT-Heart-KO and 
flox/flox control mice (Fig. 3.6B), mice from each of these strains exhibited normal serum AcAc/D-βOHB 
ratios after a 48h fast (Table 3.3) and normal fasting-induced weight loss (Fig. 3.6C). In addition, adult 
SCOT-Neuron-KO mice on the flox/flox and flox/rec backgrounds are metabolically indistinguishable 
during moderate starvation: these SCOT-Neuron-KO mouse strains do not differ in serum ketone body 
concentrations, blood glucose, body weight, or serum AcAc/D-βOHB ratios during fasting (Fig. 3.6 and 
Table 3.3). Conversely, germline flox/rec mice with intact neuronal CoA transferase do develop 
hyperketonemia relative to flox/flox control mice at 48h starvation (Fig. 3.6B). Taken together, these 
results indicate that ketone body oxidation is not required for energy transfer at the cellular or tissue level 
in the post-absorptive state for survival or preservation of glycemia.  
Relative deficiency of ketone body oxidation influences the response to a chronic ketogenic nutrient 
milieu. While tissue-specific SCOT-KO models have utility in determining the metabolic roles of 
ketolysis within individual tissues, naturally-occurring variations in ketone body oxidative capacity in 
humans likely affect all ketolytic cell types (79-81,97,101,148,149,290). Germline CoA transferase 
heterozygous (Oxct1+/-) mice are metabolically indistinguishable from Oxct1+/+ (wild-type) littermates in 
the ketogenic neonatal period, despite ~50% diminution of CoA transferase protein abundance in Oxct1+/- 
mice (78). To determine if metabolic abnormalities emerge in adult mice with ubiquitous, but partial, 
reduction of catalytically active CoA transferase, wild type and Oxct1+/- littermate mice were exposed to 
ketogenic milieus at six weeks of age. First, to measure the consequences of acute ketosis, male Oxct1+/- 
and wild type littermate control mice were subjected to a 48h period of starvation. Body composition and 
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total body weight was not different between genotypes at the onset of fasting: body fat percentage was 
16.7 ± 0.2% in wild type mice vs. 16.3 ± 0.3% in Oxct1+/- mice; n = 6/group, and mice from each 
genotype exhibited equivalent weight loss during the fast (Fig. 3.7A). As expected, fasting induces 
ketosis in both genotypes, but Oxct1+/- mice developed greater ketonemia than control mice after 24 and 
48h of fasting, consistent with a global reduction in ketone body oxidative capacity (Fig. 3.7B). Serum 
AcAc/D-βOHB ratios were not different between Oxct1+/- and control mice after 48 hr of fasting (Table 
3.3). Furthermore, fasting serum glucose and free fatty acid concentrations did not significantly differ 
between genotypes (Fig. 3.7C-D). Next, to determine if reduced ketone body oxidative capacity impairs 
adaptation to a chronic ketogenic nutrient milieu, we placed Oxct1+/- and littermate control mice on a low 
protein, very low carbohydrate, and high fat ketogenic diet that has been extensively used by our lab and 
others to study ketotic states in mice (51,53,126,291-295). Adherence to this diet for 2 weeks induces 
ketosis in both genotypes, but ketonemia was nearly three-fold greater in Oxct1+/- mice (Fig. 3.7E).  
Furthermore, compared to wild type controls, ketogenic diet-fed Oxct1+/- mice exhibited relative 
hypoglycemia (Fig. 3.7F). Taken together, these results indicate that partial ketolytic defects become 
metabolically evident after brief periods of nutrient deprivation and upon adherence to low carbohydrate 
diet regimens.  
 
Discussion  
We have used novel mouse models of CoA transferase deficiency to demonstrate that the inability to 
oxidize ketone bodies individually within neurons, cardiomyocytes, or skeletal myocytes does not impair 
the ability of mice to survive the ketogenic neonatal period, or moderate-length durations of starvation in 
the adult. However, transgene-mediated restoration of myocardial ketone body oxidation in an animal 
lacking the ability to oxidize ketone bodies elsewhere does not prevent lethal hyperketonemic 
hypoglycemia in the neonatal period. Taken together, these results support the notion that organism-wide 
CoA transferase activity provides a ketolytic reservoir that is required to maintain bioenergetic 
homeostasis in states of diminished carbohydrate intake, and that no single organ or cell type exhibits an 
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obligate energetic requirement for ketone body oxidation to support survival or preserve glycemia under 
the conditions tested. The inability of SCOT-Heart-OVEX; SCOT-KO mice to survive the ketogenic 
neonatal period, and the mild hyperketonemic hypoglycemia exhibited by adult Oxct1+/- mice maintained 
on a ketogenic diet indicate that incremental defects of the global ketolytic reservoir has significant 
impact on metabolic homeostasis in ketogenic milieus. 
Of the tissue-specific SCOT-KO mouse strains examined in the neonatal period, only SCOT-
Neuron-KO mice develop mild hyperketonemia, which supports previous observations indicating that 
neurons are a significant consumer of ketone bodies in the neonatal period (71,105). Moreover, loss of 
ketone body oxidation within neurons increases glycolysis and oxidative metabolism of glucose, 
stronglysuggesting that ketolytic impairment in neurons requires additional glucose to meet the energetic 
demands of the neonatal brain. Given the relative inability of neurons to oxidize fatty acids for energy 
(69,70), increased cerebral consumption of glucose in SCOT-Neuron-KO neonates is not unexpected. The 
liver is the most important source of glucose for the neonatal brain, which normally accounts for 60-70% 
of total energy expenditure in this period, even though the neonatal brain only comprises 10% of total 
body weight (2,71). Loss of terminal ketone body oxidation in neurons may therefore increase the liver’s 
glucogenic burden. Increased hepatic glucose production may initially be met through increased 
glycogenolysis, although hepatic glycogen stores are normally depleted rapidly after birth (20). 
Furthermore, gluconeogenic gene expression markers were not increased in livers of SCOT-Neuron-KO 
mice, suggesting that counterregulatory programs are not engaged in these mice. Thus, an alternative 
explanation for preservation of euglycemia in newborn SCOT-Neuron-KO mice is that ketone body 
oxidation within tissues that remain competent to terminally oxidize ketone bodies spares glucose for the 
neonatal brain.  
As in the neonatal period, ketone body oxidation subsumes an important role in energy transfer in 
the post-absorptive state (2,4). Interestingly, in mice subjected to 48h starvation, survival is maintained 
and glycemia is preserved when ketone body oxidation is individually eliminated from neurons, 
cardiomyocytes, or skeletal myocytes. However, in this state, SCOT-Muscle-KO and SCOT-Neuron-KO 
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mice exhibit hyperketonemia compared to fasted SCOT-Heart-KO and control strains. Hyperketonemia in 
these two models suggests that skeletal muscle and neurons each provide a major component of the 
ketolytic reservoir in the adult, consistent with previous observations indicating that ketone body 
oxidation can account for as much as two-thirds of cerebral metabolism during starvation (2,296). Due to 
bioethical considerations, these studies were not designed to determine if tissue-specific energetic 
requirements for ketone body oxidation emerge in extremes of starvation. Nevertheless, it is striking that 
animals challenged to a ketotic 48h fast, during which ~25% of total body weight is lost, do not require 
ketone body oxidation in neurons, cardiomyocytes, or skeletal myocytes for survival or maintenance of 
glycemia. In particular, SCOT-Neuron-KO mice on the flox/rec germline background have lost a 
substantial proportion of total ketone body oxidative capacity. Nonetheless, these mice do not exhibit 
greater starvation-induced ketonemia than SCOT-Neuron-KO mice on the flox/flox germline background, 
despite the fact that germline flox/rec (functionally whole-body heterozygote) mice, which have preserved 
neuronal ketolytic capacity, manifest greater starvation-induced ketonemia than flox/flox (functionally 
wild-type) mice with normal neuronal ketolytic capacity (Figs. 3.6B, 3.7B). Therefore, as dynamic 
variation of glucose metabolism occurs in these models, as described above, dynamic variations of both 
ketogenic and ketolytic capacity are likely to occur in mice on these genetic backgrounds to meet the 
collective energetic demands of all tissues. 
In contrast to genetic animal models of tissue-specific ketolytic deficiency, sporadic CoA 
transferase deficiency in humans likely affects all cells that oxidize ketones. Studies of CoA transferase 
deficient infants and their parents reveal that heterozygous carriers for loss-of-function OXCT1 mutations 
exhibit reduced CoA transferase enzymatic activity (290). Thus, we subjected germline adult Oxct1+/- 
mice to a series of ketogenic provocations. Compared to wild type littermate controls, Oxct1+/- mice 
developed hyperketonemia upon fasting, but glycemia was preserved. Prospectively, hypoglycemia may 
ensue in Oxct1+/- mice at the extremes of starvation, when readily-available gluconeogenic substrate pools 
are depleted to meet the increased gluconeogenic demand imposed by ketolytic insufficiency. This notion 
is supported by the hyperketonemic hypoglycemic response of Oxct1+/- mice maintained on a low protein, 
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very low carbohydrate, and high fat ketogenic diet for 2 weeks. These findings suggest that latent 
ketolytic defects may emerge in humans upon introduction to ketogenic nutrient milieus. Indeed, case 
reports indicate sporadic but rapid development of severe hyperketonemia with modest durations of 
nutrient deprivation or upon adherence to Atkins-style ketogenic diets for weight loss (278,279). Because 
ketogenic diets are increasingly employed for treatment of obesity, nonalcoholic fatty liver disease, and 
neurological diseases including epilepsy, attentiveness to latent ketolytic insufficiency, and the possibility 
of functional consequences of single nucleotide polymorphisms in loci that encode and regulate the 
enzymatic mediators of ketone body oxidation, is warranted. 
While these studies indicate that cell-type specific preservation of ketone body oxidation is not 
required for survival of the murine neonatal period or a moderate degree of starvation in the adult mouse, 
these tissue-specific models will also permit highly-penetrating analyses of the diverse bioenergetic roles 
that ketone body oxidation plays through physiological and pathophysiological states relevant to each 
tissue. For example, within the heart, cardiomyocytes oxidize ketone bodies in proportion to their 
delivery, at the expense of fatty acid oxidation and glucose oxidation (90,117,121-127). Compared to 
fatty acids, oxidation of ketone bodies is more energetically efficient. Unlike fatty acid oxidation, all of 
the reducing equivalents generated by ketone body oxidation are delivered through NADH to complex I 
within the electron transport chain (ETC). In addition, oxidation of ketone bodies increases the redox span 
between complexes I and III by keeping mitochondrial ubiquinone oxidized. This increases the potential 
energy of the mitochondrial proton gradient, thereby yielding more energy available for ATP synthesis 
per molecule of oxygen invested, improving the energetic efficiency of ketone bodies, and attenuating 
production of reactive oxygen species by the ETC (95,96,128,297). Furthermore, numerous studies 
indicate prospective therapeutic applications of harnessing the benefits of ketone body metabolism in 
neurons and astrocytes within the central nervous system (9,221,289,298). Therefore, these new models 
provide opportunities for metabolic and bioenergetic dissection of both ketone body metabolism and CoA 
transferase function in disease pathogenesis relevant to each organ. 
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The ability to derive conclusions from tissue-specific loss-of-function models is a function of the 
spatiotemporal fidelity of the gene inactivation system employed. The Cre-expressing strains used in this 
study effect robust and cell-type-specific recombination during mouse embryogenesis (284-287,299). 
HSA-Cre expresses Cre recombinase in a pan-fiber type distribution of skeletal myocytes; α-MHC-Cre 
drives the expression of the recombinase abundantly and specifically within cardiac myocytes, and the 
Synapsin1-Cre model was selected because it specifically expresses Cre recombinase in a pan-neuronal 
manner. Nevertheless, the complexity of the central and peripheral nervous systems is reflected by the 
>40 Cre-expressing mouse strains that are employed to target select neuronal and glial populations (300). 
Thus, it is likely that novel phenotypes will emerge from study of CoA transferase deficiency through use 
of other strains expressing Cre recombinase in other experimental settings. Finally, loss of CoA 
transferase during embryogenesis may promote adaptation to the absence of terminal ketone body 
oxidation, prospectively limiting the emergence of robust phenotypes in adult tissue-specific SCOT-KO 
mice. Use of conditionally-induced Cre expressing strains will support further insight into the metabolic 
consequences of ketolytic insufficiency in the adult animal. 
In conclusion, we demonstrate that, to sustain survival and glycemia during moderate-duration 
starvation, ketone body oxidation is not required for energy transfer in the three cell types that exhibit the 
greatest capacity to oxidize ketone bodies: neurons, skeletal myocytes, and cardiomyocytes. However, 
diminished ketone body oxidative capacity predisposes to metabolic abnormalities, including the 
development of hyperketonemia during fasting, and hyperketonemic hypoglycemia upon adherence to a 
low carbohydrate, high fat diet. A minimum threshold of organism-wide ketone body oxidation must be 
maintained to preserve bioenergetic homeostasis and support compatibility with life. 
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Figure Legends 
Fig. 3.1. Strategy for the generation of transgenic overexpresser and tissue-specific SCOT-KO mice. 
(A) SCOT-Heart-OVEX mice. Mouse Oxct1 cDNA was sub-cloned downstream of the α-MHC promoter 
to generate mice overexpressing CoA transferase specifically within cardiomyocytes. ATG, initiator 
methionine codon; TGA, stop codon; kb, kilobase; UTR, untranslated region. (B) Schematics depict the 
endogenous Oxct1 mouse gene (Wild-type); targeted Null allele (the germline knockout allele); Flox 
allele, which encodes normal CoA transferase protein; and the recombined Rec (also a null) allele. 
Polyadenylation (pA) signals in the Null locus terminate transcription after exon 5, and a splice acceptor 
(SA)/internal ribosomal entry sequence (IRES) results in a truncated and catalytically inactive product 
from residual message. Flp recombinase recognition target (FRT) sites flank the β-gal and neomycin 
resistance cassettes and the pA signals. Thus, Flp recombinase mediates removal of the pA transcriptional 
stop signals and lacZ/neomycin cassette, restoring an active Oxct1 Flox allele in the germline. Exon 6 is 
flanked by loxP recognition sequences in the Flox allele for cell type-specific Cre recombinase-mediated 
recombination and inactivation. Genotyping primers for each allele are indicated as horizontal arrows (see 
Table 3.1 for sequences). βgal, β-galactosidase-encoding lacZ gene; β-act:neo, neomycin resistance gene 
driven by the β-actin promoter. 
Fig. 3.2. Restoration of ketone body oxidative capacity selectively within cardiomyocytes of 
germline SCOT-KO mice. (A) Immunoblot for CoA transferase (SCOT) and actin in myocardial protein 
lysates derived from P0 hearts of wild type mice, SCOT-KO mice with transgene mediated restoration of 
cardiomyocyte CoA transferase (SCOT-Heart-OVEX; SCOT-KO mice), and SCOT-KO mice. (B) CoA 
transferase activity was measured spectrophotometrically in tissue lysates derived from hearts of P0 wild-
type and SCOT-KO mice, and hearts and brains of P0 SCOT-Heart-OVEX; SCOT-KO mice. n = 3/group. 
***, p < 0.001 by linear regression t test vs. SCOT-Heart-OVEX; SCOT-KO heart. †††, p < 0.001 by 
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linear regression t test vs. wild type heart. (C)  Serum ketone bodies (mM) in P1 wild type, SCOT-KO, 
SCOT-Heart-OVEX, and SCOT-Heart-OVEX; SCOT-KO mice. n = 5-6/ group; ***, p < 0.001; *, p < 
0.05 for βOHB; †††, p < 0.001 for AcAc; ‡‡‡, p < 0.001 for AcAc/D-βOHB ratio by 2-way ANOVA, 
compared to genotype control on the Oxct1+/+ (wild-type) background. (D) Blood glucose (mg/dL) in P1 
mice. n = 4-6/group, ***, p < 0.001; *, p < 0.05 by 2-way ANOVA.  
Fig. 3.3. Absence of CoA transferase protein and enzymatic activity in tissue-specific SCOT-KO 
mouse strains. CoA transferase activity was measured spectrophotometricaly (left) in tissue lysates 
derived from (A) heart, (B) skeletal muscle (quadriceps/hamstrings), and (C) brains of P0 mice. n = 3-
6/group. ***, p < 0.001 by linear regression t test. Brains of SCOT-Neuron-KO mice on both flox/flox and 
flox/rec genetic backgrounds were analyzed (depicted as flox/x). Immunoblots for CoA transferase 
(SCOT) and actin (right). (D) Immunoblot (left) and densitometric quantification (right) of CoA 
transferase protein abundance, normalized to actin in isolated hippocampi from adult SCOT-Neuron-KO 
mice. Brains of SCOT-Neuron-KO mice on both flox/flox and flox/rec genetic backgrounds were analyzed 
and did not reveal significant differences in CoA transferase protein abundances. ***, p < 0.001, **, p < 
0.01, *, p < 0.05 by 1-way ANOVA. ns, not significant. 
Fig. 3.4. Circulating metabolites in neonatal tissue-specific SCOT-KO strains. (A) Blood glucose 
(mg/dL) in P1 mice. (B) Serum AcAc and D-βOHB in P1 mice. n = 5-8/group. ***, p < 0.001; **, p < 
0.01 for serum [ketone] vs. flox/flox by 1-way ANOVA. ††, p < 0.01 for serum [ketone] vs. flox/rec by 1-
way ANOVA.  
Fig. 3.5. Increased glucose consumption by brains of neonatal SCOT-Neuron-KO mice. (A) [1-
13C]glucose labeling of lactate, a surrogate for glycolysis in brains of SCOT-Neuron-KO (on the flox/rec 
germline background) and control mice, 30 min after intraperitoneal injection of [1-13C]glucose into P2 
animals. (B) 13C labeling of glutamate (surrogate for terminal oxidation in the TCA cycle) in these same 
cerebral extracts. n = 4/group. *, p < 0.05 by Student’s t test. (C) Relative mRNA abundance of 
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gluconeogenic (Pck1) and ketogenic (Hmgcs2, Bdh1) genes in livers of P2 SCOT-Neuron-KO and control 
mice. n = 5/group.  
Fig. 3.6. Adult tissue-specific SCOT-KO mice tolerate starvation. (A) Serum glucose, (B) serum total 
ketone bodies (TKB), and (C) body weight were measured in fasting SCOT-Heart-KO, Muscle-KO, 
Neuron-KO, and control adult mice after the indicated durations of nutrient withdrawal. ***, p < 0.001; 
**, p < 0.01; and *, p < 0.05, by 2-way ANOVA, compared to same genotype at 4 hr. †††, p < 0.001; ††, p 
< 0.01 by 2-way ANOVA, compared to flox/flox at same time point. ‡‡‡, p < 0.001 by 2-way ANOVA, 
compared to flox/rec control; n ≥ 6/group for each measurement at all time points and for each genotype.  
 
Fig. 3.7. Diminished total body ketone body oxidative capacity impairs adaptation to ketotic 
nutrient states. Metabolic parameters were measured in six week-old Oxct1+/- and Oxct1+/+ (wild-type 
littermate control) male mice subjected to ketotic nutrient states. (A) Total body weight, (B) total serum 
ketone bodies (TKB), (C) serum glucose, and (D) serum free fatty acids (FFA) were measured in fasting 
mice. (E) Total serum ketone bodies and (F) serum glucose were also measured in eight week-old male 
Oxct1+/- and littermate Oxct1+/+ (wild-type) mice maintained either on a standard polysaccharide rich 
(Chow) diet or low protein, low carbohydrate, high fat ketogenic diet (KD) for two weeks. n = 7/group; 

























Impact of peripheral ketolytic deficiency on hepatic ketogenesis and gluconeogenesis during the 
transition to birth 
The work presented in this chapter has been adapted from: 
Cotter, D. G., Ercal, B., d'Avignon, D. A., Dietzen, D. J., and Crawford, P. A. (2013) J Biol Chem 
288(27), 19739-19749 
Summary 
Preservation of bioenergetic homeostasis during the transition from the carbohydrate-laden fetal diet to 
the high fat, low carbohydrate neonatal diet requires inductions of hepatic fatty acid oxidation, 
gluconeogenesis, and ketogenesis. Mice with loss-of-function mutation in the extrahepatic mitochondrial 
enzyme CoA transferase (succinyl-CoA:3-oxoacid CoA transferase, SCOT, encoded by nuclear Oxct1) 
cannot terminally oxidize ketone bodies and develop lethal hyperketonemic hypoglycemia within 48 hr of 
birth. Here we use this model to demonstrate that loss of ketone body oxidation, an exclusively 
extrahepatic process, disrupts hepatic intermediary metabolic homeostasis after high fat mother’s milk is 
ingested. Livers of SCOT-knockout (SCOT-KO) neonates induce the expression of the genes encoding 
PGC-1α, PEPCK, pyruvate carboxylase, and glucose-6-phosphatase, and the neonate’s pools of 
gluconeogenic alanine and lactate are each diminished by 50%. NMR-based quantitative fate mapping of 
13C-labeled substrates revealed that livers of SCOT-KO newborn mice synthesize glucose from 
exogenously administered pyruvate. However, the contribution of exogenous pyruvate to the TCA cycle 
as acetyl-CoA is increased in SCOT-KO livers, and is associated with diminished terminal oxidation of 
fatty acids. After mother’s milk provokes hyperketonemia, livers of SCOT-KO mice diminish de novo 
hepatic β-hydroxybutyrate synthesis by 90%. Disruption of β-hydroxybutyrate production increases 
hepatic NAD+/NADH ratios three-fold, oxidizing redox potential in liver but not skeletal muscle. 
Together, these results indicate that peripheral ketone body oxidation prevents hypoglycemia and 
supports hepatic metabolic homeostasis, which is critical for the maintenance of glycemia during the 
adaptation to birth.  
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Introduction  
At birth, a transplacental nutrient stream replete with carbohydrates is terminated and replaced with a high 
fat, low carbohydrate milk diet that is cyclically interrupted by periods of nutrient deprivation. Hepatic 
glucose production plays a critical role in providing fuel, particularly to the developing brain (20). 
Nonetheless, glucose utilization is thought to support only ~70% of the neonatal brain’s energetic needs, 
and additional substrates, including ketone bodies, are required to supply the balance (71). To meet this 
demand, a coordinated hepatic metabolic program integrates β-oxidation and terminal oxidation of fatty 
acids, gluconeogenesis, and ketogenesis (20). Ketone body metabolism mediates energy transfer by 
partially oxidizing hepatic fatty acids to water-soluble four-carbon ketone body intermediates that are 
transported to extrahepatic organs for terminal oxidation during physiological states characterized by 
limited carbohydrate supply (4,5,301). As such, contributions of ketone body metabolism to neonatal 
bioenergetic homeostasis are two-fold: (i) because the neonatal diet has high lipid content, ketogenesis 
provides a spill-over pathway for excess fatty acid oxidation-derived acetyl-CoA that would otherwise 
require terminal oxidation, storage, or secretion (5,42,302), and (ii) extrahepatic ketone body oxidation 
diminishes hepatic gluconeogenic demand because ketone body oxidation spares glucose utilization in 
peripheral tissues (4).  
Most ketogenesis occurs within hepatic mitochondria, at rates proportional to β-oxidation of fatty 
acids (5). Sequential ketogenic reactions catalyzed by mitochondrial thiolase, mitochondrial 
hydroxymethylglutaryl-CoA synthase (HMGCS2), and hydroxymethylglutaryl-CoA lyase (HMGCL) 
convert β-oxidation-derived acetyl-CoA to the ketone body acetoacetate (AcAc), which is reduced by 
mitochondrial D-β-hydroxybutyrate (D-βOHB)-dehydrogenase (BDH1) to D-βOHB in an NAD+/NADH-
coupled redox reaction (21,22,44). Within extrahepatic organs, mitochondrial BDH1 re-oxidizes D-βOHB 
to AcAc. Covalent activation of AcAc by CoA is catalyzed by the mitochondrial matrix enzyme succinyl-
CoA:3-oxoacid CoA transferase [SCOT (encoded by the nuclear gene Oxct1), the only mammalian CoA 
transferase] to generate AcAc-CoA, which upon thiolytic cleavage, liberates acetyl-CoA that enters the 
tricarboxylic acid (TCA) cycle for terminal oxidation (74). CoA transferase catalyzes a near equilibrium 
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reaction in which coenzyme A is exchanged between succinate and AcAc (72). Ketone bodies are 
efficient energetic substrates that are oxidized in proportion to their delivery (4,5,20). The neonatal brain 
extracts ketones at rates up to 40-fold greater than the adult brain and ketone body oxidation can support 
as much as 25% of the neonate’s total basal energy requirements (71,248). Because neurons oxidize fatty 
acids poorly (69,71), ketogenesis has been proposed as a key determinant in vertebrate evolution and the 
evolution of human brain size (41). 
Prior analysis of germline CoA transferase knockout (SCOT-KO) mice revealed that CoA 
transferase is required for terminal ketone body oxidation. SCOT-KO mice are born normal, but exhibit 
increased cerebral glucose oxidation. These mice ultimately develop hyperketonemic hypoglycemia and 
die within 48h of birth unless their lifespan is prolonged by frequent glucose administration (78). Unlike 
mice with a global CoA transferase defect, recent studies using cell type-specific SCOT-KO mice reveal 
that the selective absence of ketone body oxidation individually within neurons, cardiomyocytes, or 
skeletal myocytes – the three greatest consumers of ketone bodies (4,107) – does not cause 
hyperketonemia or hypoglycemia, and does not impair survival during the neonatal period or starvation in 
adulthood. As observed in brains of germline SCOT-KO neonates, selective absence of neuronal CoA 
transferase activity was associated with increased glycolysis and glucose oxidation in the neonatal brain 
(108). Taken together, the phenotypes of germline and tissue-specific SCOT-KO mice reveal that 
ketolytic cells do not require the energy stored in ketone bodies, but ketone body oxidation is necessary 
for maintenance of glycemia, and therefore survival in the neonatal period.  
During states in which dietary carbohydrates are in short supply, the balance of hepatic glucose 
output with extrahepatic glucose consumption coordinates glucose homeostasis. Increased extrahepatic 
glucose consumption in neonatal germline SCOT-KO mice may therefore contribute to the development 
of hypoglycemia. To determine whether the absence of extrahepatic ketone body oxidation influences 
hepatic glucose production and intermediary metabolic homeostasis, we used biochemical approaches to 
quantify dynamic metabolism in livers of germline neonatal SCOT-KO mice.  
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Methods 
Animals. Oxct1-/- (germline SCOT-KO) mice were generated on the C57BL/6 genetic background (78). 
To obtain unfed neonatal mice, pups were collected within one hour of birth. Pups without gastric milk 
spots were confirmed by open examination of the stomach and intestine at the time of sacrifice. Fed 
postnatal day zero (P0, the first day of postnatal life) mice were collected within 4 hr of birth. All P1 mice 
were maintained with the dam through the first 30h after birth, and were milk fed. All mice were 
maintained at 22oC on standard polysaccharide-rich chow diet (Lab Diet 5053) and autoclaved water ad 
libitum. Lights were off between 1800 and 0600. All experiments consisted of mouse pups that were 
harvested from at least three litters from three different breeder pairings. All experiments were conducted 
using protocols approved by the Animal Studies Committee at Washington University. 
Plasma metabolite measurements. Measurements of plasma AcAc and D-βOHB were performed using 
standard biochemical assays coupled to colorimetric substrates (Wako), as described previously (51). 
AcAc concentrations were determined by measuring total ketone body (TKB) concentrations and 
subtracting the corresponding measured D-βOHB concentration. Plasma lactate and pyruvate were 
measured using colorimetric and fluorescent biochemical assays, respectively (Biovision). Blood glucose 
was measured in duplicate using glucometers (Aviva). 
Gene expression analysis. Quantification of gene expression was performed using real-time RT-
quantitative PCR using the ΔΔCt approach as described, normalizing to Rpl32, using primer sequences 
listed within supplemental Table S4.1 (51). 
Immunoblotting. Immunoblots, using protein lysates from neonatal brain, heart, liver, and 
quadriceps/hamstring muscles to detect SCOT (rabbit anti-SCOT; Proteintech Group), actin (rabbit anti-
actin; Sigma), HMGCS2 (rabbit anti-mHMGCS; Santa Cruz Biotechnology), PDH-E1α (rabbit anti-
Pyruvate Dehydrogenase E1-alpha subunit antibody; abcam ab155096), phospho-serine 293 PDH-E1α 
[PhosphoDetect™ Anti-PDH-E1α (pSer293) Rabbit Antibody; Millipore AP1062], and BDH1 (rabbit 
anti-BDH1; Proteintech Group) were performed as previously described (34). Band intensities were 
quantified densitometrically using QuantityOne software (Bio-Rad). 
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In vitro ketogenesis of hepatic explants. Neonatal mice were sacrificed by decapitation. Livers were 
collected, weighed, and each liver was placed in a single well of a 6-well tissue culture plate containing 2 
mL of phosphate-buffered saline (PBS) on ice. Livers were minced and transferred to a 2 mL eppendorf 
tube. Tissues were allowed to settle on ice and were centrifuged at 500 x g for 1 min. Minced-liver pellets 
were resuspended in 1 mL of assay media [Dulbecco’s Modified Eagle’s Medium supplemented with 
2.78 mM glucose (which reflects glycemia in neonatal mice), 0.63 mM sodium pyruvate, and 150 µM 
oleic acid (conjugated to bovine serum albumin in a 2:1 molar ratio)]. Each liver preparation was plated in 
a single well of a 12-well plate containing 1 mL of media, and incubated at 37ºC. At time points indicated 
in the figure legends, 50 µL of media was removed to quantify ketone body concentrations. 
Tissue triglyceride, glycogen, and nicotinamide metabolite quantifications. Hepatic triacyglycerol (TAG) 
concentrations were determined using a Folch extract of liver and biochemical quantification using a 
biochemical assay (Wako), as previously described (126). Hepatic glycogen and NAD+(H) concentrations 
were measured in liver lysates using fluorescent biochemical assays (Biovision).  
In vivo substrate utilization. P0 or P1 mice were injected intraperitoneally with 10 µmol of sodium 
[1,2,3,4-13C4]octanoate, 10 µmol sodium [3-13C]pyruvate, or co-injected with 10 µmol of sodium [1,2,3,4-
13C4]octanoate, plus 20 µmol naturally-occurring sodium pyruvate, sodium D-βOHB, sodium L-βOHB, or 
AcAc per g of body weight (vendor for stable isotopes: Cambridge Isotope Laboratories). Base hydrolysis 
of ethyl-AcAc (Sigma W241512) was performed by addition of 50% NaOH to pH 12 and incubation at 
60º C for 30 min. The pH of base hydrolyzed AcAc was adjusted to pH 8.5, and [AcAc] was confirmed 
using standard biochemical assays coupled to colorimetric substrates (Wako), as described previously 
(51). After intraperitoneal injections, neonatal mice were maintained on a heating pad for the indicated 
durations (see text and figure legends), killed by decapitation, and tissues were rapidly freeze-clamped in 
liquid N2. Neutralized perchloric acid tissue extracts were profiled using 13C-edited proton nuclear 
magnetic resonance (NMR) measured at 11.75 T (Varian/Agilent Direct Drive-1) via first increment 
gradient heteronuclear single-quantum correlation (gHSQC). The majority of studies were carried out 
using a traditional probe, but extracts generated from mice injected with sodium [3-13C]pyruvate were 
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analyzed using a high-sensitivity cold probe at 11.75 T (Varian/Agilent Direct Drive-1). Signals were 
collected from extracts dissolved in 275 µL of D2O + 1 mM trimethylsilyl propionate (TSP), loaded into 
high precision, thin walled 5-mm tubes (Shigemi). Quantification of signals by integration from the 
1H{13C} and 13C-edited (gHSQC) collections of carbon 2 for taurine, carbon 4 for βOHB, carbon 1 for 
glucose, carbon 4 for glutamate, and 1H{13C} of carbons 3 for lactate and alanine were all performed as 
described previously (78). Tissue concentrations (pool size) of glucose, taurine, glutamate, and βOHB 
were calculated by normalizing the integrals for each metabolite obtained from the 1H{13C} collections to 
TSP and tissue weight. Because tissue taurine concentrations were constant across conditions (Tables 
S4.2-S4.3) and taurine is not enriched by administration of these experimental substrates (51,136), taurine 
was used as a normalizing metabolite between the 1H{13C} and gHSQC collections to calculate the moles 
of 13C-labeled metabolites present in each sample. The moles of 13C-labeled metabolites produced from 
the labeled substrate in each sample were calculated by subtracting the moles of 13C-labeled metabolites 
attributable to the metabolite pool size (i.e., in the absence of any enrichment from exogenous 13C-labeled 
substrates, 1.1% of the metabolites within the entire pool are expected to be 13C-labeled, based upon the 
natural abundance of 13C) from the total amount of 13C-labeled metabolites detected in the gHSQC 
collections. Fractional enrichments of 13C-labeled glutamate and βOHB were then calculated as described 
(51), by dividing taurine-normalized integral values for each queried metabolite derived from the gHSQC 
collections by the corresponding integral value obtained from the 1H{13C} collections. 
Tandem mass spectrometry (MS/MS) analysis of blood amino acids and acylcarnitines. Neonatal blood 
was spotted onto 1.3 cm spots on Whatman 903 filter paper. Amino acids were quantified as butyl ester 
derivatives using multiple precursor/product combinations in a reversed-phase liquid chromatography 
protocol coupled to MS/MS (303). Carnitine esters were measured by scanning for the precursors of the 
common m/z 85 carnitine fragment. Quantification was achieved in all cases using stable isotope (2H) 
labeled internal standards using an electrospray ionization source coupled to an API 3200-Qtrap tandem 




Neonatal SCOT-KO mice engage an hepatic gluconeogenic gene program. The liver is the most 
important source of glucose for the neonatal brain (2,71), which increases its reliance on this vital fuel 
when CoA transferase inactivation prevents ketone body oxidation in the entire brain (78) or selectively 
within neurons (108). Therefore, we hypothesized that neonatal germline SCOT-KO mice, which cannot 
terminally oxidize ketone bodies, engage compensatory mechanisms in the liver to meet increased 
peripheral glucose demand. Increased abundances of the mRNAs encoding peroxisome proliferator 
activated receptor gamma-1a (PGC-1α, encoded by Ppargc1a), pyruvate carboxylase (PC, encoded by 
Pcx), phosphoenolpyruvate carboxykinase (PEPCK, encoded by Pck1), and glucose-6-phosphatase 
(encoded by G6pc) were observed in livers of postnatal day 1 (P1, the day immediately following 
delivery) SCOT-KO mice (Fig. 4.1A), and as expected, hepatic glycogen content was depleted in livers of 
P1 SCOT-KO mice (Fig. 4.1B). Consistent with increased gluconeogenic demand, tandem mass 
spectrometry (MS/MS) analysis of circulating amino acids demonstrated that alanine, which becomes the 
gluconeogenic substrate pyruvate following transamination (36), was diminished 51% in blood of P1 
SCOT-KO mice (Fig. 4.1C). Serine, which is deaminated to pyruvate by serine dehydratase, also trended 
lower in these mice. In addition, blood concentrations of the anaplerotic amino acid glutamate, which can 
replenish TCA cycle intermediates following conversion to a-ketoglutarate, were diminished 40% in 
SCOT-KO neonates. This contrasted with many glucogenic/ketogenic, glucogenic, ketogenic, and urea 
cycle amino acids, whose circulating concentrations were increased in P1 SCOT-KO mice (Fig. 4.1D; see 
Tables S4.4-S4.5 for complete P0 and P1 blood amino acid profiles, respectively, of wild type and 
SCOT-KO mice), suggesting enhanced skeletal muscle proteolysis in P1 SCOT-KO mice. In addition, the 
total circulating pyruvate pool (the sum of pyruvate plus lactate, which form a redox couple with 
NAD+/NADH), a critical source of gluconeogenic precursors via the Cori cycle, was diminished 53% in 
P1 SCOT-KO mice (Fig. 4.1E). In SCOT-KO neonates, increased extrahepatic glucose and lactate 
consumption (78,108) are likely contributors to hypoglycemia. Unlike wild-type littermates, endogenous 
hepatic content of free glucose was below the limit of detection by proton NMR in P1 SCOT-KO mice 
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(Fig. 4.1F, left), suggesting that hepatic glucose generated from residual endogenous substrates is rapidly 
cleared to meet increased peripheral demands, and that this production is insufficient to support the 
glycemic requirements for survival in these mice. However, intraperitoneal supplementation of P1 SCOT-
KO mice with exogenous [13C]pyruvate 30 min prior to harvest of the liver demonstrated robust 
generation of 13C-glucose (Fig. 4.1F, right). Taken together, these data suggest that neonatal hepatic 
glucose production is increased to meet enhanced peripheral requirements, but is limited in these mice by 
precursor availability and not intrinsic synthetic capacity. 
Reprogrammed intermediary metabolism in livers of neonatal SCOT-KO mice. Given marked 
hypoglycemia, hyperketonemia, alterations of gluconeogenic precursor pools, and increased 
concentrations of circulating amino acids, we hypothesized that livers of P1 SCOT-KO mice would 
exhibit alterations of terminal fatty acid oxidation and pyruvate metabolism. Therefore, to determine if 
livers of P1 germline SCOT-KO mice exhibit diminished terminal oxidation of acyl-CoA-derived acetyl-
CoA, we quantified the contribution of the fatty acid [1,2,3,4-13C4]octanoate (10 µmol/g body weight, via 
the intraperitoneal route) to the acetyl-CoA entering the TCA cycle, by using 13C-glutamate fractional 
enrichment as a quantitative surrogate, because glutamate is in equilibrium with the TCA cycle 
intermediate α-ketoglutarate (51,78,108,136,304,305). Hepatic enrichment of 13C-glutamate did not differ 
between P1 wild type and SCOT-KO mice that received [13C]octanoate alone (Fig. 4.2A, left), indicating 
equal contributions of labeled octanoate to the acetyl-CoA entering the TCA cycle. However, SCOT-KO 
mice exhibited a significantly decreased glutamate pool size (Fig. 4.2A, right; 1.03±0.17 nmol 
glutamate/mg liver in P0 wild type mice, versus 0.56±0.09 nmol glutamate/mg liver in P1 SCOT-KO 
mice, p = 0.046, n = 6-8/group). Therefore, to determine if hepatic terminal fatty acid oxidation remains 
equal when glutamate pool sizes in livers of P1 wild-type and SCOT-KO mice are equal, we co-
administered [13C]octanoate with unlabeled pyruvate, which augments TCA cycle intermediates by 
stimulating anaplerosis. Co-administration of unlabeled pyruvate with [13C]octanoate increased hepatic 
glutamate pool sizes in livers of both wild type and SCOT-KO neonatal mice, and abrogated the 
diminution of this pool size in livers of SCOT-KO mice (Fig. 4.2B, right). However, compared to livers 
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of wild-type P1 mice, hepatic glutamate enrichment from [13C]octanoate was diminished nearly 50% in 
livers of P1 SCOT-KO mice delivered this combination of substrates (22.9±3.05% in wild type mice 
versus 11.8±3.0% in SCOT-KO mice, p = 0.026, n = 6-7/group; Fig. 4.2B, left), indicating diminished 
contribution of labeled octanoate to the acetyl-CoA entering the TCA cycle in livers of P1 SCOT-KO 
mice. The only competing sources of acetyl-CoA in the livers of neonatal mice in this experimental 
context are (i) endogenous fatty acids or (ii) pyruvate that is decarboxylated via the pyruvate 
dehydrogenase (PDH) complex. Thus, we directly quantified the contribution of pyruvate to the acetyl-
CoA entering the TCA cycle by administering [3-13C]pyruvate (10 µmol/g body weight), which labels > 
95% of the circulating pyruvate pool in both wild type and SCOT-KO mice, and measured hepatic 
glutamate enrichment. Hepatic 13C-enrichment of glutamate was 2.7-fold greater in SCOT-KO neonates 
administered [13C]pyruvate (5.95±1.92% versus 16.32±2.87% in livers of wild-type and SCOT-KO P1 
mice, respectively, p=0.04, n=4/group; Fig. 4.2C).  As observed in mice receiving unlabeled pyruvate 
(Fig. 4.2B), hepatic glutamate pools were not different between wild type and SCOT-KO neonates 
injected with [13C]pyruvate (data not shown). Increased 13C-glutamate enrichment from [13C]pyruvate 
occurred in SCOT-KO neonates in the absence of altered phosphorylation of PDH on the E1 a subunit, a 
post-translational modification that increases the Km of PDH (138,306,307) (Fig. S4.1).  
Because the contribution of labeled fatty acids to the acetyl-CoA entering the TCA cycle was 
diminished in livers of P1 SCOT-KO mice when glutamate pools were rendered equal by administration 
of unlabeled pyruvate, we hypothesized that signatures of diminished fatty acid oxidation would be 
evident in livers of these mice. To determine if there was a defect in the β-oxidation spiral, we quantified 
blood acylcarnitines of untreated P1 germline SCOT-KO mice by MS/MS. While medium and long chain 
acylcarnitine species were normal (Table S4.6), short chain acylcarnitine concentrations were elevated in 
P1 SCOT-KO mice (Fig. 4.2D). This result is consistent with an intact β-spiral, but diminished entry of 
its products into the TCA cycle. Abundances of transcripts encoding key mediators of fatty acid transport 
and oxidation, including Fabp1, Fgf21, Cpt1a, and Acadm mRNAs, were all normal in SCOT-KO mice 
(Fig. S4.2A). However, hepatic triacylglycerol content trended higher in P1 SCOT-KO mice (Fig. 4.2E; 
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12.7±5.0 µg/mg liver versus 3.5±1.7, respectively, p = 0.09, n=5-6/group), also suggesting impaired 
terminal fatty acid oxidation in livers of SCOT-KO mice.  
To determine whether signatures of diminished terminal fatty acid oxidation in livers of SCOT-
KO neonatal mice are innate, or the result of a perturbed metabolic environment, we delivered 
[13C]octanoate to newborn P0 SCOT-KO mice that had been collected prior to their first milk feed, and 
observed that hepatic 13C-glutamate fractional enrichment and glutamate pool size were both normal, as 
they were in livers of fed P0 SCOT-KO mice (Fig. S4.3). Moreover, unlike the observation of increased 
short chain acylcarnitines in the circulation of P1 SCOT-KO mice, blood acylcarnitine species did not 
differ between fed, but untreated P0 wild-type and SCOT-KO mice (Table S4.7). Taken together, these 
findings indicate that the observed abnormalities of fatty acid and pyruvate metabolism are likely 
secondary to increased gluconeogenic demand and the hyperketonemic state that develops in P1 SCOT-
KO mice.  
Accumulated D-βOHB suppresses normal ketogenesis in neonatal liver. Due to (i) the alterations of 
hepatic fatty acid oxidation and pyruvate metabolism in SCOT-KO mice, and (ii) our previous 
observation that the AcAc/βOHB ratio was significantly elevated in the circulation of markedly 
hyperketonemic P1 SCOT-KO mice (78), we hypothesized that regulation of hepatic ketogenesis would 
also be altered in these mice. To determine the effects of peripheral ketolytic deficiency on hepatic 
ketogenesis, we measured the hepatic 13C fractional enrichment and pool sizes of βOHB in neonatal mice 
injected with [13C]octanoate. 13C-βOHB enrichment from [13C]octanoate was decreased 15-fold in livers 
of P1 SCOT-KO mice (15.26±1.34% versus 1.21±0.08%, p < 0.0001, n = 6-8/group Fig. 4.3A, left). 
Commensurate with the marked increase in the concentration of circulating ketone bodies in P1 SCOT-
KO mice, the total hepatic βOHB pool size was expanded in P1 SCOT-KO mice (0.51±0.07 nmol 
βOHB/mg liver and 3.27±0.73 nmol βOHB/mg liver in wild-type and SCOT-KO mice, respectively, p = 
0.0009, n = 6-8/group; Fig. 4.3A, middle). Therefore, to confirm that the decreased 13C-βOHB fractional 
enrichment from [13C]octanoate in livers of  SCOT-KO mice reflects diminished de novo production of 
βOHB (rather than merely an increase in the total pool), we quantified the 13C-βOHB abundance in livers 
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of these mice, and observed a 90% decrease in livers of P1 SCOT-KO mice (72.4±12.5 pmol 13C-
βOHB/mg liver and 6.3±2.1 pmol 13C-βOHB produced/mg liver in wild-type and SCOT-KO mice, 
respectively, p = 0.0007, n=6-8/group; Fig. 4.3A, right). Messenger mRNAs encoding the ketogenic 
mediators FGF21 and HMGCS2 were both normal, while Bdh1 mRNA abundance was decreased 50% in 
livers of P1 SCOT-KO mice (Fig. S4.2A). At the protein level, SCOT-KO livers exhibited ~ 25% 
increased HMGCS2, and normal BDH1 protein abundance (Fig. S4.2B-C). 
To determine if the marked impairment of βOHB production in livers of P1 SCOT-KO mice was 
innate or acquired, we quantified 13C-βOHB production from [13C]octanoate in livers of unfed P0 SCOT-
KO mice. Hepatic 13C-βOHB enrichment, βOHB pool size, and 13C-βOHB production were all normal in 
unfed P0 SCOT-KO mice (Fig. 4.3B). Prior to milk feeding, endogenous plasma ketones were nearly 
undetectable and did not differ between wild type and SCOT-KO mice (Fig. 4.3C). However, after only a 
single feed, plasma ketone bodies exceeded 3 mM in SCOT-KO mice (versus ~ 0.3 mM in wild-type 
littermate controls), with both D-βOHB and AcAc exhibiting significant increases in SCOT-KO neonates 
(Fig. 4.3D). In contrast to the robust 13C-labeling of hepatic βOHB in unfed SCOT-KO neonates 
administered [13C]octanoate, suckling-induced hyperketonemia correlated with the emergence of a 90% 
decrease in 13C-βOHB enrichment in milk-fed P0 SCOT-KO mice, compared to littermate controls (Fig. 
4.3E, left). Similar to the observations in the pools of βOHB in P1 SCOT-KO mice, suckling in P0 mice 
correlated with a marked expansion of the hepatic βOHB pool in SCOT-KO neonates, and was associated 
with an 80% decrease in the abundance of 13C-βOHB (Fig. 4.3E, middle and right). Diminished 13C-
βOHB enrichment from [13C]octanoate occurred in livers of fed P0 SCOT-KO mice despite normal 
abundances of Fabp1, Cpt1a, Acadm, Hmgcs2, and Bdh1 mRNAs, and a 38% increase in HMGCS2 
protein (Fig. S4.4). Together, these results indicate that suckling-induced hyperketonemia in SCOT-KO 
neonates diminishes the generation of 13C-βOHB from [13C]octanoate, without impairment of the 
upstream β-spiral or diminution of expression of the enzymatic mediators of fatty acid oxidation and 
ketogenesis.  
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To determine whether the acquired deficiency of de novo hepatic βOHB production in livers of 
SCOT-KO mice was mediated by hyperketonemia, we measured ketogenesis in livers explanted into 
culture from unfed and fed P0 SCOT-KO and littermate control mice, in order to isolate them from a 
hyperketonemic milieu. As expected, explants from unfed wild type and SCOT-KO neonatal mice did not 
differ in ketogenic rate (Fig. 4.4A). However, in contrast to the defect in de novo synthesis of βOHB 
exhibited by fed P0 SCOT-KO mice in vivo, livers explanted from fed SCOT-KO mice exhibited normal 
ketogenic rates, despite the increased baseline ketone body abundance in these explants (Fig. 4.4B). 
Therefore, to test the hypothesis that the acquired ketogenic impairment in livers of SCOT-KO mice 
requires an environment in which ketone bodies accumulate, we determined the effects of 
hyperketonemia on hepatic βOHB production in vivo by performing intraperitoneal co-injections in fed 
wild-type P0 mice. Unlabeled AcAc, D-βOHB, or L-βOHB [L-βOHB is a by-product of fatty acid 
oxidation that is neither produced during hepatic ketogenesis, nor is a substrate for BDH1 (158,160)] 
were co-injected intraperitoneally with [13C]octanoate into milk-fed P0 wild-type neonatal mice, and the 
hepatic βOHB  pool sizes, fractional enrichments of hepatic 13C-βOHB, and molar contents of 13C-
βOHB/mg tissue were quantified. Co-administered AcAc, L-βOHB and D-βOHB each expanded the total 
βOHB pool significantly, although hepatic βOHB concentrations were greater in neonates co-injected 
with L- or D-βOHB compared to neonates co-injected with AcAc (Fig. 4.5A). While fractional 13C-
enrichments of βOHB from [13C]octanoate were decreased in livers of mice co-injected with each of the 
three unlabeled ketone bodies, neonatal mice co-injected with L- or D-βOHB exhibited greater 
suppression of 13C-βOHB enrichment than neonates co-injected with AcAc (Fig. 4.5B). However, only 
co-administered D-βOHB decreased the molar content/mg tissue of 13C-βOHB in livers of wild-type mice 
(by 75%), while neither AcAc nor L-βOHB produced this effect (Fig. 4.5C). Because oxidation of D-
βOHB to AcAc by BDH1 concomitantly reduces NAD+ to NADH (22,24,308), these results suggest that 
the exogenously delivered D-βOHB diminished de novo βOHB production by shifting the equilibrium of 
the BDH1-catalyzed reaction towards AcAc formation. 
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Diminished βOHB production by livers of neonatal SCOT-KO mice results in oxidation of hepatic 
redox potential. Despite the impairment of de novo synthesis of βOHB, livers of SCOT-KO neonates 
continue to channel fatty acid oxidation-derived acetyl-CoA to AcAc, which exhibits a four-fold increase 
in plasma concentration between P0 and P1 in SCOT-KO mice (78). Because AcAc and D-βOHB exist in 
an NAD+ and NADH-coupled equilibrium, we hypothesized that preservation of AcAc formation, but 
impairment of its reduction to D-βOHB would oxidize hepatic redox potential. While plasma 
AcAc/βOHB molar ratios were elevated 3.5-fold (p = 0.03, n=8-9/group) in fed P0 SCOT-KO mice over 
wild-type littermate controls, these ratios spanned a large dynamic range among SCOT-KO animals (Fig. 
4.6A), and abundances of total NAD+ and NADH were normal in both livers and skeletal muscle of fed 
P0 SCOT-KO mice (Fig. 4.6B-C). Plasma AcAc/βOHB ratios were increased 10-fold (p = 1.98X10-8, 
n=11-14/group) in P1 SCOT-KO mice compared to littermate controls, but in contrast to fed P0 SCOT-
KO mice, they exhibited less variability (Fig. 4.6D). Correspondingly, livers of P1 SCOT-KO mice 
exhibited a three-fold increased ratio of NAD+/NADH concentrations (Fig. 4.6E). This effect was neither 
attributable to, nor contributed to altered hepatic abundances of mRNAs encoding NAMPT, CD38, 
SIRT1, or Rictor (Fig. S4.5). Redox potential was unaltered in skeletal muscles of P1 SCOT-KO mice 
(Fig. 4.6F), consistent with the notion that persistent AcAc production by the liver is the primary driver 
of the redox abnormality of P1 SCOT-KO mice. Because SCOT is normally considered absent in 
hepatocytes (74,107,164), and only a scant amount of SCOT was detected in neonatal hepatic lysates 
(Fig. S4.6), these results indicate that peripheral disposal of ketone bodies is required to prevent oxidation 
of hepatic redox potential. 
 
Discussion 
Ketone bodies provide an alternative fuel in states of diminished carbohydrate supply (4,5,20). Ketone 
body oxidation is required for adaptation to birth in mice, and for adaptation to low carbohydrate states in 
humans (78,97). Here we show that extrahepatic ketone body oxidation is essential for preservation of 
hepatic metabolic homeostasis during the ketogenic neonatal period because the absence of ketone body 
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oxidation causes impaired hepatic terminal fatty acid oxidation, altered pyruvate metabolism, and 
diminished de novo βOHB production, which results in oxidation of hepatic redox potential.  
Germline SCOT-KO neonates succumb to neonatal hypoglycemia. Increased peripheral oxidation 
of lactate and glucose contribute to hypolactatemia and hypoglycemia (78), and increase the 
gluconeogenic burden of SCOT-KO livers. These mice also develop increased blood amino acid 
concentrations, indicating that hypoglycemia and the inability to derive high-energy phosphates from 
ketone bodies likely stimulate skeletal muscle proteolysis. While increased blood amino acid 
concentrations indicate that amino acid supply exceeds hepatic utilization, a subset of these amino acids 
yields gluconeogenic carbon backbones within liver and replenishes TCA cycle intermediates via 
anaplerosis (36). Notably, blood alanine concentrations are decreased in SCOT-KO neonates, although 
absolute plasma pyruvate concentrations are preserved, suggesting that pyruvate generation via both the 
glucose-alanine and Cori cycles increase to support increased gluconeogenic demand. Because livers of 
SCOT-KO neonates successfully produce glucose from exogenously delivered pyruvate, impairments of 
the hepatic gluconeogenic machinery do not account for hypoglycemia. In fact, gluconeogenic enzymes, 
which normally exhibit significant postnatal inductions (20), are further induced in livers of SCOT-KO 
neonates. Together, these data suggest that the availability of gluconeogenic substrates (i.e., alanine and 
the lactate + pyruvate pool), and not expression of enzymatic mediators of gluconeogenesis, exacerbates 
the mismatch between neonatal hepatic glucose production and extrahepatic glucose requirements in mice 
that lack CoA transferase activity. In states of limited dietary carbohydrate supply, >60% of hepatic 
gluconeogenesis is derived from pyruvate (267). Upon carboxylation by PC, pyruvate supplies the TCA 
cycle with the intermediate oxaloacetate, which can either remain in the cycle to facilitate terminal 
oxidation of acetyl-CoA, or efflux into the gluconeogenic pathway through PEPCK-dependent conversion 
to phosphoenolpyruvate (36,309). Such ‘pyruvate cycling’ governs rates of anaplerosis and TCA cycle 
intermediate efflux (309), which normally exceed the rate of TCA cycle flux in the liver (30) . Although 
limited pyruvate pool availability precludes preservation of euglycemia, transcriptional induction of these 
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enzymatic mediators of pyruvate cycling may initially help support gluconeogenesis in livers of SCOT-
KO mice.  
Hyperketonemic states, both physiological and pathophysiological, are almost always 
characterized by plasma AcAc/βOHB molar ratios that are < 1. SCOT-KO mice present a unique 
hyperketonemic state in which the AcAc/βOHB molar ratio is > 1. Following their first high fat, low 
carbohydrate milk meal, SCOT-KO mice develop hyperketonemia, which becomes associated with 
diminished de novo production of D-βOHB. NMR studies in wild type mice co-injected with the fatty 
acid [13C]octanoate and unlabeled ketone bodies indicate that increased circulating D-βOHB in germline 
SCOT-KO mice diminishes hepatic production of βOHB. In the final ketogenic reaction, AcAc is reduced 
to D-βOHB in an NAD+/NADH coupled equilibrium reaction catalyzed by BDH1 that normally favors 
βOHB production (21,22,44). However, the equilibrium of the BDH1 reaction is sensitive to 
concentrations of both AcAc and D-βOHB, such that increases in the molar concentrations of one partner 
of the couple diminish the reduction/oxidation of the other (308). Because livers of SCOT-KO mice 
initially produce D-βOHB in a normal fashion (Figs. 4.3B and 4.4), a model emerges in which loss of 
peripheral ketone body oxidation results in pooling of D-βOHB, which causes the equilibrium of BDH1 
to shift towards AcAc, such that AcAc becomes the primary ketone body synthesized by de novo hepatic 
ketogenesis. Rising AcAc concentrations initially counteract the propensity of D-βOHB to reduce hepatic 
redox potential, explaining why hepatic NAD+/NADH ratios are normal in fed P0 SCOT-KO mice. 
Continued channeling of β-oxidation-derived acetyl-CoA to AcAc ultimately results in the high plasma 
AcAc/βOHB ratios, and thus elevated hepatic NAD+/NADH ratios observed in P1 germline SCOT-KO 
mice.  
The development of oxidized hepatic redox potential may partially explain the alteration of 
pyruvate and fatty acid handling in livers of P1 SCOT-KO mice. In states of high fat/low carbohydrate 
nutrient supply, the vast majority of pyruvate delivered to the liver enters the TCA cycle via 
carboxylation, rather than decarboxylation to acetyl-CoA via the PDH complex (29).  While the pyruvate 
carboxylation pathway is active, and possibly augmented in livers of P1 SCOT-KO mice, the 13C-
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fractional enrichments of glutamate observed in both (i) the [13C]octanoate + unlabeled pyruvate and (ii) 
the [13C]pyruvate experiments both suggest that flux of pyruvate through PDH is relatively increased in 
livers of SCOT-KO mice. Phosphorylation of the E1 a subunit of PDH was not diminished in livers of P1 
SCOT-KO mice, which suggests equal PDH activity. However, pyruvate concentrations in these 
experiments were high enough that PDH flux could be governed by the concentrations of its cofactor, 
NAD+, and one of its allosteric inhibitors, NADH, whose concentrations are increased and decreased, 
respectively, in livers of P1 SCOT-KO neonates (138,307,310). These findings are consistent with the 
notion that increased gluconeogenic demand, and an oxidized hepatic redox potential together support a 
state of increased pyruvate consumption that culminates in the diminished pyruvate pools that lead to 
hypoglycemia in SCOT-KO mice. An additional consequence of augmented contribution of pyruvate to 
the TCA cycle through acetyl-CoA is diminished contribution of fatty acid oxidation-derived acetyl-CoA. 
While the NMR studies of P1 SCOT-KO mice injected with [13C]octanoate alone indicated equal 
fractional enrichment of 13C-glutamate, this observation was obtained in the context of a diminished total 
glutamate pool, raising the possibility that absolute flux of fatty acids through terminal oxidation is 
reduced in livers of P1 SCOT-KO neonates. Increased circulating concentrations of short-chain 
acylcarnitines in P1 SCOT-KO mice support this hypothesis. These integrated mechanisms merit further 
evaluation in the pathogenesis of human neonatal hypoglycemia, a high-morbidity condition with an 
incidence of 10% (311). 
At birth, mammals experience a shift towards a lipid-dominated energy economy, inducing 
hepatic fatty acid oxidation, ketogenesis, and gluconeogenesis (20). Although rodents are born at an 
earlier developmental stage and exhibit lower neonatal body fat percentages, they suckle milk with higher 
fat contents than humans, and physiological ketosis develops rapidly after birth in both (2,20,71). Case 
reports indicate that HMGCS2- and SCOT-deficient humans adapt poorly to nutrient states that are 
marked by diminished carbohydrate intake. Human HMGCS2 deficiency results in pediatric 
hypoketonemic hypoglycemia (68), and human CoA transferase deficiency manifests as spontaneous 
pediatric ketoacidosis (81,98), which in severe cases is associated with hypoglycemia, and may account 
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for a subset of idiopathic ketotic hyopoglycemia cases (79,102). SCOT-KO mice die in a manner that 
mimics human sudden infant death syndrome (SIDS)/sudden unexpected death in infancy (SUDI), the 
leading cause of death of U.S. infants after the age of one month (312). Inborn errors of ketone body 
oxidation are not currently assessed on any statewide screening protocols in the U.S. (99). Therefore, 
these metabolic abnormalities merit further evaluation, as supported by a recent observational study in 
which metabolic autopsies performed on 255 SIDS patients detected three individuals with underlying 
disorders of ketone body metabolism (216). Thus, a small subset of sudden infant death cases could be 
attributable to undetected defects in ketone body oxidation.  
Due to their small size and delicate nature, steady state analyses of metabolic flux in neonatal 
mice are not currently possible. Therefore, we performed NMR substrate fate mapping after bolus 
injections of octanoate to quantify hepatic fatty acid fate in neonatal mice. This medium chain fatty acid 
avidly enters the mitochondrial matrix independently of allosterically regulated mitochondrial carnitine 
palmitoyltransferase 1a (5), and thus reports the activities of β-oxidation, fractional contribution to the 
TCA cycle, and ketogenesis.  
We have demonstrated that global disruption of ketone body oxidation reprograms hepatic 
intermediary metabolism, initiating a cascade that alters ketogenesis and oxidizes hepatic redox potential, 
and ultimately consumes pyruvate at the expense of terminal hepatic fatty acid oxidation, resulting in 
accumulation of circulating short chain acylcarnitines and hepatic triacylglycerols. Thus, extrahepatic 
ketone body oxidation helps integrate hepatic ketogenesis, redox potential, fatty acid oxidation, and 
glucose production in the neonatal period. Future studies will be needed to determine whether these 
relationships extend to other physiological and pathophysiological states characterized by excess fatty 
acid availability and limited carbohydrate supply (or inefficient carbohydrate utilization), including 
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Figure 4.1. Absence of extrahepatic ketone body oxidation engages an hepatic gluconeogenic 
program in neonatal mice. (A) Relative mRNA abundance of encoded mediators of pyruvate 
metabolism and gluconeogenesis in livers of P1 mice. n = 5/group. (B) Liver glycogen content (µg 
glycogen/mg tissue) in P1 neonates. n = 8/group. p = 0.06 by Student’s t test. (C) Blood alanine, serine, 
and glutamate concentrations (µM) in P1 mice. n = 5-7/group. (D) Circulating amino acid concentrations 
(µM) in blood of P1 mice. n = 5-10/group. (E) Plasma pyruvate pool (pyruvate + lactate) in P1 mice. n = 
8-11/group. (F) Endogenous hepatic glucose concentration (left) and accumulated [13C]glucose in livers 
(right) of P1 mice that had been injected with [3-13C]pyruvate (10 µmol per g body weight) 30 min prior 
to collection of tissues and generation of extracts for NMR. n = 4/group. *, p < 0.05; **, p < 0.01; ***, p 
< 0.001 by Student’s t test. Ppargc1a, PPARg coactivator 1α; Pcx, pyruvate carboxylase; Pck1; 
phosphoenolpyruvate carboxykinase; G6pc, cytoplasmic glucose-6-phosphatase. 
 
Figure 4.2. Alterations of terminal fatty acid oxidation and pyruvate handling in livers of SCOT-
KO mice. (A) Hepatic fractional 13C-enrichments of glutamate (left) and total hepatic glutamate pools 
(right) 20 min after ip injection of sodium [1,2,3,4-13C4]octanoate (10 µmol per g body weight) in P1 
mice. n=6-8/group. (B) Fractional 13C-enrichments of glutamate (left) and total hepatic glutamate pools 
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(right) 20 min after ip injection of sodium [1,2,3,4-13C4]octanoate (10 µmol per g body weight) + 
unlabeled pyruvate (20 µmol/g) in livers P1 mice. n=6-7/group. (C) Fractional 13C-enrichments of 
glutamate 30 min after ip injection of sodium [3-13C]pyruvate (10 µmol per g body weight) in livers P1 
mice. n=4/group. (D) Short-chain acylcarnitine concentrations in blood of untreated P1 mice. n = 5-10/ 
group. (E) Hepatic triacylglycerol (TAG) content in livers of untreated P1 mice. n = 5-6/group. *, p < 
0.05; **, p < 0.01; ***, p < 0.001 by Student’s t test.  
 
Figure 4.3. Mother’s milk-induced impairment of de novo βOHB production in neonatal SCOT-KO 
liver. (A) Hepatic fractional 13C-enrichments of β-hydroxybutyrate (βOHB) (left), total βOHB pools 
(middle), and 13C-βOHB concentration (right) 20 min after ip injection of sodium [1,2,3,4-13C4]octanoate 
(10 µmol per g body weight) in P1 mice. n=6-8/group. (B) Fractional 13C-enrichments of βOHB (left), 
total βOHB pools (middle), and 13C-βOHB concentration (right) 20 min after ip injection of sodium 
[1,2,3,4-13C4]octanoate (10 µmol per g body weight) in livers of unfed P0 mice. n=6/group. (C) Plasma 
total ketone body (TKB) concentration, mM, measured in P0 wild type and SCOT-KO mice prior to the 
onset of suckling. n = 4/group. (D) Plasma TKB, mM, measured in P0 wild type and SCOT-KO mice 
within 2 hours after the onset of suckling. The distributions of D-βOHB and AcAc are shown. n = 8-10/ 
group. †, p < 0.05 for AcAc; *, p < 0.05 for βOHB. n = 6-7/group. (E) Fractional 13C-enrichments of 
βOHB (left), total βOHB pools (middle), and 13C-βOHB concentration (right) 20 min after ip injection of 
sodium [1,2,3,4-13C4]octanoate (10 µmol per g body weight) in milk-fed P0 mice. n = 6-7/group. ***, p 
<0.001 by Student’s t test. AcAc, acetoacetate. 
 
Figure 4.4. Normal in vitro hepatic ketogenesis of livers from SCOT-KO mice. Determination of 
ketone body production (pmol ketone/mg liver), 0.25, 1, and 8 hr after stimulation with BSA-conjugated 
oleic acid (150 µM), was used to derive ketogenic rate (pmol/mg/liver/hr) in liver explants derived from 
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(A) unfed and (B) fed P0 mice. n = 4/group for unfed pups and n = 8-10/group for fed pups. **, p < 0.01; 
***, p <0.001 by 1-way ANOVA. 
 
Figure 4.5. D-βOHB inhibits neonatal hepatic ketogenesis in vivo. (A) Total βOHB pools, (B) 
fractional 13C-enrichments of βOHB, and (C) 13C-βOHB concentrations, 20 min after ip injection of 
sodium [1,2,3,4-13C4]octanoate (10 µmol per g body weight) alone, or co-injected with [13C]octanoate 
plus 20 µmol per g body weight unlabeled AcAc, L-βOHB, or D-βOHB, in livers of milk-fed P0 mice. 
The [13C]octanoate alone datasets (the white bars in these panels) are reproduced from Fig. 3E for 
comparison. n = 5-7/group for each panel. *, p < 0.05; **, p < 0.01; ***, p <0.001 vs. wild type neonates 
injected with [13C]octanoate alone, or as indicated by 1-way ANOVA. ††, p < 0.01, †††, p < 0.001 vs. AcAc 
co-injected neonates. 
 
Figure 4.6. Oxidized hepatic redox potential in P1 SCOT-KO mice. (A) Plasma AcAc/D-βOHB molar 
ratios in milk-fed P0 mice. n = 8-9/group. (B) NAD+/NADH ratios, NAD+, NADH, and total NAD 
[NAD+ + NADH; NADt (nmol/g tissue)] in livers (n = 5/group) and (C) skeletal muscles of fed P0 
neonates (n = 6/group). (D) Plasma AcAc/D-βOHB molar ratios in P1 mice. n = 11-14/group. (E) 
NAD+/NADH ratios, [NAD+], [NADH], and [NADt] (nmol/g tissue) in livers and (F) skeletal muscles of 
P1 wild type and SCOT-KO mice. n = 13-14/group. **, p < 0.01; ***, p <0.001 by Student’s t test. 
 
Figure S4.1. PDH-E1α Ser293 phosphorylation in P1 Liver. (A) Immunoblot for phosphorylated 
Ser293 of Pyruvate Dehydrogenase (PDH) E1α subunit (PDH-p293) and total PDH-E1α (PDHt) in 
protein lysates derived from livers of P0 mice. (B) Densitometric quantification of phosphorylated Ser293 
of PDH-E1α (pSer293-PDHE1α) normalized to total PDHE1α. n = 7/group. 
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Figure S4.2. Normal oxidative and ketogenic machinery in livers of P1 SCOT-KO mice. (A) Relative 
mRNA abundances of Fabp1, Fgf21, Cpt1a, Acadm, Hmgcs2, and Bdh1 in livers of P1 mice. n = 5/group. 
(B) Immunoblots for HMGCS2 and actin in protein lysates derived from livers of P1 mice. Densitometric 
quantification normalized to actin below. n = 4/group. (C) Immunoblots for BDH1 and actin in protein 
lysates derived from livers of P1 mice. Densitometric quantification normalized to actin below. n 
=7/group. *, p < 0.05 by Student’s t test. 
 
Figure S4.3. Normal hepatic fractional enrichment of 13C-glutamate from [13C]octanoate in P0 
SCOT-KO mice. (A) Fractional 13C-enrichments of glutamate (left) and total hepatic glutamate pools 
(right) 20 min after intraperitoneal injection of sodium [1,2,3,4-13C4]Octanoate (10 µmol per g body 
weight) in livers of unfed (n=6-7/group) and (B) milk-fed P0 mice (n = 6/group). 
 
Figure S4.4. Normal oxidative and ketogenic machinery in livers of milk-fed P0 SCOT-KO mice. 
(A) Relative mRNA abundance of Fabp1, Cpt1a, Acadm, Hmgcs2, and Bdh1 in livers of fed P0 mice. n = 
5/group. (B) Immunoblots for HMGCS2 and actin in protein lysates derived from livers of P0 mice. 
Densitometric quantification normalized to actin on right. n = 4/group. *, p < 0.05 by Student’s t test. 
 
Figure S4.5. Relative abundances of mRNAs encoding mediators of NAD+ metabolism and 
signaling in livers of P0 and P1 mice. n = 5/group. Nampt, nicotinamide adenine dinucleotide 
phosphoribosyl transferase. Sirt1, silent mating type information regulation 2 homolog 1. 
 
Figure S4.6. CoA transferase protein abundance in neonatal tissues. CoA transferase (SCOT) and 
actin immunoblots of protein lysates derived from brain, heart, skeletal muscle, and liver collected from 




























    
Sequence (5'-3')  RT-
qPCR 
Primers Forward Reverse  
Acadm GCTGGAGACATTGCCAATCA TCTTGGCGTCCCTCATCAG  
Bdh1 TGCAACAGTGAAGAGGTGGAGAAG CAAACGTTGAGATGCCTGCGTTGT  
Cpt1a CATGTCAAGCCAGACGAAGA TGGTAGGAGAGCAGCACCTT  
Fabp1 AAAGTGGTCCGCAATGAGTTCACC TTGTCACCTTCCAGCTTGACGACT  
Fgf21 CCAGATGTGGGCTCCTCTGAC AGAAACAGCCCTAGATTCAGGAAGAGT  
G6pc AAAGTCAACCGCCATGCAAAGGAC TAGCAAAGAAAGACAGGGCTACCAG  
Hmgcs2 TGGTTCAAGACAGGGACACAGAAC AGAGGAATACCAGGGCCCAACAAT  
Rpl32 CCTCTGGTGAAGCCCAAGATC TCTGGGTTTCCGCCAGTTT  
Pck1 GGAAGGACAAAGATGGCAAGTTC AGGCGTTTTCCTTAGGGATGTAG  
Pcx ACAGCACACACACTACCTGCAATG GCAGGCCCTTATTTGGCAAGAGAT  
Ppargc1a CGGAAATCATATCCAACCAG TGAGGACCGCTAGCAAGTTTG  

















PPARα-dependent ketogenesis prevents hepatic steatosis in neonatal mice 
The work presented in this chapter has been adapted from: 
Cotter, D. G., Ercal, B., d'Avignon, D. A., and Crawford, P. A. Submitted. 
Abstract 
Peroxisome Proliferator Activated Receptor alpha (PPARα) is a master transcriptional regulator of 
hepatic intermediary metabolism. PPARα mediates the adaptive response to fasting. Like fasting, nutrient 
supply is abruptly altered at birth when a transplacental supply of carbohydrates is replaced by a high-fat, 
low-carbohydrate milk diet. Here we use 13C-labeled substrates to quantify dynamic metabolism and 
complimentary systems physiology approaches in neonatal mice to demonstrate a critical role for PPARα 
in hepatic metabolic adaptation to birth. PPARα-Knockout (KO) neonates exhibit hypoglycemia due to 
impaired conversion of glycerol to glucose. Quantitative substrate fate mapping of the medium-chain fatty 
acid [13C]Octanoate in neonatal liver revealed normal contribution of this fatty acid to the hepatic TCA 
cycle in PPARα-KO neonates. Moreover, livers of PPARα-KO neonates showed evidence of direct 
contribution of octanoate-derived 13C-labeled carbons to glucose. These mice also exhibited 
hypoketonemia, which could be mechanistically linked to a 50% decrease in hepatic ketogenesis from 
[13C]Octanoate. Decreased ketogenesis was associated with diminished mRNA and protein abundance of 
the fate-committing ketogenic enzyme mitochondrial 3-hydroxymethylglutarly-CoA synthase and 
decreased protein abundance of the ketogenic enzyme Beta-hydroxybutyrate dehydrogenase 1. Finally, 
hepatic triglyceride and free fatty acid concentrations were increased 6.9- and a 2.7-fold, respectively, in 
PPARα-KO neonates. Together, these findings indicate an important role for PPARα-dependent 







Nutrient supply and organismal bioenergetics shift dramatically at birth. At birth, a continuous 
transplacental nutrient stream replete with carbohydrates ceases and is replaced by a high-fat, low-
carbohydrate milk diet (20,71). Thus, the neonatal liver must coordinate inductions of hepatic fatty acid 
oxidation, ketogenesis, and gluconeogenesis to meet the metabolic demands required for adaptation to 
extrauterine life (20,71). Fatty acid oxidation yields high-energy phosphates and reducing equivalents 
used to fuel the endergonic reactions of hepatic gluconeogenesis, and acetyl-CoA, which can be converted 
to ketone bodies through ketogenesis. While glucose produced in the liver is the primary fuel source for 
the neonatal brain, ketone bodies serve as an important glucose-sparing fuel source (2,4,71,301). Mice 
that cannot oxidize ketone bodies exhibit lethal neonatal hypoglycemia, indicating that ketone body 
metabolism is required for adaptation to birth (78). 
 Ketone body metabolism is a high capacity energy conduit between the liver and extrahepatic 
tissues that can dispose of up to two-thirds of the fat entering the liver (281). In liver mitochondria, a 
series of ketogenic reactions catalyzed by mitochondrial thiolase, mitochondrial 3-
hydroxymethylglutarly-CoA synthase (HMGCS2; fate-committing), and HMG-CoA lyase condense 
acetyl-CoA derived from beta-oxidation of fatty acids into the ketone body, acetoacetate (AcAc), which is 
reduced to beta-hydroxybutyrate (βOHB) by beta-hydroxybutyrate dehydrogenase 1 [(BDH1); reviewed 
in (2,4,5,301)]. Within mitochondria of extrahepatic tissues, BDH1 oxidizes βOHB to AcAc. Terminal 
oxidation of ketone bodies requires covalent activation of AcAc by coenzyme A (CoA), which is 
catalyzed by mitochondrial succinyl-CoA-3:oxoacid CoA transferase (SCOT), the fate committing 
enzyme of ketone body oxidation. SCOT is uniquely required for ketone body oxidation, and thus, 
oxidation of ketones does not occur in its absence (301).  
 Our past studies of germline SCOT-Knockout (KO) mice indicate that ketone body oxidation is 
required for life. All germline SCOT-KO mice die within the first 48 hr of life with hyperketonemia and 
hypoglycemia, and in a manner that phenocopies human sudden infant death syndrome (78,313). 
Surprisingly, ketone body oxidation is dispensable for survival of the neonatal period and starvation in 
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adults when individually eliminated from cardiomyocytes, skeletal myocytes, and neurons, which 
comprise the three greatest consumers of ketone bodies (108). Paradoxically, ketone body oxidation, an 
exclusively extrahepatic process (74,164), contributes to hepatic metabolic homeostasis by preventing 
toxic accumulation of ketone bodies, which alters pyruvate metabolism, fatty acid oxidation, inhibits 
ketogenesis, and oxidizes redox potential in liver (313). Thus, inter-organ coordination of ketogenesis and 
ketone body oxidation is critical for preservation of hepatic intermediary metabolism, which is vital 
during the transition to extrauterine life. 
The nuclear receptor Peroxisome Proliferator Activated Receptor alpha (PPARα) acts as a master 
transcriptional regulator of hepatic intermediary metabolism (314,315). Fasted PPARα-KO mice exhibit 
hypoglycemia, hypoketonemia, and hepatic steatosis (316,317). In response to fatty acids, PPARα 
promotes ketogenesis by inducing enzymatic mediators of fatty acid oxidation, Fibroblast growth factor 
21 (Fgf21), and by directly stimulating Hmgcs2 transcription (50,52,53,318,319). Significant overlap 
exists between the bioenergetic challenges faced during fasting and during the transition to birth. 
Therefore, we applied high-resolution measures of dynamic metabolism using 13C-labeled substrates and 
systems physiology approaches to neonatal mice to determine the mechanisms by which PPARα supports 
adaptation to birth. 
 
Methods 
Animals. Fed postnatal day zero (P0, the first day of postnatal life) mice were collected within 4 hr of 
birth. All P1 mice were maintained with the dam through the first 30h after birth, and were milk fed. The 
presence of gastric milk spots was checked in all mice, both by visual inspection of the abdomen prior to 
experimentation and by gross examination of the gastric contents after sacrifice. Breeder pairs were 
maintained at 22oC on standard polysaccharide-rich chow diet (Lab Diet 5053) and autoclaved water ad 
libitum. Lights were off between 1800 and 0600. All experiments consisted of mouse pups that were 
harvested from at least two litters from two different breeder pairings. All experiments were conducted 
using protocols approved by the Animal Studies Committee at Washington University. 
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Plasma Metabolite Quantification. Serum total ketone bodies (TKB) were determined using standard 
biochemical assays coupled to colorimetric substrates as described previously (51). Blood glucose was 
measured in duplicate using handheld glucometers (Aviva). 
Tissue Metabolite Quantification. Hepatic triacylglyceride (TAG) and free fatty acid (FFA) 
concentrations were quantified biochemically using a Folch extract of liver, as described previously 
(126). 
Gene expression analysis. Quantification of gene expression was performed using real-time RT-
quantitative PCR using the ΔΔCt approach as described (51), normalizing to Rpl32, using primer 
sequences listed within Table 5.1.  
Immunoblotting. Lysates from liver were generated in a protein lysis buffer: 20 mM Tris-HCl, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 1% phosphatase inhibitor cocktail (Sigma), and protease inhibitor 
cocktail (complete mini EDTA-free, Roche), pH 7.5. Immunoblots to detect HMGCS2 (rabbit anti-
mHMGCS; Santa Cruz Biotechnology), BDH1 (rabbit anti-BDH1; Proteintech Group), and actin (rabbit 
anti-actin, Sigma) were performed as described (78). Band intensities were quantified densitometrically 
using Quantity One software (Bio-Rad). 
Glycerol and glucose tolerance tests. Glucose and glycerol tolerance were measured in fed P0 mice that 
had been removed from the dam and maintained on a heating pad for the duration of the experiment. For 
glucose tolerance tests, neonates were injected intraperitoneally (ip) with 4% glucose dissolved in milliQ 
H2O (2g/kg body weight). Blood glucose was measured at 15 min and at 60 min after glucose 
administration via tail snip and decapitation, respectively. For glycerol tolerance tests, neonates were 
injected with 4% glycerol in phosphate buffered saline (2g/kg body weight). Blood glucose was measured 
prior to glycerol administration via tail snip and 45 min after glycerol administration via decapitation. 
In vivo substrate utilization. P0 or P1 mice were injected ip with 10 µmol of sodium [1,2,3,4-
13C4]octanoate per g of body weight (vendor for stable isotopes: Cambridge Isotope Laboratories). After 
intraperitoneal injections, neonatal mice were maintained on a heating pad for 20 min, killed by 
decapitation, and tissues were rapidly freeze-clamped in liquid N2. Neutralized perchloric acid tissue 
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extracts were profiled using 13C-edited proton nuclear magnetic resonance (NMR) measured at 11.75 T 
(Varian/Agilent Direct Drive-1) via first increment gradient heteronuclear single-quantum 
correlation (gHSQC). Signals were collected from extracts dissolved in 275 µL of D2O + 1 mM 
trimethylsilyl propionate (TSP), loaded into high precision, thin walled 5-mm tubes (Shigemi). 
Quantification of signals by integration of the 1H{13C} and 13C-edited (gHSQC) collections of carbon 2 
for taurine, carbon 4 for βOHB, carbon 1 for glucose, and carbon 4 for glutamate were as described 
previously (78). Fractional enrichments of 13C-labeled glucose, glutamate, and βOHB and tissue 




PPARα deficient neonates exhibit hypoglycemia due to impaired gluconeogenesis from glycerol. During 
fasting, the switch to a lipid-dominated nutrient supply evokes hypoglycemia in adult PPARα-KO mice 
(316,317). Similarly, the shift to a high-fat, low-carbohydrate milk diet caused hypoglycemia in neonatal 
PPARα-KO mice. On the first day of life, postnatal day zero (P0), glycemia did not differ between wild 
type and PPARα-KO neonates (Fig. 5.1A, left). As expected, wild type neonates significantly increased 
glycemia between P0 and the second day of life [(P1); Fig. 5.1A, white bars]. In contrast, PPARα-KO 
neonates failed to increase glycemia between P0 and P1 (Fig. 5.1A, black bars), and on P1, blood 
glucoses were significantly lower in PPARα-KO neonates compared to control mice (Fig. 5.1A, right). 
Glucose tolerance tests in P0 mice demonstrated that glucose utilization was not different between wild 
type and PPARα-KO neonates (Fig. 5.1B), suggesting that impaired gluconeogenesis might underlie the 
hypoglycemia of PPARα-KO neonates. While hepatic mRNA abundances of the gluconeogenic mediators 
Phosphoenol pyruvate carboxykinase (Pck1), Glucose-6-phosphatase (G6Pc), and Glycerol Kinase (Gyk) 
did not differ between groups of mice on P0 or P1, expression of Glycerol phosphate dehydrogenase 
(Gpd2) trended lower in PPARα-KO neonates on P0 and P1 (Fig. 5.2A-D). Furthermore, blood glucoses 
were lower in P0 PPARα-KO neonates following intraperitoneal glycerol administration (glycerol 
126 
tolerance test), suggesting that PPARα-KO neonates do not effectively convert glycerol to glucose (Fig. 
5.2E). These results indicate that PPARα supports glycemia during adaptation to birth by promoting 
gluconeogenesis from glycerol. 
Loss of PPARα does not disrupt oxidation of medium-chain fatty acids in neonatal liver. PPARα 
influences hepatic energy metabolism through transcriptional regulation of the mediators of fatty acid 
oxidation, which is critical for gluconeogenesis. Surprisingly, mRNA abundances of many known PPARα 
target genes involved in fatty acid oxidation, including Peroxisome proliferator activated receptor gamma 
coactivator 1-alpha (Ppargc1a), Carnitine palmitolytransferase 1a (Cpt1a), and Acyl-CoA oxidase (ACO) 
were not different between groups of mice on either P0 or P1 (Fig. 5.3A-C). In fact, PPARα-KO neonates 
significantly induced Cpt1a between P0 and P1 (Fig. 5.3B). Of the mediators of fatty acid oxidation 
analyzed, only medium chain acyl-CoA dehydrogenase (Acadm) transcript abundances were significantly 
decreased in PPARα-KO neonates, and only on P1 (Fig. 5.3D). Next, we directly analyzed fatty acid 
oxidation in neonatal liver using proton edited 13C-nuclear magnetic resonance (NMR) spectroscopy to 
quantify contribution of the medium-chain fatty acid [13C]octanoate to the hepatic tricarboxylic acid 
(TCA) cycle. Following a 20 min incubation with [13C]octanoate (10µmol/g body weight), neonates were 
sacrificed and livers were extracted for NMR profiling. 13C-enrichment of glutamate, which serves as a 
quantitative surrogate for entry of 13C-acetyl-CoA into the TCA cycle for terminal oxidation (136), and 
tissue glutamate concentrations (pool)  did not differ between groups of mice on P0 or P1 (Fig. 5.3E). 
Concentrations of taurine, a normalizing metabolite, also did not differ between groups of mice on P0 or 
P1 (Fig. 5.3F). Moreover, 13C-glucose enrichment from [13C]octanoate was detected in both wild type and 
PPARα-KO neonates on P0 and in PPARα-KO neonates on P1 (Fig. 5.3G, left). On P1, enrichment of 
13C-glucose from octanoate was 3-fold greater in PPARα-KO neonates compared to wild type mice (Fig. 
5.3G, left). Since hepatic glucose pools did not differ between groups, increased enrichment reflects 
increased gluconeogenesis from octanoate in the PPARα-KO neonates. 13C –enrichments of 2-3% are 
very low, as 1% enrichment occurs from naturally abundant 13C. Nonetheless, these results indicate 
preserved contribution of fatty acids to the hepatic TCA cycle in PPARα-KO neonates. 
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Hepatic steatosis is linked to impaired ketogenesis in PPARα deficient neonates. To test the hypothesis 
that loss of PPARα, which is an important inducer of Hmgcs2 and ketogenesis in adult mice, would 
disrupt ketone body metabolism during the highly ketogenic neonatal period (2,4,20,50,316,317), we 
performed a series of experiments in wild type and PPARα deficient neonatal mice. Circulating total 
ketone body (TKB) concentrations were significantly lower in PPARα-KO neonates on P1 (Fig. 5.4A). 
Blunted ketonemia was associated with a 3-fold decrease in Hmgcs2 transcript abundance on P1 (Fig. 
5.4B). Conversely, Bdh1 transcript abundance increased significantly between P0 and P1 in both wild 
type and PPARα-KO neonates (Fig. 5.4C). Immunoblots in liver demonstrated that HMGCS2 protein 
abundance was decreased ~25% on P0 and ~ 20% on P1 in PPARα-KO neonates (Fig. 5.4D, middle). 
Despite decreased Hmgcs2 mRNA abundance in P1 PPARα-KO livers, HMGCS2 protein abundance 
increased ~ 25% in both genotypes. BDH1 protein abundance was decreased ~25% on P1 in PPARα-KO 
neonates, and unlike wild type mice, did not increase from P0 to P1 (Fig. 5.4D, bottom). NMR profiling 
of [13C]Octanoate metabolism in neonatal liver revealed that blunted ketonemia was due to impaired 
ketogenesis. Enrichment of 13C-βOHB was decreased ~ 33% on P0 and ~50% on P1 in PPAR-α-KO 
livers (Fig. 5.5A, left). Because hepatic βOHB concentrations did not differ between genotypes on P0 or 
P1 (Fig. 5.5A, right), decreased 13C-βOHB enrichment reflects decreased ketogenesis. In addition, livers 
of PPAR-α-KO mice exhibited significantly increased concentrations of hepatic triacylglycerides (TAG) 
and free fatty acids (FFA) on P1 (Fig. 5.5B-C). Together, these results indicate an important role for 
PPARα-dependent ketogenesis in prevention of hepatic steatosis in neonatal mice. 
 
Discussion 
The transition to extrauterine life incurs marked shifts in nutrient availability and energy metabolism. In 
contrast to the carbohydrate-replete nutrient state experienced in utero, the neonatal energy economy is 
dominated by lipid metabolism. Thus, it is surprising that mice deficient in PPARα, a master regulator of 
lipid metabolism, survive the neonatal period. Using NMR to quantitatively map substrate fate in neonatal 
liver and systems physiology approaches, we have identified and mechanistically dissected the metabolic 
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defects exhibited by PPARα-KO neonates. These mice showed hypoglycemia that was mechanistically 
linked to decreased gluconeogenesis from glycerol. Surprisingly, livers of PPARα-KO mice exhibited 
normal expression of many mediators of fatty acid oxidation. Furthermore, terminal oxidation of the 
medium-chain fatty acid octanoate was normal in livers of these mice. Unlike fatty acid oxidation, 
ketogenesis was markedly impaired in PPARα-KO neonates. These mice displayed hypoketonemia due to 
a 50% decrease in hepatic ketogenesis that was linked to decreased expression of ketogenic enzymes and 
was associated with hepatic steatosis. Together, our results identify a critical role for PPARα-dependent 
ketogenesis in disposal of excess hepatic fatty acids in the neonatal period.  
PPARα-KO neonates exhibited hypoglycemia, hypoketonemia, and hepatic steatosis, and thus, 
phenocopy fasted adult PPARα-KO mice (316,317). The mechanisms underlying fasting hypoglycemia in 
adult PPARα-KO mice are controversial. Kersten and colleagues have linked hypoglycemia to decreased 
hepatic glucose production from glycerol (320), while Xu et al. has shown preserved gluconeogenesis 
from glycerol (321). Our results in neonates are most consistent with the findings of Kersten et al., as 
glycerol tolerance tests revealed that PPARα-KO neonates do not effectively convert glycerol to glucose. 
While increased glucose utilization could drive hypoglycemia, adult PPARα-KO mice actually exhibit 
decreased glucose utilization (320). Similarly, glucose tolerance did not differ between groups of neonatal 
mice, suggesting that increased glucose utilization was not responsible for neonatal hypoglycemia. 
Since hepatic fatty acid oxidation supports gluconeogenesis, impaired fatty acid oxidation is 
frequently offered as a cause of hypoglycemia in PPARα-KOs (316,317). However, due to the challenges 
associated with directly measuring contribution of fatty acids to the TCA cycle, ketonemia is often used 
as a surrogate for fatty acid oxidation. Here we used [13C]Octanoate, a medium chain fatty acid avidly 
enters the mitochondrial matrix independently of allosterically regulated mitochondrial carnitine 
palmitoyltransferase 1a (5), to directly interrogate the activities of β-oxidation, fractional contribution to 
the TCA cycle, and ketogenesis. Our results indicate that impaired fatty acid oxidation does not contribute 
to hypoglycemia in PPARα-KO neonates, since contribution of [13C]Octanoate to the TCA cycle for 
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terminal oxidation was normal in livers of these mice. Second, our results indicate that ketogenesis is a 
poor surrogate for fatty acid oxidation, as ketonemia and ketogenesis are diminished in PPARα-KO 
neonates (Fig. 5.4A and 5.5A), while contribution of fatty acid oxidation-derived Ac-CoA to the TCA 
cycle is preserved (Fig. 5.3E). In fact, contribution of [13C]Octanoate to the hepatic TCA cycle is robust 
enough to measure its incorporation into 13C-glucose (Fig. 5.2G). Fatty acid carbons do not normally 
contribute to gluconeogenesis because rates of pyruvate carboxylation (to the TCA cycle intermediate 
oxaloacetate) and subsequent efflux into gluconeogenesis (pyruvate cycling) greatly exceed TCA cycle 
flux in liver (30,322). Prospectively, impaired mitochondrial pyruvate carboxylase activity (encoded by 
Pcx, a PPARα target gene) could permit increased incorporation of fatty-acid derived carbon into glucose 
and impair gluconeogenesis from pyruvate. Furthermore, 13C-labeling of glucose detected in the present 
study does not reflect net gluconeogenesis from fatty acids. Unlike lower organisms, mammals cannot 
channel net acetyl-CoA carbon into glucose due to absence of the glyoxyalte cycle enzymes isocitrate 
lyase and malate synthase (323). Ac-CoA entering the mammalian TCA cycle must instead pass through 
two obligatory decarboxylation reactions, catalyzed by isocitrate dehydrogenase and alpha-ketoglutarate 
dehydrogenase, before proceeding on to generate gluconeogenic intermediates. Because two moles of 
carbon are lost as CO2 for every mole of Ac-CoA that enters the mammalian TCA cycle, net 
gluconeogenesis from fat does not occur.  
As indicated above, PPARα-KO neonates exhibited marked suppression of hepatic ketogenesis. 
On P0, ketogenesis was diminished by ~33%, and by P1, the diminution of ketogenesis reached 50%. 
Such ketogenic suppression seems disproportionate to the moderately decreased HMGCS2 and BDH1 
protein abundances observed in livers of these mice. Prospectively, decreased activity of the NAD+-
dependent mitochondrial deacylases Sirtuin 3 and 5, which increase HMGCS2 enzymatic activity via 
deacetylation and desuccinylation, respectively (64,324), could account for the apparent mismatch 
between low 13C-βOHB enrichment and nearly normal HMGCS2 and BDH1 protein abundances. 
Nonetheless, ketogenic suppression was associated with massive hepatic steatosis. PPARα-KO livers 
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exhibited 6.9- and 2.7-fold increases in TAG and FFA concentrations, respectively. Together, these 
results reveal an important role for PPARα-dependent ketogenesis in disposal of excess hepatic fat that 
may be relevant to nonalcoholic fatty liver diseae (NAFLD). 
NAFLD and nonalcoholic steatohepatitis (NASH) affect approximately one billion individuals 
worldwide and incur significant morbidity and mortality (325-327). Nonetheless, effective therapies that 
directly target NAFLD and NASH do not currently exist (328). While PPARα deficiency increases 
NASH susceptibility (329,330), treatment with the PPARα agonist Wy-14643 protects against diet-
induced steatohepatitis in mice (330). Similarly, fenofibrate treatment ameliorated NASH in mice (331). 
Unfortunately, fenofibrate treatment does not decrease hepatic triglyceride content in human NAFLD 
(332,333). One resolution for this interspecies discrepancy is offered by the finding that PPARα agonists 
stimulate ketogenesis much more robustly in rodents than in humans (334-338). Thus, development and 
testing of direct ketogenic activators for mitigation of human NAFLD is warranted. 
 
Figure legends: 
Figure 5.1: PPARα-KO mice exhibit neonatal hypoglycemia. A. Blood glucose on postnatal day zero and 
one (P0 and P1) in suckling wild type and PPARα-KO mice. B. Glucose tolerance in P0 mice. Basal 
glycemia (0 min timepoint) is replicated from A since glycemia can only be measured twice in neonatal 
mice. n > 10/group, ***, p < 0.001 by 2-way ANOVA, as indicated. 
 
Figure 5.2: PPARα promoted gluconeogenesis from glycerol in neonatal mice. A-D. mRNA abundances 
of gluconeogenic mediators in liver. n = 5/group, **, p < 0.01 by 2-way ANOVA, as indicated. 
 E. Glycerol tolerance test in fed P0 mice, n > 10/group**, p < 0.01 by Student’s t test, as indicated. 
Phosphoenolpyruvate carboxykinase 1, Pck1; Glucose-6-phophatase, G6pc; Glycerol kinase, Gyk; 
Glycerol phosphate dehydrogenase, Gpd2. 
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Figure 5.3: Normal hepatic fatty acid oxidation in PPARα-KO neonates. A-D. Hepatic mRNA 
abundances of mediators of fatty acid oxidation. n = 5/group, *, p < 0.05 by 2-way ANOVA, as indicated. 
E. Hepatic fractional 13C-enrichments of glutamate (left) and total hepatic glutamate pools (right) 20 min 
after ip injection of sodium [1,2,3,4-13C4]octanoate (10 µmol per g body weight) in neonatal mice. n=3-
8/group. F. Total hepatic taurine pools from the same mice as in E. G. Hepatic fractional 13C-enrichments 
of glucose (left) and total hepatic glucose pools (right) from the same mice as in E.  **, p < 0.01 by 2-way 
ANOVA, as indicated. Peroxisome proliferator activated receptor gamma coactivator 1-alpha, Pparg1a; 
Carnitine palmitoyl transferase 1a, Cpt1a; Acyl-CoA oxidase, ACO; Medium chain acyl-CoA 
dehydrogenase, Acadm. 
 
Figure 5.4: PPARα-KO neonates exhibit hypoketonemia due to decreased expression of ketogenic 
enzymes. A. Serum total ketone bodies (TKB) in fed neonatal mice, n > 6/group. B-C. Hepatic mRNA 
abundances of ketogenic enzymes, n = 5/group. D. Immunoblots for mitochondrial 3-
hydroxymethylglutaryl CoA synthase 2 (HMGCS2), beta-hydroxybutyrate dehydrogenase 1 (BDH1), and 
actin in neonatal liver (quanitification normalized to actin below). n = 4/group, *, p < 0.05, **, p < 0.01, 
***, p < 0.001 by 2-way ANOVA, as indicated. 
 
Figure 5.5: Ketogenic suppression is associated with neonatal hepatic steatosis. A. Hepatic fractional 13C-
enrichments of β-hydroxybutyrate (βOHB) (left) and total βOHB pools (right) 20 min after ip injection of 
sodium [1,2,3,4-13C4]octanoate (10 µmol per g body weight) in neonatal mice. n = 3-8/group, 
*, p < 0.05 by 2-way ANOVA. B. Hepatic triacylglyceride (TAG) and free fatty acid (FFA; C) 

















Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia through coenzyme A 
recycling 
The work presented in this chapter and subchapters has been adapted from: 
Cotter, D. G., Ercal, B., Leid, J. M., d'Avignon, D. A., Graham, M. J., Dietzen, D. J., Brunt, E. M., and 
Crawford, P. A. Submitted. 
Summary 
Nonalcoholic fatty liver disease (NAFLD) spectrum disorders affect approximately one billion 
individuals worldwide, and incur significant morbidity and mortality (325-327). The driver mechanisms 
that underlie NAFLD remain incompletely defined, impeding the development of effective treatments 
(328,339,340). Here we use a murine model of mitochondrial 3-hydroxymethylglutaryl CoA synthase 
(HMGCS2)-deficiency to demonstrate a critical role for ketogenesis in the modulation of hepatic glucose 
production and prevention of hepatic injury and inflammation in ‘non-ketogenic’ nutrient states. Using 
nuclear magnetic resonance spectroscopy to quantitatively map 13C-labeled substrate fate in perfused 
livers, we show that adult-onset loss of HMGCS2 increases hepatic gluconeogenesis from pyruvate and 
causes mild hyperglycemia in the fed state. High-fat diet feeding of ketogenesis insufficient mice causes 
extensive hepatocyte injury, pan-acinar inflammation, and elevated serum alanine aminotransferase 
activity. Hepatocellular injury in ketogenesis insufficient mice fed a high fat diet was associated with 
decreased glycemia, which could be mechanistically linked to fatty acid-induced sequestration of free 
coenzyme A (CoASH) that caused secondary derangements of hepatic tricarboxylic acid (TCA) cycle 
intermediate concentrations and impaired gluconeogenesis. Supplementation of the CoASH precursors 
pantothenic acid and cysteine normalized TCA intermediates and hepatic glucose production in 
ketogenesis insufficient livers. These findings identify hepatic ketogenesis as a critical regulator of 
hepatic glucose metabolism and TCA cycle function via coordination of CoASH homeostasis in the 





Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are now the most 
common causes of liver disease in Western countries (325). NAFLD-induced liver failure is one of the 
most common reasons for liver transplantation. NAFLD increases the risk of developing type 2 diabetes, 
worsens glycemic control, and contributes to the pathogenesis of cardiovascular disease and chronic 
kidney disease (341-343). The pathogenic mediators that favor a NAFLD or NASH phenotype are 
incompletely understood, but are thought to involve abnormalities of hepatocyte metabolism, hepatocyte 
autophagy and endoplasmic reticulum stress, hepatic immune cell function, adipose tissue inflammation, 
and systemic inflammatory mediators (341,343-345). Perturbations of carbohydrate, lipid, and amino acid 
metabolism occur in and contribute to obesity, diabetes, and NAFLD in humans and in model organisms 
[reviewed in (346-350)]. While hepatocyte abnormalities in cytoplasmic lipid metabolism are commonly 
observed in NAFLD (335), the role of mitochondrial metabolism, which governs the oxidative and 
terminal ‘disposal’ of fats, in NAFLD pathogenesis is less clear. Nonetheless, most investigators agree 
that abnormalities of mitochondrial metabolism occur in and contribute to NAFLD [reviewed in (351-
353)]. 
Ketogenesis can dispose of as much as two-thirds of the fat entering the liver (281), and thus 
dysregulation of ketone body metabolism could potentially contribute to NAFLD pathogenesis. Hepatic 
ketogenesis is activated in states of high fatty acid and diminished carbohydrate availability, and/or when 
circulating insulin concentrations are very low (2,4,5,301). Within hepatic mitochondria, ketogenic 
reactions condense β-oxidation-derived acetyl-CoA into the ketone bodies acetoacetate (AcAc) and beta-
hydroxybutyrate (βOHB). In doing so, ketogenesis disposes of acetyl-CoA generated in excess of the 
liver’s own energetic needs and simultaneously recycles two moles of free CoASH per mole of ketone 
produced [reviewed in (4,5,301)]. Robust ketogenesis is limited to hepatocytes due to relatively restricted 
expression of the fate-committing ketogenic enzyme, mitochondrial 3-hydroxymethylglutaryl-CoA 
synthase (HMGCS2), under normal conditions (44). In contrast, oxidative disposal of ketone bodies is 
nearly ubiquitous, as all cells, except for hepatocytes, express the fate-committing enzyme of ketone body 
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oxidation, succinyl-CoA:3-oxoacid CoA transferase [SCOT; (74,164)]. Within mitochondria of 
extrahepatic tissues, βOHB is re-oxidized to AcAc, and via a reaction uniquely catalyzed by SCOT, is 
directed towards the TCA cycle for terminal oxidation (301). Despite the high capacity for disposal of 
hepatic fatty acids, ketone body metabolism has been overlooked as a potential therapeutic target in 
NAFLD.  
Through incompletely defined mechanisms, obesity-associated hyperinsulinemia suppresses 
ketogenesis creating a state of ketogenic insufficiency and leading to relative hypoketonemia in obese 
animal models and humans, when compared to lean controls (12,42,238,239,354,355). To test the 
hypotheses that impaired ketogenesis, even in carbohydrate replete and thus ‘non-ketogenic’ states, 
contributes to abnormal glucose metabolism and provokes steatohepatitis, we generated a mouse model of 
ketogenic insufficiency, and used complementary high-resolution measures of dynamic metabolism using 




Ketogenic insufficiency causes abnormal hepatic glucose and lipid metabolism. The ability of 
ketogenesis to influence hepatic glucose and lipid homeostasis has only been preliminarily defined. To 
determine the consequences of impaired ketogenesis during the highly ketogenic neonatal period, 
suckling mice were injected subcutaneously (25 mg/kg) with an HMGCS2 targeted antisense 
oligonucleotide (ASO) daily beginning on the second day of extrauterine life. Compared to littermates 
injected with scrambled sequence control ASO, HMGCS2 ASO treatment decreased hepatic HMGCS2 
protein abundance by 70% by postnatal day 12 (Fig. 6.1A). These mice exhibited normal body weights 
and blood glucose concentrations, and displayed mildly decreased plasma ketone body concentrations 
(0.9 ± 0.05 mM vs. 1.3 ± 0.17 mM in controls, n =4-6/group, p < 0.05; Fig. 6.1B and Fig. S6.1A-B). 
Intriguingly, this partial loss of ketogenesis was associated with a nearly seven-fold increase in hepatic 
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triacylglycerol (TAG) concentrations (6.56 ± 1.2 vs. 0.96 ± 0.2 mg/g tissue in controls, n =4-6/group, p < 
0.001; Fig. 6.1C). To determine whether HMGCS2-mediated ketogenesis plays a role in a model of adult 
NAFLD, we performed intraperitoneal injections of HMGCS2 ASO (25 mg/kg biweekly for four weeks) 
into C57BL/6 male mice maintained on a standard low-fat chow diet. After four weeks, hepatic Hmgcs2 
transcript abundance was decreased by 88% (n = 8-10 per group, p < 0.001), without diminishing the 
scant Hmgcs2 transcript abundance normally observed in subcutaneous adipose tissue [(356), (Fig. 
S6.1C-D)], and immunoreactive HMGCS2 was eliminated from liver compared to mice treated with a 
scrambled sequence control ASO (Fig. 6.1D). ASO treatment did not diminish protein abundance of 
cytoplasmic 3-hydroxymethylglutaryl-CoA synthase (HMGCS1), which catalyzes the penultimate 
reaction in mevalonate synthesis (Fig. S6.1E).  
HMGCS2 ASO-treated mice exhibited markedly blunted ketonemia at both baseline (fed state) 
and in response to nutrient deprivation (Fig. 6.1E). To confirm the inability of HMGCS2 ASO-treated 
mice to effectively incorporate fatty acid-derived carbon into ketone bodies, livers from control and 
HMGCS2 ASO-treated mice were perfused via the portal vein with an oxygenated buffer containing 
[13C]octanoic acid. Quantitative mapping of 13C-label into the ketone body βOHB, using 13C-edited 
proton NMR profiling (51,78,108,313), revealed markedly blunted hepatic ketogenesis in livers of 
HMGCS2 ASO-treated mice in both the fed and fasted state, confirming that HMGCS2 is required for 
effective derivation of ketone bodies from fatty acids, indicating that livers of these mice exhibit impaired 
ketogenesis, i.e. are ketogenesis insufficient (Fig. S6.1F). Despite exhibiting marked ketogenic 
impairment, HMGCS2 ASO-treated mice fed a standard low fat chow diet did not differ in body weights, 
body composition, or food intake compared to control mice (Fig. S6.2A-C). HMGCS2 ASO-treated mice 
also exhibited normal serum free fatty acid (FFA) and TAG concentrations and a normal physiologic 
distribution of residual βOHB and AcAc (Fig. 6.2D-F). Interestingly, HMGCS2 ASO-treated mice 
displayed mild, but very consistently elevated blood glucose concentrations (160.9 ± 3.2 vs. 145.0 ± 3.4 
mg/dL in controls, n = 28-36/group, p = 0.0013) without changes in serum insulin concentrations (Fig. 
S6.2G-H).  
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Ketogenic insufficiency causes hepatic inflammation, injury, and reprogrammed intermediary 
metabolism in the setting of carbohydrate-replete overnutrition. To determine the effects of ketogenic 
insufficiency in the context of overnutrition, mice previously receiving ASOs for two weeks while on a 
standard low-fat chow diet were then maintained for eight weeks on a 60% high fat diet (HFD) that is 
commonly used to induce hyperglycemia and hepatic steatosis and inflammation in wild-type mice. 
HMGCS2 immunoblots indicated that hepatic HMGCS2 protein abundance was decreased by 93% within 
two weeks of ASO treatment (Fig. S6.3A), and continued to decrease to undetectable levels by the end of 
the eight week HFD-feeding interval, during which time ASO treatments were continued biweekly (Fig. 
S6.3B). While serum TAG and FFA concentrations did not differ between groups of HFD-fed mice (Fig. 
S6.3C-D), serum ketone body concentrations were significantly decreased in HFD-HMGCS2 ASO-
treated mice (0.04 ± 0.02 mM vs. 0.26 ± 0.03 mM, p < 0.0001, n = 8-10/group; Fig. S6.3E). After 8 
weeks of HFD-feeding, control and HMGCS2 ASO-treated mice exhibited mild hepatic steatosis to an 
equal extent, as determined by biochemical quantification of hepatic TAG (Fig. 6.2A). As expected, 
serum alanine aminotransferase (ALT) activity, a circulating biomarker of hepatocellular injury, was not 
elevated in HFD-fed control mice, given the relatively brief duration of HFD maintenance (Fig. 6.2B). 
Conversely, HFD-feeding increased serum ALT activity by nearly four-fold in HMGCS2 ASO-treated 
mice compared to those maintained on standard chow (223.5 ± 37.65 vs. 61.2 ± 4.03 U/L in chow-fed 
HMGCS2 ASO-treated mice, n = 4-5/group, p < 0.0001) and three-fold compared to HFD-fed control 
mice [(223.5 ± 37.65 vs. 74.25 ± 6.14 U/L in controls, n = 4/group, p < 0.0001); (Fig. 6.2B)]. Blinded 
histopathologic evaluation of liver tissue from ketogenesis insufficient mice fed a HFD exhibited 
evidence of injury, including pan-acinar inflammatory infiltrates and acidophil bodies [(dying 
hepatocytes; (Fig. 6.2C)]. These findings were not observed in livers from HFD-fed control ASO-treated 
mice or chow-fed HGMCS2-deficient mice (Fig. 6.2C). In addition, livers of HFD-fed HMGCS2 ASO-
treated mice exhibited increased numbers of sinusoidal macrophages, confirmed with F4/80 
immunohistochemical staining (80.47 ± 6.09 vs. 49.33 ± 3.17 F4/80+ cells/20X field, p < 0.001, n = 5 
fields/liver from three livers/group; Fig. 6.2D) and increased evidence of stellate cell activation, as 
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indicated by anti-smooth muscle actin immunostaining (8.19 ± 1.00 vs. 3.36 ± 0.61 SMA+ cells/10X field, 
p < 0.001, n = 19 fields/liver from three livers/group; Fig. 6.2E). These results indicate that ketogenic 
insufficiency in the setting of overnutrition accelerates a pronounced NASH-like phenotype. 
To determine the metabolic effects of ketogenic insufficiency in the setting of overnutrition, we 
monitored blood glucose concentrations during the course of HFD administration. While blood glucose 
levels were higher in HMGCS2 ASO-treated mice at the onset of HFD, glycemia began to decline in 
these mice after five weeks of maintenance on this diet (Fig. 6.3A-B). HFD-fed HMGCS2 ASO-treated 
mice also gained significantly less weight than control mice (final weight after HFD-feeding: 26.82 ± 0.7 
g vs. 30.32 ± 1.2 g in controls, p = 0.019, n = 8-10/group) and ingested fewer calories [(9.96  ± 0.3 
kCal/mouse/day vs. 12.91 ± 0.3 kCal/mouse/day in controls, p < 0.0001, n = 8-10 mice/group over 16 
measurements of food intake); (Fig. S6.4A-B)]. Furthermore, gluconeogenesis from [13C]pyruvate (and 
its redox partner [13C]lactate, which was also included in these perfusions in physiological proportion to 
maintain normal NAD+/NADH redox potential) was decreased four-fold in livers of HFD-fed HMGCS2 
ASO-treated mice (1.8 ± 0.3% vs. 7.3 ± 1.1 enrichment as [13C]glucose in controls, p = 0.0009, n = 4-
5/group; Fig. 6.3C). While the total hepatic glucose pool was expanded in perfused livers of HFD-fed 
HMGCS2 ASO-treated mice (Fig. S6.5A), de novo 13C-labeling of glucose from [13C]pyruvate was 
markedly diminished in HFD-fed HMGCS2 ASO-treated livers (3.91 ± 1.67 vs. 10.44 ± 0.9 pmol 
[13C]glucose produced/mg tissue in controls,  p = 0.0156, n = 4-5/group; Fig. 6.). Similar to the responses 
to the 60% HFD, HMGCS2 ASO-treated mice maintained on a distinct 40% fat/sucrose enriched diet for 
8 weeks also exhibited decreased weight gain, decreased caloric intake, decreased body fat percentages, 
and decreased blood glucoses (Fig. S6.4C-F). Ketogenesis insufficient mice fed a 40% fat diet also 
exhibited equivalent hepatic steatosis to control HFD-fed mice, modestly increased serum ALT activity, 
and microgranuloma formation and inflammatory infiltrates in liver (Fig. S6.6A-C). Importantly, both the 
elevation of serum ALT activity and the degree of histopathologic evidence of hepatic inflammation was 
diminished in HMGCS2 ASO-treated mice fed a 40% fat diet compared to those fed a 60% HFD, 
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suggesting that chronic exposure to excess dietary fat drives the NASH-like phenotype observed in 
HMGCS2 ASO-treated mice. 
To define the specific metabolic mechanisms leading to fatty acid induced hepatocellular 
dysfunction, we quantified gluconeogenesis from [13C]pyruvate in perfused livers of ASO-treated mice 
fed a standard low-fat chow diet in the presence and absence of octanoic acid, a medium chain fatty acid 
that enters the mitochondrial matrix independently of carnitine palmitoyltransferase 1 (CPT1), and rapidly 
stimulates mitochondrial β-oxidation and gluconeogenesis (5). Consistent with hyperglycemia in chow-
fed HMGCS2 ASO-treated mice (Fig. S6.2G), basal gluconeogenesis from pyruvate was increased (15.21 
± 2.06% 13C-enrichment of glucose, vs. 9.04 ±1.01% in controls, n = 7-8/group, p = 0.015, Fig. 6.3D). 
Because total hepatic glucose concentrations did not differ between groups (Fig. S6.5C), increased 
enrichment reflects increased production from pyruvate. As expected, addition of unlabeled octanoic acid 
to the perfusion buffer stimulated gluconeogenesis in livers of control animals (Fig. 6.3D, white bars) but 
in contrast, HMGCS2 ASO-treated livers perfused with octanoic acid did not increase gluconeogenesis, 
and in fact exhibited decreased 13C-glucose enrichment compared to control livers [(11.83 ± 1.70% 13C-
enrichment of glucose vs. 17.61 ± 1.34% in controls, n-7-8/group, p = 0.018, Fig. 6.3D), without altering 
total glucose pools (Fig. S6.5C). The inability of octanoic acid to stimulate glucose production in 
HMGCS2 ASO-treated livers was observed despite increased mRNA abundances of Ppara, Aco, Cpt1a, 
Ppargc1a, Pck1, and Me2 and normal mRNA abundances of Acadm, Fgf21, and G6Pc in liver (Fig. 
S6.5D), suggesting that a metabolic mechanism, rather than insufficient expression of the enzymatic 
mediators of fatty acid oxidation and gluconeogenesis, underlies the observed defect in fatty-acid 
stimulated glucose production in the setting of ketogenic insufficiency.  
Ketogenic insufficiency sequesters free coenzyme A. Because induction of gluconeogenesis by fatty 
acids is dependent on the NADH and ATP generated through the TCA cycle (281,357,358), we 
hypothesized that the failure of mitochondrial fatty acids to stimulate gluconeogenesis in the absence of 
ketogenesis could be mechanistically linked to a failure to couple β-oxidation of fatty acids to their 
terminal oxidation in the TCA cycle. To determine whether there were abnormalities of TCA cycle 
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function in livers of HMGCS2 ASO-treated mice, we measured TCA cycle intermediate pool 
concentrations in perfused livers of control and HMGCS2 ASO-treated mice. While tissue α-KG 
concentrations were normal in livers perfused in the absence of octanoate, inclusion of this fatty acid in 
the perfusion buffer increased concentrations of α-KG by two-fold in HMGCS2 ASO-treated livers (0.75 
± 0.08 nmol/mg tissue vs. 0.34 ± 0.08 nmol/mg tissue in control livers perfused with octanoate, n = 7-
8/group, p = 0.0032, Fig. 6.3E). Perfusion with octanoic acid also increased hepatic concentrations of 
glutamate, an equilibrium partner of α-KG, by two-fold, and decreased hepatic succinate concentrations 
by 43% in HMGCS2 ASO-treated livers (99.89 ± 12.89 pmol/mg tissue vs.162.8 ± 20.08 pmol/mg tissue 
in controls, p < 0.01,  n = 7-8/group; Fig. S6.5E and Fig. 6.3F). Collectively, these findings suggest a 
block at the TCA cycle reaction catalyzed by the α-KG dehydrogenase complex. Because the oxidative 
decarboxylation of α-KG to succinyl-CoA, which is subsequently converted to succinate, requires free 
CoASH, we quantified CoASH concentrations in unperfused and perfused livers of ASO-treated mice. 
While HMGCS2-ASO treatment did not alter CoASH concentrations in unperfused livers of standard 
chow-fed mice, or in livers perfused in the absence of octanoate, hepatic CoASH concentrations were 
decreased 60% in HMGCS2 ASO-treated livers perfused with octanoic acid (40.73 ± 14.35 pmol/mg 
tissue vs. 106.6 ± 24.31 pmol/mg tissue in controls, p = 0.035, n = 8/group, Fig. 6.3G). Fatty acid-
induced depletion of CoASH observed in HMGCS2 ASO-treated livers occurred despite normal 
expression of Pank1a, and increased expression of Pank1b (1 ± 0.022 vs. 2.5 ± 0.6, p = 0.04, n = 8-
10/group), which phosphorylate pantothenic acid in the first step of de novo CoASH biosynthesis (Fig. 
S6.5F). 
Consistent with the octanoate-induced derangements of TCA cycle intermediates and CoASH 
depletion in livers of standard chow-fed HMGCS2 ASO-treated mice, unperfused livers of HMGCS2 
ASO-treated mice fed a 60% HFD displayed increased [glutamate] (2.56 ± 0.4 vs. 1.12 ± 0.12 nmol/mg 
tissue in controls, p = 0.018, n = 4-5/group), a trend towards decreased [succinate], and decreased hepatic 
[CoASH] (28.40 ± 11.51 pmol CoASH/mg tissue vs.103.10 ± 32.62 in controls, p = 0.049, n = 8/group; 
Fig. S6.5G-I). Finally, circulating short- and medium-chain acylcarnitine concentrations, but not those of 
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long-chain acylcarnitines, were significantly increased in HMGCS2 ASO-treated mice fed a 40% fat diet 
(Fig. S6.7; for a full profile for chow-fed and 40% HFD-fed mice, see Table S6.1-2). Taken together, 
these results suggest that ketogenic insufficiency in the setting of high fat delivery to mitochondria 
depletes free CoASH and thereby impairs TCA cycle function, which inhibits entry of acetyl-CoA and 
thus favors increased accumulation of shorter-chain acylcarnitines. 
To determine if supplementation of the CoA precursors pantothenic acid (vitamin B5) and 
cysteine, could restore glucose production and normalize TCA cycle intermediate concentrations in 
HMGCS2 ASO-treated livers, we perfused livers of HMGCS2-deficient and control animals with 
exogenous octanoate and CoA precursors. While inclusion of pantothenic acid and cysteine with 
[13C]lactate, [13C]pyruvate, and unlabeled octanoic acid during a 15 min perfusion failed to normalize 
gluconeogenesis in HMGCS2 ASO-treated livers, (Fig. 6.4A, left), prolonged repletion of CoASH 
precursors by perfusing livers with pantothenic acid and cysteine for 45 min prior to perfusion with 
[13C]lactate and [13C]pyruvate, unlabeled octanoic acid, pantothenic acid, and cysteine for 15 min 
normalized 13C-glucose enrichment (Fig. 6.4A, right). Total hepatic glucose concentrations did not differ 
between control and HMGCS2 ASO-treated livers in either perfusion experiment (Fig. S6.8). Moreover, 
pre-perfusion with CoASH precursors attenuated the expansion of the α-KG and glutamate pools in 
HMGCS2 ASO-treated livers, with pre-perfused HMGCS2 ASO-treated livers exhibiting a 29% decrease 
in [α-KG] and a 43% decrease in [glutamate] compared to HMGCS2 ASO-treated livers that were not 
pre-perfused with CoASH precursors (n= 5-7/group, p < 0.05 for α-KG, and p < 0.001 for glutamate; Fig. 
6.4B-C). Finally, inclusion of pantothenic acid and cysteine normalized succinate concentrations in livers 
of HMGCS2 ASO-treated mice irrespective of the length of the perfusion (Fig. 6.4D). Taken together, 
these results mechanistically link the HFD-induced hypoglycemia and fat-induced impairment of hepatic 
gluconeogenesis observed in ketogenesis insufficient mice to CoASH depletion and inhibition of the α-






Hepatic ketogenesis is activated when fatty acids are plentiful, carbohydrates are in short supply, and/or 
circulating insulin concentrations are low (2,4,5,44,301). This spillover pathway converts β-oxidation-
derived acetyl-CoA, produced in excess of the hepatocyte’s own energy needs, into ketone body 
intermediates, thus diverting carbon away from the hepatic TCA cycle and providing extrahepatic tissues 
with an avidly oxidized fuel source. This paradigm forms an ‘altruistic’ model of ketone body 
metabolism, in which the hepatocyte shares ‘pre-catabolized’ energy stored in fatty acids with other 
organs that may require it, particularly in states of diminished carbohydrate availability. However, this 
model neither accounts for the hepatocyte’s need to support ketogenesis for its own metabolic 
homeostasis, nor considers the importance of basal hepatic ketogenesis in physiological states that are not 
considered ‘ketogenic’ (i.e., carbohydrate restricted). These are the first studies to demonstrate a critical 
role for hepatic ketogenesis in the normal absorptive state and in prevention of metabolic decompensation 
in the setting of overnutrition, which triggers a cascade of events that culminates in hepatic injury and 
hepatic inflammation when ketogenic capacity is markedly impaired. 
Our data are consistent with a model in which ketogenesis that is inadequately matched to the 
supply and availability of fat (ketogenic insufficient) in the normal fed state will channel β-oxidation-
derived acetyl-CoA into the TCA cycle, generating the ATP and NADH to support increased 
gluconeogenesis from pyruvate, predisposing to hyperglycemia (Fig. 6.4E). Therefore, even in the non-
lipolytic absorptive state, in which dietary carbohydrates are abundant, hepatic ketogenesis serves a 
critical role in regulating glycemia. When ketogenesis is insufficient, acute delivery of fatty acids and 
chronic exposure to a ‘non-ketogenic’ (not carbohydrate restricted) high-fat diet both result in the 
inability to couple increased fat availability to increased gluconeogenesis through mechanisms that can be 
linked to sequestration of free CoASH, a critical by-product yielded by ketogenesis. Our data are most 
consistent with a model in which the CoASH liberated by ketogenesis is critical in states of high fat 
delivery, supporting the α-KG dehydrogenase reaction and therefore effective TCA cycle function. Taken 
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together, these results mechanistically link ketogenesis to hepatic CoASH homeostasis and 
gluconeogenesis, and provide strong evidence for a previously unknown role of ketogenesis in prevention 
of hyperglycemia and hepatic injury. These findings are underscored by our recent studies of germline 
SCOT-knockout (KO) mice, which cannot terminally oxidize ketone bodies in any tissue. These mice 
exhibit hyperketonemic hypoglycemia and die within 48 hr of birth in a manner that phenocopies human 
sudden infant death syndrome [SIDS, (78)]. Despite the fact that SCOT is normally excluded from 
hepatocytes, livers of SCOT-KO mice develop abnormalities of hepatic fatty acid oxidation, pyruvate 
metabolism, redox potential, and even ketogenesis (164,313). In stark contrast to the severe metabolic 
derangements and SIDS-like phenotype observed in neonatal SCOT-KO mice, mice that cannot oxidize 
ketone bodies selectively within neurons, cardiomyocytes, or skeletal myocytes, which comprise the three 
greatest consumers of ketone bodies, survive the neonatal period and starvation as adults (108). Together, 
these results indicate that coordination of ketogenesis and ketone body oxidation may be of even greater 
importance to preserve the dynamic intermediary metabolic network in the liver than it is to provide 
energy to extrahepatic tissues. 
Genome-wide association and exome sequencing studies have revealed associations between 
numerous genes encoding mediators of lipid metabolism and NAFLD/NASH (327,359). Variations in the 
genes encoding ketogenic mediators, including HMGCS2, HMG-CoA lyase, and βOHB dehydrogenase 
have not yet been unveiled as independent predictors of liver pathology or diabetes. While complete 
HMGCS2-deficiency is very rare in humans, case reports indicate that encoded variation in ketogenic 
capacity exists in populations worldwide. Total HMGCS2 enzymatic deficiency is associated with 
pediatric hypoketonemic hypoglycemia and hepatic steatosis (66-68,360-362). Importantly, our studies of 
neonatal mice revealed that partial loss of HMGCS2 activity caused marked hepatic steatosis vastly out of 
proportion to the diminution in neonatal ketosis, but did not result in neonatal hypoglycemia or failure to 
thrive. These findings raise the possibility that insidious genetic polymorphisms yielding very subtle 
ketogenic defects could latently predispose to fatty liver disease, and attest to the critical fine-tuning role 
that hepatic ketogenesis plays in the regulation of hepatic glucose and lipid metabolism.  
149 
In the setting of ketogenic insufficiency, perfusion with octanoate depletes CoASH, inhibiting the 
α-KG dehydrogenase reaction of the TCA cycle, which manifests as increased α-KG and decreased 
succinate concentrations. Similarly, perfused livers of HFD-fed HMGCS2 ASO-treated mice exhibit 
decreased hepatic glucose production from pyruvate, and unperfused livers of HFD-fed HMGCS2 ASO-
treated mice demonstrate a trend towards decreased [CoASH]. Only longer-term replenishment of the 
CoA precursors pantothenic acid and cysteine prevented the octanoate-induced impairment of glucose 
production in livers of ketogenesis-insufficient mice, diminished the increase in [α-KG], and mitigated the 
decrease in [succinate]. The findings suggest severe depletion of CoASH precursors in HMGCS2 ASO-
treated livers or that the kinetics of CoASH biosynthesis and mitochondrial import [(CoASH biosynthesis 
and transport reviewed in (363)] occur too slowly to mitigate these metabolic abnormalities. Together, 
these findings identify ketogenesis as a significant modifier of the TCA cycle and gluconeogenesis 
through modulation of acetyl-CoA pools and CoASH homeostasis. 
Unlike many tissues that must synthesize CoASH de novo or regenerate it via acyl-CoA 
thioesterases (363,364), hepatocytes can robustly engage ketogenesis to regenerate CoASH (4,5,301). 
After a brief eight week interval of HFD-feeding that is insufficient to cause hepatic injury in control 
mice [(42) and Fig. 6.2B-C], mice that cannot effectively liberate CoASH from acetate through 
ketogenesis exhibit significantly elevated serum ALT activity and histopathologic evidence of hepatic 
injury and inflammation. The severity of hepatic injury positively correlates with dietary fat content, 
indicating an important postprandial role for ketogenesis in (i) disposal of excess dietary fat and (ii) 
liberation of CoASH from acetyl-CoA. Furthermore, ASO-treated mice fed a HFD developed equivalent 
steatosis, but only ketogenic insufficient mice developed severe inflammation, suggesting that of the two 
major NAFLD subtypes, simple steatosis and NASH, impaired ketogenesis is an important determinant of 
NASH (325). Other forms of hepatocellular injury are also associated with decreased CoASH 
concentrations. In acute acetaminophen toxicity, CoASH levels decrease simultaneously with decreasing 
HMGCS2 enzymatic activity (365,366). Potentially fatal valproic acid therapy-induced hepatic 
dysfunction, which is associated with impaired β-oxidation of fatty acids and ketogenesis due to 
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sequesteration of CoASH into poorly metabolized valproyl CoA, can be prevented by administration of 
CoA precursors (367,368). In rodents, hepatic CoASH concentrations decrease in response to HFD (369), 
while the concentration of pantothenic acid actually increases (370), suggesting that hepatic CoASH 
homeostasis is dysregulated in obesity. De novo CoASH synthesis is required for life in mice and 
impaired CoASH synthesis is associated with fasting induced hepatic steatosis (371,372). Nonetheless, 
the importance of de novo CoASH synthesis in obesity and its relation to NAFLD remain relatively 
unexplored.  
No current pharmacological therapies directly treat NAFLD or NASH. These diseases are 
currently addressed through lifestyle modifications such as weight loss and treatment of dyslipidemia and 
hyperglycemia (328). A variety of agents are at various stages of investigation, including compounds 
targeting oxidative stress, nuclear receptor activators, insulin sensitizers, modifiers of dyslipidemias, and 
immunomodulatory agents (342,345). Ketogenesis has not yet been considered as a metabolic target. 
Obese humans and mice exhibit diminished whole body ketone body turnover (12,42). Furthermore, 
circulating ketone body concentrations are generally decreased in obese humans (238,239,354), and serve 
as predictive biomarkers for conversion to type 2 diabetes in patients with impaired fasting glucose (373). 
Furthermore, compared to BMI-matched individuals, obese patients with NAFLD exhibit increased 
hepatic glucose production and TCA cycle flux, but not ketogenesis (355). DNA methylation, nuclear 
receptor-mediated transcriptional activation, and reversible succinylation, acetylation, and 
phosphorylation all exert multi-tiered transcriptional and post-translational regulation of Hmgcs2 
expression and HMGCS2 enzymatic activity to coordinate ketogenesis during diverse physiologic 
contexts [(11,47,64,65,324) and reviewed in (301)]. Therefore, HMGCS2 and other enzymatic mediators 
of ketogenesis may be considered in future investigations of metabolic regulation of abnormal hepatic 






Animals. All adult mice studied were males on a C57BL/6N X C57BL/6J hybrid background. For 
neonatal experiments, both sexes were studied. Unless otherwise noted, mice were maintained on 
standard low fat chow diet in which 13% of the calories are from fat, 25% from protein, and 62% from 
carbohydrates (Lab Diet 5053) and autoclaved water ad libitum. Lights were off between 1800 and 0600 
in a room maintained at 22oC. For all adult mouse experiments, mice were housed in groups of 4-5 on 
sawdust bedding. ASO treatment was initiated in six week-old mice by intraperitoneal injection (25 
mg/kg) with HMGCS2 targeted ASOs (ISIS 191229; CTGTTTGTCACTGCTGGATG) or with 
scrambled sequence control ASOs (ISIS 141923; 5′-CCTTCCCTGAAGGTTCCTCC-3′) biweekly for 
four weeks. For HFD studies, after two weeks of ASO treatment, mice were maintained for eight weeks 
on either a high fat diet in which 60% of calories are from fat, 20% from protein, and 20% from 
carbohydrates (D12492, Research Diets) or, in separate cohorts, a diet in which 40.7% of calories are 
from fat, 19% from protein, and 40.3% from carbohydrates (TD 110290, Harlan Teklad), during which 
time biweekly ASO administration continued. For the neonatal experiments, ASOs were administered (25 
mg/kg) subcutaneously daily, beginning on the second day of life and until postnatal day 12 (P12). Pups 
were marked on the abdomen daily with a permanent marker to enable longitudinal monitoring of body 
weight and blood glucose. Marking also enabled control and HMGCS2 ASOs to be administered to 
different pups within the same litter, thus, minimizing inter-litter variance in metabolic parameters. All 
experiments were conducted using protocols approved by the Animal Studies Committee at Washington 
University. 
Measurements of food intake, body weight, and body composition. Food intake was monitored beginning 
on day 1 of ASO treatment for each cage of mice. Food intake was measured biweekly for the duration of 
each experiment and normalized to the number of mice per cage and the number of days between 
measurements, which was always three or four days. Mice were also weighed biweekly at the onset of all 
experiments. Body weights and body composition were recorded following a four-hour fast (1000-1400), 
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after which food was returned immediately. Percent body fat and lean body mass were determined in 
awake adult animals using an EchoMRI instrument (Echo Medical Systems, Houston, TX). 
Plasma Metabolite Quantification. Serum triacylglycerol (TAG), free fatty acids (FFAs), total ketone 
bodies (TKB), beta-hydroxybutryate (βOHB), and acetoactate (AcAc) were determined using standard 
biochemical assays coupled to colorimetric substrates as described previously (51). Blood glucose was 
measured in duplicate using handheld glucometers (Aviva). Serum insulin was measured using an 
enzyme-linked immunosorbent assay (Millipore) and serum alanine aminotransferase (ALT) was 
measured using an assay from Teco Diagnostics, according to manufacturer’s instructions. 
Tissue Metabolite Quantification. Hepatic [TAG] were quantified biochemically using a Folch extract of 
liver, as described previously (126). Tissue CoASH concentrations were measured in freeze-clamped and 
bio-pulverized liver tissue. Approximately 75 mg of tissue were homogenized using a glass on glass 
dounce in 10x-volume of ice-cold deionized water. Homogenates were spun at 4oC and 15,000 x g for 20 
min. Supernatants were transferred to clean tubes on ice and were then dehydrated using a rotary speed-
vacuum. Tissue pellets were resuspended to 2 mg/µl and 20 mg of tissue (10 µl) were loaded into a 96 
well plate for CoASH detection using an enzyme linked colorimetric assay (Biovision). 
Histology. Immediately following sacrifice, liver specimens were collected and fixed in 10% neutral 
buffered formalin (Fisher, Wilmington, DE) or cryopreserved in Optimal Cutting Temperature Compound 
(O.C.T. Tissue Tek). For hematoxylin and eosin stained sections, paraffin-embedded tissue was 
microtome-sectioned, stained and photographed using standard methods. For F4/80 immunostains, rat 
anti-F4/80 (Abcam, ab6640) was incubated for 1 h at room temperature on liver cryosections (diluted 
1:200 in 1% bovine serum albumin/0.1% Triton X-100 in phosphate buffered saline), followed by Alexa 
Fluor 594 conjugated goat anti-rat IgG (Invitrogen, Carlsbad, CA; diluted 1:250 in 1% bovine serum 
albumin/0.1% Triton X-100 in phosphate-buffered saline) and coverslip application as previously 
described (1). For smooth muscle actin (SMA) immunostains, mouse monoclonal anti-SMA-Cy3 
conjugate (Sigma C-6198) was incubated for 1 h at room temperature on liver cryosections (diluted 1:100 
in 1% bovine serum albumin/0.1% Triton X-100 in phosphate buffered saline), followed by coverslip 
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application. 4’,6-Diamidino-2-phenylindole (DAPI) was used as a cell nuclear counterstain (40 ng/ml in 
phosphate buffered saline for 5 min). All immunofluorescence images were acquired at 0.5 µm slice 
thickness using a Zeiss LSM 700 confocal microscope and Zeiss Zen software. For F4/80 and SMA 
immunostains, five random 20X fields and nineteen random 10X fields per liver, respectively (n = 3 
animals/group), were quantified manually. In each case, only staining that was clearly associated with 
nuclei were counted, and for SMA, only cells outside of vessel walls were counted as activated stellate 
cells.  
Gene expression analysis. Quantification of gene expression was performed using real-time RT-
quantitative PCR using the ΔΔCt approach as described (51), normalizing to Rpl32, using primer 
sequences listed within Supplemental Table 6.2.  
Immunoblotting. Lysates from liver were generated in a protein lysis buffer: 20 mM Tris-HCl, 150 mM 
NaCl, 1 mM EDTA, 1% Triton X-100, 1% phosphatase inhibitor cocktail (Sigma), and protease inhibitor 
cocktail (complete mini EDTA-free, Roche), pH 7.5. Immunoblots to detect HMGCS2 (rabbit anti-
mHMGCS; Santa Cruz Biotechnology), HMGCS1 (rabbit anti-HMGCS1; Thermo Scientific), and actin 
(rabbit anti-actin, Sigma) were performed as described (78). Band intensities were quantified 
densitometrically using Quantity One software (Bio-Rad). 
Liver perfusions. Ten minutes prior to each liver perfusion, mice received an intramuscular injection of 
heparin (100 Units). Mice were then anesthetized with 10µl of sodium pentobarbital (Fatal Plus, 390 
mg/ml) administered IP. Once fully anesthetized, the abdomen was sprayed with 70% ethanol, and the 
mouse was placed on a surgical platform within a large reservoir to contain run-off buffer and body 
fluids. A transverse incision was made through the skin, fascia, and muscular layers of the lower 
abdomen. A lateral sagittal incision was made on each side of the body, exposing the abdominal contents. 
A second transverse incision was made inferior to the right kidney and towards the dorsal aspect of the 
mouse to allow for perfusion buffer and body fluids to drain from the abdomen. The portal vein was then 
exposed by gently moving the intestines laterally towards the left body wall. A suture needle was 
threaded under the portal vein and tied loosely. Next, the portal vein was cannulated with a 24 gauge 
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catheter needle, the needle was withdrawn, and tubing with buffer was reconnected to the catheter. The 
abdominal aorta and inferior vena cava were cut and the catheter was firmly tied into the portal vein. 
Finally, the heart was exposed by cutting through the diaphragm and thorax. The right atrium was cut to 
prevent recirculation of buffer to the liver and to terminate perfusion to the brain. All livers were perfused 
with an oxygenated Krebs-Henseleit bicarbonate buffer (118 mM NaCl, 25 mM NaHCO3, 4.7 mM 
KCl, 0.4 mM KH2PO4, 2.5 mM CaCl2, 1.22 mM MgSO4-7•H20, pH 7.4), warmed to 37°C using a 
counter-current heat exchange circuit and a recirculating water bath, at a rate of 8 ml/min using a 
peristaltic pump for 15 min, unless otherwise noted. At the end of the perfusion, the liver was freeze-
clamped and rapidly frozen in a bath of liquid nitrogen. Tissue was stored at -80°C until further 
processing. For measurements of ketogenesis in perfused livers, buffers contained sodium [1,2,3,4-
13C4]octanoate (0.2 mM), sodium lactate (1.5 mM), and sodium pyruvate (0.15 mM). For all 
measurements of gluconeogenesis, livers were perfused with sodium [3-13C]lactate (1.5 mM) and sodium 
[3-13C]pyruvate (0.15 mM), and in a subset of these experiments, unlabeled sodium octanoate (0.2 mM) 
was included in the buffer (vendor for stable isotopes: Cambridge Isotope Laboratories). For the CoASH 
repletion experiments, unlabeled pantothenic acid and L-cysteine were included in the perfusion buffer at 
0.15 mM and 0.1 mM, respectively, in addition to sodium [3-13C]lactate (1.5 mM), sodium [3-
13C]pyruvate (0.15 mM), and unlabeled sodium octanoate (0.2mM). Livers pre-perfused with CoASH 
precursors received unlabeled pantothenic acid (0.15 mM), Cys (0.1 mM), sodium lactate (1.5 mM), and 
sodium pyruvate (0.15mM) for 45 min before being switched to a buffer containing pantothenic acid  
(0.15 mM), cysteine (0.1 mM), sodium [3-13C]lactate (1.5 mM), sodium [3-13C]pyruvate (0.15 mM), and 
unlabeled sodium octanoate (0.2 mM) for 15 min. 
NMR-based quantitative substrate fate mapping. Neutralized perchloric acid tissue extracts were prepared 
and profiled using 13C-edited proton nuclear magnetic resonance (NMR) measured at 11.75 T 
(Varian/Agilent Direct Drive-1) via first increment gradient heteronuclear single-quantum 
correlation (gHSQC). Signals were collected from extracts dissolved in 275 µL of D2O + 1 mM 
trimethylsilyl propionate (TSP), loaded into high precision, thin walled 5-mm tubes (Shigemi). Tissue 
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concentrations and fractional enrichments of metabolites were determined from quantification of signals 
by integration from the 1H{13C} and 13C-edited (gHSQC) collections of carbon 2 for taurine, carbon 4 for 
βOHB, carbon 1 for glucose, carbon 4 for glutamate, and 1H{13C} of carbon 3 for α-ketoglutarate and 
carbon 2/3 for succinate as described previously (78,313). 
Tandem Mass Spectrometry (MS/MS) Analysis of Blood Amino Acids and Acylcarnitines. Blood was 
spotted onto 1.3-cm spots on Whatman 903 filter paper. Amino acids were quantified as butyl ester 
derivatives using multiple precursor/product combinations in a reversed-phase liquid chromatography 
protocol coupled to MS/MS (22). Carnitine esters were measured by scanning for the precursors of the 
common m/z 85 carnitine fragment. Quantification was achieved in all cases using stable isotope 2H-
labeled internal standards using an electrospray ionization source coupled to an API 3200-Qtrap tandem 
mass spectrometer (Applied Biosystems). 
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Fig. 6.1. Ketogenic insufficiency in mice treated with Hmgcs2 ASO. (A) Immunoblot for HMGCS2 
and actin using protein lysates derived from livers of neonatal mice treated with either a scrambled 
sequence control ASO or HMGCS2 ASO. Mice were treated with ASO daily for 11 days, beginning on 
the second day of life, and tissues and serum were collected on postnatal day 12 (P12). Protein abundance 
is quantified below. (B) Serum total ketone body (TKB, mM) and (C) hepatic TAG (mg/g tissue) 
concentrations on P12 in ASO-treated mice. (D) Immunoblot for HMGCS2 and actin using protein 
lysates derived from livers of adult mice treated with control or HMGCS2 ASO biweekly for four weeks 
beginning at six weeks of age. (E) Serum [TKB] (mM) during fasting in adult mice treated with ASO for 
four weeks, n = 3-5/group. *, p < 0.05, ***, p < 0.001 by Student’s t test vs. HMGCS2-ASO treated mice, 
or as indicated. 
 
Fig. 6.2. Hepatic injury in ketogenesis insufficient HFD-fed mice. (A) Hepatic [TAG] (mg/g tissue) 
and (B) serum ALT activity (U/L) in ASO-treated mice fed a standard chow diet fed a low fat diet 
(standard chow diet) for four weeks or a high fat diet for eight weeks, n = 4-5/group. (C) Representative 
hematoxylin and eosin stained sections of liver from ASO treated mice fed the indicated diet. Arrowheads 
indicate dying hepatocytes (acidophil bodies). (D) Representative 20X fields showing immunostaining for 
F4/80- and (E) smooth muscle actin (SMA)-positive cells in cryosections of liver from ASO treated mice 
fed HFD for eight weeks. Quantification for each is on right. **, p < 0.01, ***, p < 0.001 by Student’s t 
test or 2-way ANOVA as appropriate, as indicated.  
 
Fig. 6.3. Hepatic metabolic reprogramming in ketogenesis insufficient mice. (A) Blood glucose 
(mg/dL) and (B) the percent of basal blood glucose in ASO-treated mice beginning at the onset of 60% 
HFD-feeding, n = 8-10/group. (C) Quantification of 13C-enrichment of glucose from [13C]pyruvate (a 
surrogate for gluconeogenesis) determined by 13C-edited proton NMR spectroscopy in liver extracts of 
60% HFD-fed ASO-treated mice perfused via the portal vein with [13C]lactate and [13C]pyruvate in a 
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physiological ratio, n =4-5/group. (D) 13C-enrichment of glucose from [13C]pyruvate, (E) total alpha-
ketoglutarate (α-KG, nmol/mg tissue), and (F) succinate concentrations (pmol/mg tissue) determined by 
NMR in liver extracts of standard chow diet-fed ASO-treated mice perfused with the indicated substrates, 
n = 7-8/group. (G) Free coenzyme A (CoASH, pmol/mg tissue) concentrations in livers of unperfused 
standard chow diet-fed ASO-treated mice or livers perfused with the indicated substrates, n = 3-8/group. 
*, p < 0.05, **, p < 0.01, ***, p < 0.001 by Student’s t test or 2-way ANOVA as appropriate, vs. 
HMGCS2-ASO treated mice, or as indicated.  
 
Fig. 6.4. Replenishing CoA precursors restores gluconeogenesis and TCA cycle intermediate 
abnormalities in livers of ketogenesis insufficient mice. (A) Gluconeogenesis in perfused livers of 
standard chow diet-fed ASO-treated mice perfused with either [13C]lactate, [13C]pyruvate, octanoic acid, 
cysteine, and pantothenic acid for 15 min [Pre-perfusion (-)] or Pre-perfused with for 45 min with 
unlabeled lactate, pyruvate, cysteine, and pantothenic acid followed by 15 min of perfusion with 
[13C]lactate, [13C]pyruvate, octanoic acid, cysteine, and pantothenic acid. (B) [α-KG] (nmol/mg tissue), 
(C) [glutamate] (nmol/mg tissue), and (D) [succinate] (pmol/mg tissue) in the same livers as in (A). n = 5-
7/group, *, p < 0.05, **, p < 0.01, ***, p < 0.001 by 2-way ANOVA as indicated. (E) Schematic model of 
fatty acid handling in normal liver and in fatty liver disease. NAFLD livers exhibit increased esterification 
to and liploysis from lipid droplets, increased β-oxidation of fatty acids, increased terminal oxidation, 
increased gluconeogenesis, and diminished ketogenesis, relative to the availability of fat. Our studies 
demonstrate that severe ketogenic suppression sequesters CoASH due to impaired CoASH recycling, 
disrupts the tricarboxylic acid (TCA) cycle, and is associated with hepatic injury and inflammation. 
 
Fig. S6.1. Metabolic parameters of ketogenesis insufficient neonatal mice, specificity of HMGCS2 
ASO treatment in adult mice, and quantification of ketogenesis in perfused livers. (A) Body weight 
(g) and (B) blood glucose levels (mg/dL) in neonatal mice treated with ASO daily for 11 days, beginning 
on the second day of life (P1), n > 4/group. (C) Hmgcs2 transcript abundance in liver (n = 8-10/group) 
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and (D) in subcutaneous adipose tissue (n = 4/group) of adult mice treated with control or HMGCS2 ASO 
biweekly for four weeks beginning at six weeks of age. (E) Cytoplasmic 3-hydroxymethylglutaryl-CoA 
synthase (HMGCS1) protein content in livers of adult mice treated with ASOs for four weeks. (F) 13C-
βOHB enrichment in perfused livers of ASO treated mice, demonstrating diminished production of 
ketone bodies from [13C]octanoic acid. Decreased 13C-βOHB enrichment in fasted control livers 
compared to fed control livers is likely due to increased competition from endogenous fatty acids, which 
are mobilized to the liver from adipose stores during the fast, preceding the perfusion. n = 4-8/group. **, 
p < 0.01, ***, p < 0.001 by Student’s t test or 2-way ANOVA as appropriate, as indicated.  
 
Fig. S6.2. Metabolic parameters of ketogenesis insufficient adult mice fed a standard chow diet. (A) 
Body weight (g), (B) average food intake (kCal/mouse/day), and (C) body composition (g) in ASO 
treated mice fed a low fat diet (standard chow diet) for four weeks. (D) Serum free fatty acids (FFAs, 
mM; n = 20/group), (E) triacylglyceride (TAG, mg/dL; n = 15-19) (F) acetoacetate (AcAc) and βOHB 
(mM, n = 7 group for each ketone body), (G) blood glucose (mg/dL, n = 28-36/group), and (H) serum 
insulin (ng/ml, n = 20-23/group) concentrations in standard chow diet-fed ASO treated mice. **, p < 0.01 
by Student’s t test as indicated.  
 
Fig. S6.3.  Serum metabolites of ASO-treated mice fed a 60% HFD. (A) Immunoblot for HMGCS2 
and actin using protein lysates derived from livers of adult mice treated with control or HMGCS2 ASO 
biweekly for two weeks beginning at six weeks of age, during which time mice were maintained on a 
standard chow diet (quantification on right) and (B) following an additional eight weeks of 60% high fat 
diet (HFD). (C) Serum [TAG] (mg/dL), (D) [FFA] (mM), and (E) [TKB] (mM) in ASO-treated mice fed 





Fig. S6.4. Body weight, energy intake, and body composition of ketogenesis insufficient mice fed 
either a 60% HFD or a 40% fat diet. (A) Body weight (g) and (B) caloric intake (kCal/mouse/day) 
during 60% HFD and 40% fat diet (C-D) maintenance and ASO treatment, n = 8-10/group, ***, p  < 
0.001 by linear regression t test. (E) Body composition (g) pre- and post 40% fat diet feeding. n = 
10/group, *, p < 0.05, **, p < 0.01 ***, p < 0.001 by 2-way ANOVA as indicated. (F) Blood glucose 
concentration (mg/dL) in mice fed a 40% fat diet for eight weeks. n =10-15, *, p < 0.05, by Student’s t 
test. 
 
Fig. S6.5. Metabolite concentrations and gene expression in livers of ketogenesis insufficient mice. 
(A) Total hepatic glucose concentration (pmol/mg tissue) and (B) moles of 13C-glucose produced from 
[13C]lactate and [13C]pyruvate, quantified by NMR profiling of perfused liver extracts from ASO-treated 
mice fed a 60% HFD for eight weeks, n = 4-5/group. (C) Total [glucose] (pmol/mg tissue) in livers from 
standard chow diet-fed ASO-treated mice perfused with the indicated substrates, n = 7-8/group. (D) 
Relative transcript abundances of key mediators of fatty acid oxidation and gluconeogenesis in livers 
from standard chow diet-fed ASO-treated mice, n = 8-10/group. peroxisome proliferator activated 
receptor alpha, Ppara; peroxisome proliferator activated receptor gamma coactivator 1-alpha, Pgc1α; 
acyl-CoA oxidase, Acox1; carnitine palmitoyl transferase 1a, Cpt1a; medium chain acyl-CoA 
dehydrogenase, Acadm; fibroblast growth factor 21, Fgf21; malic enzyme 2; Me2;  phosphoenol pyruvate 
carboxykinase, Pck1; glucose-6-phosphatase, G6pc. (E) Total [glutamate] (nmol/mg tissue) in livers from 
standard chow diet-fed ASO-treated mice perfused with the indicated substrates, n = 7-8/group. (F) 
Pantothenate kinase 1a and 1b (Pank1a and Pank1b) relative mRNA abundance in livers of standard 
chow diet-fed ASO-treated mice, n = 8-10/group. (G) [Glutamate] (nmol/mg tissue) and (H) [succinate] 
(nmol/mg tissue) in unperfused livers of 60% HFD-fed ASO-treated mice n = 4-5/group. (I) Free 
coenzyme A (CoASH, pmol/mg tissue) concentrations in unperfused livers of 60% HFD-fed ASO-treated 
mice, n = 8/group. *, p < 0.05, **, p < 0.01, ***, p < 0.001 by Student’s t test or 2-way ANOVA as 
appropriate, as indicated.  
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Fig. S6.6. Hepatic injury in ketogenesis insufficient mice fed a 40% HFD. (A) Hepatic [TAG] (mg/g 
tissue) and (B) serum alanine aminotransferase (ALT, U/L) activity in ASO-treated mice fed a 40% fat 
diet for eight weeks, n = 9/group for [TAG] and n = 4-5/group for ALT. (C) Representative hematoxylin 
and eosin stained sections of liver from ASO treated mice fed the indicated diet. Black arrowheads 
indicate microgranulomas comprised of lipid laden Kupffer cells and grey arrowheads indicate nests of 
inflammatory cells. *, p < 0.05, by Student’s t test as indicated. 
 
Fig. S6.7. Elevation of short- and medium-chain blood acylcarnitines in ketogenesis insufficient 
mice fed a 40% fat diet. Blood acylcarnitines (µM) in 40% fat diet-fed ASO treated mice, determined by 
tandem mass spectrometry from blood spotted onto 1.3-cm spots on Whatman 903 filter paper. *, p < 
0.05, **, p < 0.01 by Student’s t test, as indicated. n = 9-10/group.  
 
Fig. S6.8.  Hepatic glucose pools in livers perfused with supplemental CoASH precursors. (A) Total 
hepatic glucose concentrations (pmol/mg tissue) in livers of standard chow diet-fed ASO-treated mice 
perfused with [13C]lactate, [13C]pyruvate, octanoic acid, cysteine, and pantothenic acid for 15 min, n = 6-
7/group. (B) Total hepatic glucose concentrations (pmol/mg tissue) in livers of standard chow diet-fed 
ASO-treated mice perfused for 45 min with unlabeled lactate, pyruvate, cysteine, and pantothenic acid, 
followed by 15 min of perfusion with [13C]lactate, [13C]pyruvate, octanoic acid, cysteine, and pantothenic 

































13C-edited proton NMR spectroscopy method for measurement of gluconeogenesis from pyruvate in 
the perfused mouse liver  
 
Abstract 
Measurement of hepatic glucose production (HGP) in rodent models is integral to obesity and diabetes 
research. Nonetheless, HGP is not routinely measured due to the challenges associated with clamp 
techniques, in vivo tracer studies, and ex vivo carbon NMR methods. Thus, we have developed a simple 
proton-edited 13C-NMR method to measure HGP from pyruvate in situ in the mouse. Here we 
demonstrate the validity of this method in cohorts of chow-fed and 24 hr fasted wild type male mice. 
Contribution of [13C]pyruvate, delivered via the portal vein in a euthermic oxygenated buffer, to the TCA 
cycle for terminal oxidation and to gluconeogenesis was quantified by NMR in mouse liver extracts. As 
expected, contribution of [13C]pyruvate to hepatic gluconeogenesis increased and hepatic pyruvate 
oxidation decreased with fasting. The methods contained here provide a relatively simple means of 
measuring hepatic gluconeogenesis from pyruvate using proton edited 13C-NMR and can easily be 
adapted to map the fate of various substrates. 
 
Methods 
Animals. All adult mice studied were males on a C57BL/6N X C57BL/6J hybrid background. Mice were 
maintained on standard low fat chow diet in which 13% of the calories are from fat, 25% from protein, 
and 62% from carbohydrates (Lab Diet 5053) and autoclaved water ad libitum. Lights were off between 
1800 and 0600 in a room maintained at 22oC. For all experiments, mice were housed in groups of 4-5 on 
sawdust bedding. All experiments were conducted using protocols approved by the Animal Studies 
Committee at Washington University. 
Liver perfusions. Ten minutes prior to each liver perfusion, mice received an intramuscular injection of 
heparin (100 Units). Mice were then anesthetized with 10µl of sodium pentobarbital (Fatal Plus, 390 
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mg/ml) administered IP. Once fully anesthetized, the abdomen was sprayed with 70% ethanol, and the 
mouse was placed on a surgical platform within a large reservoir to contain run-off buffer and body 
fluids. A transverse incision was made through the skin, fascia, and muscular layers of the lower 
abdomen. A lateral sagittal incision was made on each side of the body, exposing the abdominal contents. 
A second transverse incision was made inferior to the right kidney and towards the dorsal aspect of the 
mouse to allow for perfusion buffer and body fluids to drain from the abdomen. The portal vein was then 
exposed by gently moving the intestines laterally towards the left body wall. A suture needle was 
threaded under the portal vein and tied loosely. Next, the portal vein was cannulated with a 24 gauge 
catheter needle, the needle was withdrawn, and tubing with buffer was reconnected to the catheter. The 
abdominal aorta and inferior vena cava were cut and the catheter was firmly tied into the portal vein. 
Finally, the heart was exposed by cutting through the diaphragm and thorax. The right atrium was cut to 
prevent recirculation of buffer to the liver and to terminate perfusion to the brain. All livers were perfused 
with an oxygenated Krebs-Henseleit bicarbonate buffer (118 mM NaCl, 25 mM NaHCO3, 4.7 mM 
KCl, 0.4 mM KH2PO4, 2.5 mM CaCl2, 1.22 mM MgSO4-7•H20, pH 7.4), warmed to 37°C using a 
counter-current heat exchange circuit and a recirculating water bath, at a rate of 8 ml/min using a 
peristaltic pump for 15 min. At the end of the perfusion, the liver was freeze-clamped and rapidly frozen 
in a bath of liquid nitrogen. Tissue was stored at -80°C until further processing. For measurements of 
gluconeogenesis in perfused livers, buffers contained sodium [3-13C]lactate (1.5 mM), sodium [3-
13C]pyruvate (0.15 mM), and unlabeled sodium octanoate (0.2 mM; vendor for stable isotopes: 
Cambridge Isotope Laboratories).  
NMR-based quantitative substrate fate mapping. Neutralized perchloric acid tissue extracts were prepared 
and profiled using 13C-edited proton nuclear magnetic resonance (NMR) measured at 11.75 T 
(Varian/Agilent Direct Drive-1) via first increment gradient heteronuclear single-quantum 
correlation (gHSQC). Signals were collected from extracts dissolved in 275 µL of D2O + 1 mM 
trimethylsilyl propionate (TSP), loaded into high precision, thin walled 5-mm tubes (Shigemi). Tissue 
concentrations and fractional enrichments of metabolites were determined from quantification of signals 
178 
by integration from the 1H{13C} and 13C-edited (gHSQC) collections of carbon 2 for taurine, carbon 1 for 
glucose, and carbon 4 for glutamate, as described previously (78,313). 
 
Results and Discussion 
Pyruvate oxidation decreases during fasting and gluconeogenesis from pyruvate increases. Numerous 
metabolic, allosteric, and molecular mechanisms ensure pyruvate oxidation decreases and hepatic glucose 
production (HGP) increases during fasting. Thus, the fed-fasted transition provides an optimal paradigm 
in which to test the validity of new approaches that quantify HGP. In liver, pyruvate can enter the TCA 
cycle either through oxidation to acetyl-CoA in a reaction catalyzed by pyruvate dehydrogenase (PDH) or 
via carboxyaltion to OAA (oxaloacetate), which is catalyzed by phosphoenolpyruvate carboxykinase 
(PEPCK, encoded by Pck1). Oxidative entry of pyruvate to the TCA cycle via PDH destines the pyruvate 
for terminal oxidation, while anaplerotic entry as OAA replenishes TCA intermediates and supports 
gluconeogenesis (Fig. 7.1A). As expected, 13C-glutamate enrichment, which serves as a quantitative 
surrogate for carbon entry into the TCA cycle for terminal oxidation, was decreased significantly in 
perfused livers of fasted mice (Fig. 7.1B, left). Since total hepatic glutamate concentrations (pools) were 
not different between fed and fasted mice (Fig. 7.1B, right), these results indicated that pyruvate 
oxidation decreased during fasting. In addition, 13C-glucose enrichment was increased in perfused livers 
of fasted mice (Fig. 7.1C, left), which reflected increased HGP, as total hepatic glucose pools did not 
differ between fed and fasted mice (Fig. 7.1C, middle). Morevover, fasted livers produced more total 
moles of 13C-labeled glucose (Fig. 7.1C, right). Our results are consistent with published findings that 
indicate that pyruvate oxidation decreases and pyruvate carboxylation increases during fasting to support 
HGP, and thus, validate our NMR method.  
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Figure legends 
Figure 7.1: Fasting alters pyruvate fate in perfused livers. A. Schematic of mitochondrial pyruvate and 
fatty acid fates. B. 13C-glutamate enrichment (pyruvate oxidation) in extracts of perfused livers of chow-
fed and 24 hr fasted mice (left) and total hepatic glutamate concentration (pool; right). C. 13C-glucose 
enrichment in extracts of perfused livers of chow-fed and 24 hr fasted mice (left) and total hepatic glucose 
pool (middle), and moles of 13C-glucose produced per mg tissue (right). FAO, fatty acid oxidation; PDH, 
pyruvate dehydrogenase; OAA, oxaloacetate; α-KG, alpha-ketoglutarate; GDH, glutamate 








Ketogenesis insufficient mice exhibit impaired fasting glucose and hepatic steatosis 
 
Main findings: 
Fasted ketogenesis insufficient mice exhibited hyperglycemia and hepatic steatosis. 
13C-pyruvate oxidation was decreased in perfused livers of ketogenesis insufficient mice, both in the 
presence and absence of exogenous unlabeled fatty acids. 
Exogenous fatty acids increased anaplerosis from pyruvate in perfused ketogenesis insufficient livers. 
Conclusion: 
Ketogenesis supports disposal of excess hepatic fat. 
Decreased pyruvate oxidation is likely due to increased competition from fatty acids that cannot be 
disposed of through ketogenesis. 
Accumulation of Ac-CoA, due to insufficient ketogenesis, may allosterically activate pyruvate 
carboxylase, and thus, stimulate anaplerosis. 
Future Direction: 
Determine if increased terminal fatty acid oxidation and increased pyruvate cycling support increased 
hepatic glucose production in fasted HMGCS2-deficient mice. 
Figure legends 
Figure 8.1: Fasting-induced hyperglycemia is associated with hepatic steatosis in ketogenesis insufficient 
mice. A. Blood glucose during fasting in ASO treated mice. B. Hepatic triacylglyceride (TAG) 
concentrations in fasted ASO treated mice. n > 5/group, **, p < 0.01, ***, p < 0.001 by Student’s t test, as 
indicated. 
Figure 8.2: Altered hepatic pyruvate fate in ketogenesis insufficient mice. A. Schematzed pyruvate fate 
within hepatic mitochondria. PDH, pyruvate dehydrogenase; PCx, pyruvate carboxylase; ME, malic 
enzyme; OAA, oxaloacetate; α-KG, alpha-ketoglutarate. B. 13C-enrichment of glutamate carbon 4 
(pyruvate oxidation) in livers of ASO-treated mice perfused with the indicated substrates. C. Immunoblot 
for phosphoserine 293 PDH-E1α and total PDH-E1α in livers of chow-fed ASO-treated mice. D. 13C-
enrichment of α-KG carbon 3 (pyruvate anaplerosis) in livers of ASO-treated mice perfused with the 









Ketone body metabolism is classically described as a two-compartment metabolic pathway wherein an 
altruistic liver provisions extrahepatic tissues with avidly oxidized ketone bodies during states 
characterized by limited carbohydrate availability. Up to two-thirds of the fat entering the liver is 
channeled into ketogenesis (281). During human starvation in humans, ketogenic rates approach 150 g 
ketone produced/day, which exceeds hepatic glucose production during starvation by 50% (84,374). The 
bioenergetic benefits of extrahepatic ketone body oxidation are manifold (reviewed in Ch. 1). Ketone 
bodies supplant glucose as the primary fuel source in the brain during starvation and can support up to 
25% of the neonate’s basal energy requirements (2,71,82). While ketone bodies undoubtedly comprise a 
significant and quantifiable metabolic fuel, an energetic requirement for ketone body oxidation has never 
been demonstrated experimentally. Moreover, the mechanisms by which hepatic ketogenesis coordinates 
intermediary metabolic homeostasis in liver has never been considered. Thus, my work has sought to 
mechanistically determine i) if ketone bodies comprise an essential fuel class, ii) which tissues, if any, 
energetically require ketone bodies for adaptation to birth and during starvation in the adult, and iii) novel 
roles for hepatic ketogenesis in preservation of the dynamic intermediary metabolic network in liver. 
Biochemistry of ketone body metabolism. Pioneering investigators, including John McGarry, Daniel 
Foster, Dermot Williamson, John Williamson, and Hans Krebs originally defined the biochemistry of 
ketone body metabolism [(4,5,375) and reviewed in Ch. 1]. Briefly, ketogenesis is restricted to liver due 
to absence of the fate committing ketogenic enzyme mitochondrial 3-hydroxymethlglutarly-CoA 
Synthase (HMGCS2) from most tissues under normal conditions. In liver mitochondria, a series of 
ketogenic reactions condense acetyl-CoA derived from beta-oxidation of fatty acids into the circulating 
ketone bodies, acetoacetate (AcAc) and beta-hydroxybutyrate (βOHB). In mitochondria of extrahepatic 
tissues, beta-hydroxybutyrate dehydrogenase 1 (BDH1) re-oxidizes βOHB to AcAc, which is directed 
towards the tricarboxylic acid (TCA) cycle for terminal oxidation by mitochondrial succinyl-CoA-
3:oxoacid CoA transferase (SCOT), the fate committing enzyme of ketone body oxidation. 
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Human inborn errors of ketone body metabolism. Ketone body metabolism is required for normal 
fitness in humans. Individuals with genetic defects in either the ketogenic or ketolytic arms of this 
metabolic pathway typically present early life. Nine cases of human HMGCS2-deficiency have been 
described. These patients classically present with hypoketotic hypoglycemia (66-68,360-362,376). SCOT-
deficient patients, of which there have been ~30 described cases, typically present with spontaneous 
ketoacidosis with or without hypoglycemia. Viral illness or brief periods of nutrient deprivation can also 
trigger ketoacidosis in these patients (77,79-81,97,98,100,101,148,149,290,377,378). Acute ketoacidotic 
episodes of SCOT-deficieny can raplidly progess to vomiting, coma, and even death, if intravenous 
glucose, insulin, and NaHCO3 therapy is not initiated rapidly. Diagnosis of HMGCS2- and SCOT-
deficiency is difficult due to the need for genetic testing, enzymatic assays, and liver biopsy in the case of 
HMGCS2-deficiency. Avoidance of fasting and ingestion of carbohydrate-replete diets are primary 
treatments of both of these diseases (66-68,77,79-81,97,98,100,101,148,149,290,360-362,376-378). 
 Latent defects in either ketogenesis or ketone body oxidation could predispose to metabolic 
disease later in life. Encoded variation in both ketogenesis and ketone body oxidation occur in humans 
(see case reports above) and both of these pathways are susceptible to down-regulation in response to a 
variety of stimuli (Reviewed in Ch. 1). Prospectively, latent defects in ketone body metabolism may 
emerge in genetically susceptible individuals and exacerbate common pathophysiologic states, including 
obesity, diabetes, fatty liver disease, and heart failure. 
Ketone body oxidation is required for life in neonatal mice. To mechanistically dissect the 
bioenergetic roles of ketone body metabolism during the transition to extrauterine life, our lab generated 
novel germline and tissue-specific SCOT-Knockout (KO) mice. SCOT catalyzes the fate committing 
reaction of ketone body oxidation, is expressed in all tissues except liver, and is uniquely required for 
ketone body oxidation (reviewed in Ch. 1). My studies of germline SCOT-KO mice revealed that ketone 
body oxidation is required to prevent lethal hyperketonemia and hypoglycemia. SCOT-KO mice are 
indistinguishable from wild littermates at birth, but die within the first 48 hr of life in a manner that 
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phenocopies human sudden infant death syndrome (SIDS). During ketosis, serum βOHB concentrations 
typically increase, such that the serum AcAc/βOHB ratio falls. In contrast, hyperketonemia in germline 
SCOT-KO neonates is marked by a pathological increase in the serum AcAc concentration that drives an 
increased serum AcAc/βOHB ratio (presented in Ch. 2). Because AcAc and βOHB are members of an 
NAD+/NADH-linked redox couple, the metabolic consequences of an increased AcAc/βOHB were 
investigated (presented in Ch. 4 and see below). 
Ketone bodies do not comprise an essential fuel source in mice. In stark contrast to the neonatal 
lethality exhibited by germline SCOT-KO mice, tissue-specific SCOT-KO mouse strains survive the 
neonatal period and starvation as adults with few metabolic abnormalities. Selective genetic targeting of 
SCOT in neurons, cardiomyocytes, and skeletal myocytes, which comprise the three greatest consumers 
of ketone bodies, resulted in specific and complete loss of SCOT protein and enzymatic activity within 
each of the targeted tissues. Of the tissue-specific SCOT-KO strains generated, only neonatal SCOT-
neuron-KO mice exhibited mildly elevated ketonemia, suggesting that neurons comprise a large ketolytic 
sink in neonatal mice. Furthermore, compound germline SCOT-heterozygous; SCOT-neuron-KO mice 
(which exhibit a 50% decrease in SCOT protein abundance in all tissues and also completely lack SCOT 
in all neurons), were viable and indistinguishable from SCOT-neuron-KO mice. Adult tissue-specific 
SCOT-KO strains adapted well to starvation. SCOT-Neuron-KO and SCOT-Muscle-KO mice exhibit 
hyperketonemia during fasting, but maintained glycemia and body weight normally during fasting. 
Moreover, all tissue-specific SCOT-KO strains exhibited the physiologic ratio of AcAc/βOHB during the 
neonatal period and during starvation as adults. Together, these results demonstrated that ketone body 
oxidation is not required in any single tissue for survival of the neonatal period or starvation in the adult, 
and suggested that minimal ketolytic reserve is required to prevent toxic accumulation of ketone bodies 
(presented in Ch. 3). 
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Extrahepatic disposal of ketone bodies preserves hepatic metabolic function in neonatal mice. 
SCOT-KO mice die with hypoglycemia and hyperketonemia that is marked by a pathological increase in 
the ratio of AcAc/βOHB in serum. Incredibly, total loss of ketone body oxidation, an exclusively 
extrahepatic process, deranged hepatic metabolism in neonatal SCOT-KO mice. βOHB accumulation in 
blood impaired de novo hepatic βOHB synthesis, but permitted continued production of AcAc, which 
selectively oxidized hepatic redox potential and increased the serum AcAc/βOHB ratio. Oxidized hepatic 
redox potential drove a maladaptive increase in pyruvate oxidation, which contributed to depletion of the 
neonate’s gluconeogenic precursor pool, and thus, limited hepatic glucose production in vivo. Together, 
these results indicated that a primary role for extrahepatic ketone body oxidation is to prevent toxic 
accumulation of ketone bodies, which provokes hepatic metabolic abnormalities (presented in Ch. 4). 
PPARα-dependent ketogenesis prevents neonatal hepatic steatosis. Peroxisome Proliferator Activated 
Receptor alpha (PPARα) is a master transcriptional regulator of hepatic intermediary metabolism. PPARα 
mediates the adaptive response to fasting. Like fasting, nutrient supply is abruptly altered at birth when a 
transplacental supply of carbohydrates is replaced by a high-fat, low-carbohydrate milk diet. Using 13C-
labeled substrates to quantify dynamic metabolism and complimentary systems physiology approaches in 
neonatal mice, I demonstrated a critical role for PPARα in hepatic metabolic adaptation to birth. PPARα-
KO neonates exhibited hypoglycemia, hypoketonemia, and hepatic steatosis. Hypoketonemia was 
mechanistically linked to a 50% decrease in hepatic ketogenesis and was associated with neonatal fatty 
liver. These findings indicated an important role for PPARα-dependent ketogenesis in disposal of excess 
hepatic fatty acids during the neonatal period, and prospectively, could extend to pathological 
nonalcoholic fatty liver disease (NAFLD) in adults (presented in Ch. 5). 
Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia through coenzyme A 
recycling. NAFLD spectrum disorders affect approximately one billion individuals worldwide. The 
mechanisms driving progressive steatohepatitis remain incompletely defined, impeding the development 
of effective treatments. Thus, we developed a murine model of HMGCS2-deficiency to determine if 
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ketogenesis plays a critical role in prevention of diet-induced steatohepatitis. To permit mechanistic 
dissection of the phenotypes offered by HMGCS2-deficient mice, I developed an in situ method to 
quantify hepatic energy metabolism in the perfused mouse liver using 13C-edited proton NMR 
spectroscopy (presented in Ch. 6a). HMGCS2 deficient mice could not effectively convert fatty acids into 
ketone bodies, and were thus ketogenic insufficient. Adult-onset loss of HMGCS2 caused mild 
hyperglycemia and increased hepatic gluconeogenesis from pyruvate in chow-fed mice. Ketogenesis 
insufficient mice also exhibited impaired fasting glucose and fasting-induced hepatic steatosis (presented 
in Ch. 6b). High-fat diet (HFD) feeding of ketogenesis insufficient mice caused extensive hepatocyte 
injury and inflammation, decreased glycemia, deranged hepatic TCA cycle intermediate concentrations, 
and impaired hepatic gluconeogenesis due to fatty acid-induced sequestration of free coenzyme A 
(CoASH). Supplementation of the CoASH precurosrs pantothenic acid and cysteine normalized TCA 
intermediates and gluconeogenesis in ketogenesis insufficient livers. These findings identify ketogenesis 
as a critical regulator of hepatic glucose metabolism and TCA cycle function via coordination of CoASH 
homeostasis in the absorptive state and indicate that ketogenesis modulates fatty liver disease (presented 
in Ch. 6). 
Future directions. 
Neonatal hypoglycemia has an incidence of 10% and pathological neonatal hypoglycemia occurs in 
2/1000 live births. Neonates born preterm, with intrauterine growth restriction, that are small for 
gestational age, with congenital anomalies or inborn errors of metabolism, and those born to diabetic 
mothers are at risk of developing neonatal hypoglycemia. Nonetheless, epidemiologic factors only 
identify 50% of at risk neonates and cannot predict which individuals will spontaneously recover from 
transient neonatal hypoglycemia and which will develop pathological hypoglycemia. Thus, guidelines 
that direct when and in which patients to intervene are lacking. My findings in neonatal mice have been 
leveraged into a clinical study designed to risk-stratify neonates for hypoglycemia using metabolite 
profiles. Current statewide screening protocols identify inborn errors of metabolism using tandem mass 
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spectrometric (MS/MS) quantification of blood amino acids and acylcarnitines in heel stick blood that is 
collected from neonates shortly after birth. Unfortunately, these screening regimens do not identify 
patients at risk of developing hypoglycemia that is not due to an underlying enzymatic deficiency, nor do 
they identify inborn errors of ketone body metabolism. Our current clinical study expands upon my 
findings in neonatal mice by using MS/MS to quantify circulating concentrations of ketone bodies, 
lactate, pyruvate, amino acids, and acylcarnitines, as well as blood AcAc/βOHB and pyruvate/lactate 
ratios as reporters of hepatic redox potential, in neonatal blood collected 6-12 and 24-48 hr after birth. 
Blinded statistical analyses of metabolic profiles, epidemiologic factors, and clinical course will be used 
to risk-stratify individuals for neonatal hypoglycemia. 
Inborn errors of ketone body metabolism are rarely diagnosed. These diseases may truly be rare. 
Alternatively, because they are difficult to diagnose, many cases may go undetected and could contribute 
to a subset of SIDS cases. In fact, one recent retrospective study that performed metabolic autopsies on 
255 SIDS patients identified 3 individuals with underlying defects in ketone body metabolism. Finally, 
identification of patients with partial loss of function within ketone body metabolism may have 
prognostic value, as abnormalities of ketone body metabolism occur in and may directly contribute to 
metabolic diseases, such as heart failure, diabetes, obesity, and fatty liver disease. 
My work has mechanistically defined a critical and novel role for ketogenesis in regulation of 
hepatic glucose production, glycemia, and prevention of diet-induced steatohepatitis. These findings 
warrant follow-up studies to determine if therapeutic activation of ketogenesis can ameliorate 
hyperglycemia and mitigate fatty liver disease. Genetic and viral approaches designed to augment 
ketogenesis can be employed in mouse models to determine if ketogenic activation can ameliorate 
hyperglycemia in diabetes models and prevent diet-induced NAFLD and NASH. Simultaneously, small 
molecule screens in primary hepatocytes to identify non-toxic, specific, and potent ketogenic activators, 
followed by subsequent compound optimization and validation in perfused livers and in vivo should be 
performed. Hepatic injury in HFD-fed ketogenesis insufficient mice is prospectively linked to pancellular 
metabolic dysfunction due to CoASH depletion. Therefore, we are currently performing interventions 
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designed to replenish hepatocellular CoASH pools in vivo in HFD-fed control and ketogenesis 
insufficient mice. These experiments include dietary supplementation of CoASH precursors (pantothenic 
acid and L-cysteine) and genetic, viral, and pharmacologic approaches to augment CoASH biosynthesis 
and/or increase CoASH liberation from acyl-CoAs. Because ketogenesis supports noncombustive and 
thus ‘safe’ disposal of mitochondrial fat, we are also performing studies to determine if excessive 
mitochondrial reactive oxygen species (ROS) production contributes to hepatic injury in HFD-fed 
ketogenesis insufficient mice. Furthermore, studies of mitochondrial biogenesis, mitochondrial 
respiration, mitochondrial Ca++ buffering, mitochondrial permeability transition pore opening, and 
mitochondrial ultrastructure are underway. We are working to characterize and to deconstruct the hepatic 
inflammation in HFD-fed ketogenesis insufficient mice using immunocompromised mouse models. 
Finally, because ketogenic capacity decreases with increasing age, we are studying aged control and 
ketogenesis insufficient mice fed a low-fat chow diet to determine if suppressed ketogenesis is sufficient 
to drive fatty liver disease in mice.  
Abnormal lipid and carbohydrate metabolism occur in and contribute to obesity, diabetes, and 
NAFLD. In liver, fluxes of carbohydrate and fatty acid metabolism are tightly linked to ketogenic flux. 
Nonetheless, ketogenesis has largely been overlooked as both a driver and as a modifier of metabolic 
disease states. My work is the first to mechanistically identify insufficient ketogenesis as a driver of 
hyperglycemia and NASH. Prospectively, ketonemia may serve as a predictive biomarker of fatty liver 
disease and diabetes progression. Future studies may reveal that therapeutic augmentation of hepatic 
ketogenesis can mitigate hyperglycemia and ameliorate fatty liver disease. 
Final thought. 
My most sincere hope is that this body of work will vitalize interest in ketone body metabolism as a 
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